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Breast cancer is the most prevalent form of cancer in females: one of nine women develops 
breast cancer during her lifetime and it is predicted that one in 27 women will die as a result of 
this disease. Moreover, it is anticipated that with almost 30 % of females affected, breast cancer 
will be the most frequently diagnosed cancer in 2009 (www.cancer.org). Given these facts, 
much time and resources have been provided to research in the breast cancer area. 
The ErbB2 receptor tyrosine kinase is one of the most-studied oncogenes in breast cancer as 
amplification and overexpression of the ERBB2 gene is known to occur in up to 25 % of all 
affected patients and is correlated with a highly aggressive disease and poor patient prognosis. 
Our study focused on signaling molecules interacting with the C-terminal regulatory region of 
the ErbB2 receptor. We used T47D breast cancer cells metabolically labeled with SILAC to 
identify binding partners of the pTyr1248 site of ErbB2. Using a peptide affinity pull-down 
approach followed by quantitative mass spectrometry, we identified Copine III as a novel 
interaction partner of ErbB2-pTyr1248. 
Copine III belongs to a family of Ca2+-dependent phospholipid binding proteins that is 
conserved from plants to humans. All copines carry two C2 domains followed by an A domain, 
similar to the von Willebrand A domain of integrins, in their C-terminus. Although Copine III is 
ubiquitously expressed, to date it has not been assigned a function downstream of ErbB2. 
In this study we first analyzed the biochemical properties of Copine III and its interaction with 
ErbB2. We show that Copine III is a cytoplasmic protein that localizes to the nucleus and the 
plasma membrane in a Ca2+-dependent manner and upon stimulation of the cells with the ErbB 
ligand heregulin (HRG). We used FRET acceptor photobleaching to show that Copine III and 
ErbB2 not only co-localize in HRG-stimulated breast cancer cells, but also interact at the plasma 
membrane. This co-localization is blocked when the cells are treated with the ErbB2 inhibitor 
AEE788, implying that Copine III only interacts with phosphorylated active ErbB2.  
The second goal of my studies was to place Copine III within a signaling pathway downstream 
of ErbB2. For this, we again used SILAC together with quantitative mass spectrometry and 
identified the scaffolding protein RACK1 as a binding partner of Copine III. We were able to 
show that Copine III, RACK1 and the adaptor molecule Shc form a complex with ErbB2 in HRG-
stimulated cells. RACK1 has been implicated in focal-adhesion mediated cell migration and 
here we demonstrate that Copine III localizes to focal adhesions and is required for ErbB2-
dependent cell migration. Moreover, knock-down of Copine III affects Src kinase activity and 
the subsequent phosphorylation of focal adhesion kinase, resulting in the observed defects in 





Finally, we analyzed Copine III expression in the broader context of cancer, looking at 
carcinomas of the breast, prostate and ovary. In a set of 49 breast cancer tumor samples, 10 of 
the 11 cases with ERBB2 amplification display elevated levels of Copine III. This connected well 
with the protein expression levels of Copine III in a panel of breast cancer cell lines that also 
correlated with ErbB2 amplification. In published ovarian and prostate transcriptome studies, 
Copine III mRNA levels are upregulated in cancer as compared to normal tissue. Based on these 
findings, we performed immunohistochemistry (IHC) stainings of Copine III on breast, prostate 
and ovarian tissue microarrays. While some Copine III staining was evident in normal breast, 
normal prostate and ovarian tissues have very low levels of Copine-III. Strikingly, tumors of all 
three types showed higher Copine III levels.  
 
To summarize, we present Copine III here for the first time as an interaction partner of the 
ErbB2 receptor. Copine III interacts with ErbB2 in a Ca2+- and HRG-dependent manner and is 
required for tumor cell migration. Furthermore, Copine III levels were found to be upregulated 
in tissue microarrays of breast, ovarian and prostate tumor tissue as compared to normal tissue.  
Together, these findings imply a biological function for Copine III in cancer progression and 
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1 INTRODUCTION  
1.1 Cell signaling and cancer 
 
Each cell receives a plethora of external signals that it must integrate in order to initiate, 
maintain and attenuate cellular signaling pathways, thereby regulating such diverse processes 
as protein synthesis, cell growth, cell cycle progression and cell movement. Most cellular 
signaling pathways are involved in regulating several cellular functions, and in addition, can 
interact and cross-regulate other pathways thus generating a complex signaling network. 
Proper functioning of this network is essential for maintaining cell growth and homeostasis. 
Cancer cells are characterized by the acquisition of mutations leading to deregulated cell 
growth and homeostasis. In the past years it has become apparent that different types of 
cancer are characterized by the different mutations they acquire. Furthermore, the majority of 
cancers display disruption not only in one but several pathways, which results in the effects 
observed in cancer progression. The different alterations occurring in cancer can be grouped 
into six categories: self-sufficiency in growth signals, insensitivity to growth-inhibitory 
(antigrowth) signals, evasion of programmed cell death (apoptosis), limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis (Figure 1-1) (Hanahan 
and Weinberg, 2000). 
 
       (Hanahan and Weinberg, 2000) 
 
Figure 1-1 Acquired traits of cancer  
It was suggested that most, if not all, types of cancer have acquired the same set of 
capabilities during their development. 
 
Three of these traits, namely growth signal autonomy, insensitivity to antigrowth signals and 
resistance to apoptosis, lead to an uncoupling of intracellular signaling from extracellular cues. 
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The proteins that receive these extracellular signals and convert them into information to 
guide intracellular responses are designated transmembrane receptors. Therefore, signaling 
pathways downstream of transmembrane receptors should be studied carefully in order to 
elucidate, which functional mutations give rise to specific cancer traits.  
1.2 The ErbB family of RTKs 
 
Certain classes of signaling proteins, such as molecules governing extracellular growth, 
differentiation and developmental signals are targeted much more frequently by oncogenic 
mutations than others. Good examples for this phenomenon are the receptor tyrosine kinases 
(RTKs), a subclass of transmembrane receptors carrying an intrinsic, ligand-stimulated kinase 
activity (Blume-Jensen and Hunter, 2001).  
 
 
      (Blume-Jensen and Hunter, 2001) 
 
Figure 1-2 Human receptor tyrosine kinases 
Depicted are the 20 families of human receptor tyrosine kinases. The prototypic 
receptor for each family is indicated above the receptor and the known members are 
listed below. EGFR, epidermal growth factor receptor; InsR, insulin receptor; PDGFR, 
platelet-derived growth factor receptor; VEGFR; vascular endothelial growth factor 
receptor; FGFR, fibroblast growth factor receptor; KLG/CCK, colon carcinoma kinase; 
NGFR, nerve growth factor receptor; HGFR, hepatocyte growth factor receptor, EphR, 
ephrin receptor; Axl, a Tyro3 PTK; TIE, tyrosine kinase receptor in endothelial cells; RYK, 
receptor related to tyrosine kinases; DDR, discoidin domain receptor; Ret, rearranged 
during transfection; ROS, RPTK expressed in some epithelial cell types; LTK, leukocyte 
tyrosine kinase; ROR, receptor orphan; MuSK, muscle-specific kinase; LMR, Lemur. 
Other abbreviations: AB, acidic box; CadhD, cadherin-like domain; CRD, cysteine-rich 
domain; DiscD, discoidin-like domain; EGFD, epidermal growth factor-like domain; 
FNIII, fibronectin type III-like domain; IgD, immunoglobulin-like domain; KrinD, 
kringle-like domain; LRD, leucine-rich domain. The symbols α and β denote distinct 
subunits. Members in bold and italic type are implicated in human malignancies. An 
asterisk indicates lack of intrinsic kinase activity. 
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RTKs belong to a larger family consisting of > 90 genes encoding for protein tyrosine kinases in 
the human genome. Of these, 58 encode transmembrane RTKs, which are distributed among 
20 subfamilies (Figure 1-2).  
Subfamily I, also called the Epidermal Growth Factor (EGF/ErbB) family was originally named 
because of their homology to the erythroblastoma viral gene product v-erbB (Downward et al., 
1984). It encompasses four structurally related type I growth factor receptors: EGF receptor 
(ErbB1/HER1), ErbB2 (Neu/HER2), ErbB3 (HER3) and ErbB4 (HER4), as well as a number of soluble 
ligands, which bind to their cognate receptor (Yarden and Sliwkowski, 2001). 
All ErbBs have a common extracellular ligand-binding domain, a single membrane-spanning 
region, a cytoplasmic kinase domain and a C-terminal regulatory domain (Holbro et al., 2003b). 
Ligand binding induces receptor homo- and heterodimerization, which leads to the activation 
of their intrinsic kinase domain and auto- and transphosphorylation of specific tyrosine 
residues in their C-terminal intracellular domain (Schlessinger, 2000). These phosphorylated 
tyrosine residues act as docking sites for various adaptor molecules carrying Src-homology 2 
(SH2) or phosphotyrosine-binding (PTB) domains, which then in turn initiate downstream 
signaling (Olayioye et al., 2000).  
Under normal physiological conditions the activity of ErbBs is controlled by the temporal and 
spatial expression of their ligands. Thus, ErbB receptor activity in a resting, non-transformed 
cell is tightly controlled. However, in transformed cells these receptors are often mutated, 
structurally altered or overexpressed, making them potent oncogenes.  Over 30 RTKs have 
been implicated in human cancer, including ErbB2 and ErbB1, which are amplified, mutated or 
overexpressed in several prevalent cancers such as ovarian and non-small-cell lung cancers 
(Blume-Jensen and Hunter, 2001). Moreover, cancer patients, whose tumors have an alteration 
in either ErbB1 or ErbB2, tend to have a more aggressive disease associated with poor clinical 
outcome (Hynes and Stern, 1994).  
 
1.2.1 Evolution of the ErbB signaling network 
 
The ErbB family has developed from a single ligand/single receptor combination to a complex 
network of four receptors and multiple ligands throughout evolution. 
Both the nemotode Caenorhabditis elegans and the fruitfly Drosophila melanogaster have linear 
primordial versions of the ErbB signaling network, with one receptor and one ligand in C. 
elegans and one receptor and five ligands in D. melanogaster (Blume-Jensen and Hunter, 2001). 
 
In C. elegans the ErbB receptor homolog LET-23 and its ligand LIN-3 have a known role in vulval 
development. Vulval development is substrate dependent. The gonadal precursor cell secretes 
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LIN-3, which is sensed by LET-23 expressed on the six vulva precursor cells (VPCs). Thus, LET-23 
is involved in fate determination with regard to which VPC will differentiate into vulval tissue. 
This is underlined by the fact that loss-of-function of let-23 leads to a vulvaless phenotype and 
overexpression of the receptor induces a multivulva phenotype (Aroian and Sternberg, 1991). 
 
As in C. elegans the fruitfly D. melanogaster possesses a single ErbB2 homolog, DER, however, in 
contrast to C. elegans, it expresses five ligands: Spitz, Gurken, Keren, Vein and Argos. Receptor 
activation plays a role in successive cell fate determination events during oogenesis, 
embryogenesis, and the proliferation and differentiation of imaginal discs (Schweitzer and 
Shilo, 1997). The binding of Spitz, Gurken and Keren, all transforming growth factor α (TGFα) 
homologs, or Vein, a neuregulin-like ligand, leads to receptor activation. Contrary to this, Argos 
functions to inhibit DER activation by competing for binding to the other ligands. Recently, it 
was shown that Argos mediates inhibition by sequestering the other ligands (Klein et al., 2004; 
Klein et al., 2008).  
It is intriguing that D. melanogaster has such an inhibitory ligand, since no inhibitory ligand has 
been discovered in higher vertebrates. In higher eukaryotes the ErbB signaling network 
evolved into a richly interactive, multilayered network, in which combinatorial expression and 
activation of components permits context-specific biological responses throughout 
development and adulthood (Yarden and Sliwkowski, 2001). The higher complexity of the 
system, consisting of four receptors and a multitude of ligands, confers tight regulatory control 
and therefore minimizes the need for inhibitory ligands. 
 
1.3 The human ErbB receptor/ligand network 
 
As previously mentioned, the ErbB receptor/ligand system evolved from a linear pathway in C. 
elegans into a complex signaling network in higher eukaryotes. The human ErbB 
receptor/ligand signaling network consists of four receptors, ErbB1, ErbB2, ErbB3 and ErbB4 
and at least 12 ligands. One way of conferring context-specific responses of the cell to external 
stimuli is provided by the functional selectivity of the 11 ligands. Different ligands can 
stimulate divergent biological outcomes from the same receptor.   
All of the identified ErbB ligands belong to the EGF family of peptide growth factors and are 
divided into three groups depending on their affinity for one or more receptors (Riese and 
Stern, 1998). The first group binds ErbB1 and includes EGF, transforming growth factor α 
(TGFα), amphiregulin (AR) and epigen (EPG). Ligands that bind both ErbB1 and ErbB4 comprise 
the second group, which contains betacellulin (BTC), heparin- binding EGF like growth factor 
(HB-EGF) and epiregulin (EPR). The third and final group consists of the neuregulins (NRGs), also 
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referred to as heregulins, which are again further subdivided into two groups: NRG-1 and NRG-
2 that can bind to both ErbB1 and ErbB3; and NRG-3 and NRG-4 that are specific for ErbB4 
(Olayioye et al., 2000). Of note, none of these ligands binds ErbB2. Yet, despite having no 
ligand, the ErbB2 receptor is able to dimerize with all of the other receptors of the family and 
plays a pivotal role in cancer progression (Holbro et al., 2003a). This aspect will be addressed in 
later sections. 
 
1.3.1 Ligand induced receptor activation 
 
Ligands can be produced both in an autocrine, where the cell produces its own growth factors, 
and paracrine manner, in which growth factors are released from surrounding cells. Autocrine 
ligands are produced as transmembrane proteins that are then cleaved by cell surface 
proteases to release the mature growth factor. The process by which the membrane-anchored 
forms (pro-forms) of the ligand are cleaved is called ectodomain shedding. The main enzymes 
performing this task are members of the family of zinc binding matrix metalloproteinases 
(MMPs) and the A disintegrin–like and metalloproteinase-containing (ADAM) family. 
Ectodomain shedding is a crucial step in controlling ligand availability and receptor activation 
(Higashiyama et al., 2008). This is underlined by the fact that several members of the ADAMs 
family, including ADAM8, ADAM9, ADAM10, ADAM12, ADAM15, ADAM17, ADAM19, ADAM28, 
ADAMTS1, ADAMTS4 and ADAMTS5, have been associated with various types of cancer (breast, 
uterus, prostate, gastric, etc.) (Higashiyama et al., 2008; Hynes and Schlange, 2006). ADAMs are 
activated by a variety of stimuli, like growth factor and cytokine signaling, or PKC activation, 
which induce ectodomain shedding (Figure 1-3). 
 




(adapted from Higashiyama et al., 2008) 
 
Figure 1-3 Activation of ADAMs, ectodomain-shedding of EGF ligands and 
receptor activation  
Disintegrin and metalloprotease (ADAM) proteins are activated by various stimuli 
including wounding, ion influx, G-protein coupled receptor (GPCR) signaling, growth 
factor and cytokine signaling, protein kinase C (PKC) activation, and binding of 
cytoplasmic interactive proteins. EGFR ligand molecules are proteolytically cleaved by 
specific metalloprotease-activity of ADAMs, resulting in the production of soluble 
ligands and stimulation of EGFR in autocrine and paracrine manners. AngII, 
angiotensin II; Cyts, cytokines; GFs, growth factors; HB-EGF, Heparin-binding 
epidermal growth 
factor carboxy-terminal fragment; LPA, lysophosphatidic acid; MAPK, mitogen-
activated protein kinase; NRG, neuregulin; PI3K, phosphatidylinositol 3-kinase; PKC, 
protein kinase C; ROS, reactive oxygen species; TGF-α, transforming growth factor-α; 
TPA, 12-O-tetradecanoylphorbol-13-acetate. 
  
Each of the mature peptide growth factors is characterized by a consensus sequence of six 
spatially conserved cysteine residues that form three intramolecular disulfide bridges. This 
consensus sequence is known as the EGF motif and is crucial for binding to members of the 
ErbB family of RTKs. EGF ligands also contain additional structural motifs such as 
immunoglobulin-like domains, heparin-binding sites and glycosylation sites (Harris et al., 2003). 
In addition to ectodomain shedding, juxtacrine stimulation of growth factors has been 
described in the case of uncleaved HB-EGF, which was able to stimulate ErbB1 in adjacent cells 
(Higashiyama et al., 1995). 
All four ErbB receptors are single-chain glycoproteins composed of an extracellular ligand-
binding domain, a single transmembrane-spanning domain and a cytoplasmic domain 
containing the tyrosine kinase domain and a C-terminal regulatory region (Burgess et al., 2003).  
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The extracellular domain is heavily glycosylated and is composed of four distinct protein 
domains: two homologous large (L) domains and two cysteine-rich (CR) domains, which occur 
in the order L1-CR1-L2-CR2 (Ward et al., 1995).  These domains can alternatively be named I-II-
III-IV (Figure 1-4). Ligand binding occurs through domains I and III. Domain II contains the so-
called dimerization arm, a prominent loop that reaches across the interface between two 
receptors to interact with its counterpart in the dimerization partner (Burgess et al., 2003).  
The ErbB receptors can exist in a closed inhibited or an open active conformation (Moasser, 
2007). Crystal structures of ErbB1 (Ferguson et al., 2003) and ErbB3 (Cho et al., 2003) showed 
that these receptors form a “tethered” conformation, which is stabilized by an interaction of 
the two CR domains (II and IV) and restrains the dimerization arm of domain II and substantial 
domain rearrangement is required to switch between the closed and open conformation. A 
receptor in the tethered conformation cannot dimerize with another receptor.   Moreover, the 
two ligand binding surfaces on domain I and III are too far apart for a single ligand to bind to 
both simultaneously (Burgess et al., 2003) and so this tethered conformation confers only low 
ligand affinity. When a ligand does bind to the receptor, both domain I and III perform a ~130° 
counterclockwise rotation around the x/y axis in addition to a ~20Å translation along the z-axis. 
This rearrangement gives rise to an extended or open active conformation, in which the 
dimerization arm is exposed and able to form inter- rather than intramolecular interactions. 
Only the extended configuration of the receptor is capable of both high affinity ligand binding 
and efficient dimerization (Burgess et al., 2003). ErbB2 plays a pivotal role in the family, because, 
unlike the other receptors, it does not exist in a tethered conformation, but is always found in 
the extended active conformation (Figure 1-4). 
 





(adapted from Burgess et al., 2003) 
 
Figure 1-4 Schematic illustration of ligand-induced conformational changes in 
sEGFR 
A transition between two sEGFR structures is shown in both ribbons and cartoon 
representation. The unactivated (tethered) sEGFR structure (Ferguson et al., 2003) is 
shown on the left. A model of the EGF-induced dimer is shown on the right. This 
model uses the coordinates of (Ogiso et al., 2002), which lacked 5 of the 7 disulfide-
bonded modules of domain IV. The missing modules of domain IV have been added 
using the structure of unactivated sEGFR, and assuming that the domain III/IV 
relationship in sEGFR is unaltered upon ligand binding. L domains in the receptor 
(domains I and III) are colored red, and CR domains (domains II and IV) are green. 
Ligand is colored cyan. Domains I and III are distinguished from one another by the 
addition of gray to the outer surfaces of strands and helices. The two subunits in the 
dimer are distinguished by the fogging of the right-hand dimerization partner. 
Individual domains are labeled. The mutual “hooking” of the two domain II 
dimerization arms across the dimer interface can be observed in the center of the 
structure. The additional domain II contacts across the interface, at module 2 and 
module 6 are marked with asterisks. The speculated position of the plasma membrane 
is depicted as a gray bar. EGF binding is proposed to induce a 130° rotation of a rigid 
body containing domains I and II, about the axis represented by a filled black circle (at 
the domain II/III junction). This exposes the dimerization arm and allows dimerization 
of sEGFR, as depicted on the right. 
 
 
Dimerization induces activation of the intracellular kinase domain and subsequent 
transphosphorlyation of specific tyrosine residues in the C-terminal regulatory region. 
Dimerization partner selection appears to be a key determinant for the signaling activity of the 
ErbB receptors. They show a distinct hierarchical order for dimerization, preferring 
heterodimers over homodimers (Moasser, 2007). Under normal circumstances, neither ErbB2 
nor ErbB3 homodimers support linear signaling as ErbB2 does not bind any ligand and ErbB3 
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has an impaired kinase domain. However, when overexpressed, ErbB2 can form potent 
homodimers, and is the preferred heterodimerization partner of the other receptors (Beerli and 
Hynes, 1996). These ErbB2-containing heterodimers are the most oncopotent dimers (Harari 
and Yarden, 2000).  
 
 
(Hynes and MacDonald, 2009) 
 
Figure 1-5 The  human ErbB receptor/ligand family  
There are four members of the ErbB family of RTKs, EGFR (1), ErbB2 (2), ErbB3 (3), and 
ErbB4 (4). Upon ligand binding the receptors undergo a conformational change 
allowing for the formation of homodimers and heterodimers. The receptors then 
become phosphorylated on tyrosine residues within their cytoplasmic kinase domain, 
initiating downstream signaling. Four groups of ErbB ligands have been described on 
the basis of their receptor specificity. The first group binds EGFR exclusively and 
includes EGF, TGFa, AR, and EPG. Members of the second group (BTC, HB-EGF, and 
EPR) exhibit dual specificity for EGFR and ErbB3. The neuregulins make up the third 
and fourth groups on the basis of their ability to bind both ErbB3 and ErbB4 (NRG-1 
and NRG-2), or ErbB4 alone (NRG-3 and NRG-4). ErbB2 does not bind any of the ErbB 
ligands; however, its open conformation makes it the preferred dimerization partner 
for all of the other ErbB receptors. 
 
1.3.2 Signal transduction of ErbB receptors 
 
ErbB ligands influence downstream signaling diversity by exhibiting differential binding 
affinities, signal strengths and duration, and receptor specificities. Temporally and spatially 
controlled ligand binding first induces homo- and heterodimerization of ErbB receptors, a 
process which results in activation of their intrinsic kinase domains and subsequent auto- and 
transphosphorylation of specific tyrosine residues at their C-terminal regulatory region. A 
model for the process of kinase activation following receptor dimerization has been proposed 
(Zhang et al., 2006). It suggests that the ErbB1 kinase domain is intrinsically autoinhibited. 
Upon dimerization of two receptors, the C-lobe of one receptor`s kinase domain allosterically 
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activates the kinase module of the other receptor by contacting its N-lobe. This interaction 
repositions the activation loop in a conformation which facilitates catalysis (Zhang et al., 2006). 
The mechanism whereby ErbB2 is phosphorylated whilst partnered with the kinase inactive 
ErbB3 receptor remains poorly understood. However, one model predicts that activation of 
ErbB2 is possible due to an interaction between the C-lobe of ErbB3 and the N-lobe of ErbB2 
(Zhang et al., 2006).  
Tyrosine phosphorylation (pTyr) of the receptors results in the formation of docking sites for 
adaptor proteins containing either a phosphotyrosine binding (PTB) or Src-homology 2 (SH2) 
domains, with which they bind to pTyr (Olayioye et al., 2000). Each ErbB receptor displays a 
unique pattern of C-terminal autophosphorylation sites and thus recruits specific adapter 
proteins providing again means of selectivity and diversity for the system.  
Several pathways crucial for cellular functioning are found to be activated downstream of the 
ErbB receptors. The mitogen-activated protein kinase (MAPK) pathway can be activated by all 
members of the ErbB family, via the adaptors Grb2 and Shc. A second important signaling 
pathway, most often selectively activated by ErbB3, is the phosphatidylinositol 3-kinase (PI3K) 
pathway. Though either ErbB3 or ErbB4 can bind directly to the p85 subunit of PI3K to induce 
signaling, ErbB1 has been shown to mediate activation of this pathway via its interaction with 
Grb2, which recruits Gab1 and thereby couples the receptor to the PI3K pathway (Hynes and 
Lane, 2005).  Despite sharing some pathways, each receptor is also coupled to a distinct set of 
signaling proteins that allows them to activate discrete downstream targets (Yarden and 
Sliwkowski, 2001). For example, ErbB1 couples to the ubiquitin ligase Cbl, ErbB2 to PLCγ, Grb2 
and the Ras-specific GTPase-activating protein (Gap), and ErbB3 to Shc and Grb7 (Yarden and 
Sliwkowski, 2001).  
 




(Yarden and Sliwkowski, 2001) 
 
Figure 1-6 The ErbB signaling network  
a | Ligands and the ten dimeric receptor combinations comprise the input layer. 
Numbers in each ligand block indicate the respective high-affinity ErbB receptors. For 
simplicity, specificities of receptor binding are shown only for epidermal growth factor 
(EGF) and neuregulin 4 (NRG4). ErbB2 binds no ligand with high affinity, and ErbB3 
homodimers are catalytically inactive (crossed kinase domains). Trans-regulation by G-
protein-coupled receptors (such as those for lysophosphatidic acid (LPA), thrombin 
and endothelin (ET)), and cytokine receptors is shown by wide arrows. b | Signaling to 
the adaptor/enzyme layer is shown only for two receptor dimers: the weakly 
mitogenic ErbB1 homodimer, and the relatively potent ErbB2–ErbB3 heterodimer. 
Only some of the pathways and transcription factors are represented in this layer. c | 
How they are translated to specific types of output is poorly understood at present. 
(Abl, a proto-oncogenic tyrosine kinase whose targets are poorly understood; Akt, a 
serine/threonine kinase that phosphorylates the anti-apoptotic protein Bad and the 
ribosomal S6 kinase (S6K); GAP, GTPase activating protein; HB-EGF, heparin-binding 
EGF; Jak, janus kinase; PKC, protein kinase C; PLCγ, phospholipase Cγ; Shp2, Src 
homology domain-2-containing protein tyrosine phosphatase 2; Stat, signal 
transducer and activator of transcription; RAF–MEK–MAPK and PAK–JNKK–JNK, two 
cascades of serine/threonine kinases that regulate the activity of a number of 
transcription factors.) 
 
Signaling cascades activating MAPK, protein kinase C (PKC) or the PI3K pathway translate 
signals directly into the nucleus. There, distinct transcriptional programs are initiated by 
transcription factors including not only some proto-oncogenes like fos, jun and myc, several of 
the STATS (signal transducers and activators of transcription) family members, but also a family 
of zinc-finger-containing transcription factors such as Sp1, Egr1 or the Ets family member GA-
binding protein (GABP). In this way signaling through the ErbB receptors can induce a variety 
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of cellular phenotypes such as cell division and migration, adhesion, differentiation and 
apoptosis (Figure 1-6). 
In addition to multiple ligands, receptors and downstream effectors, the ErbB signaling 
network is made more complex still by combinatorial interactions with other receptor families 
and their downstream pathways. Thus, given the importance of these receptors for proper cell 
functioning, the kinetics of their signaling needs to be tightly controlled. In principal, this is 
controlled by ligand-mediated receptor endocytosis, a process whose kinetics also depends 
heavily on the receptor composition (Yarden and Sliwkowski, 2001). 
 
1.3.3 Transactivation of ErbB receptors  
 
Transactivation of the receptors by other signaling molecules can happen both outside of the 
cell by the production of soluble ligands, as well as inside the cell through receptor 
phosphorylation (Figure 1-7).  
The production of soluble EGF ligands through ectodomain shedding by ADAMs was first 
shown following the activation of G-protein-coupled receptors (GPCRs). The process by which 
GPCR activation causes ErbB1 activation is termed ErbB1 transactivation (Hynes and Lane, 
2005).  More recently, other pathways capable of transactivating ErbB receptors through the 
production of extracellular ligands have been described: the binding of Wnt to its seven-pass 
membrane receptor frizzled leads to the transactivation of ErbB1 in a process similar to that of 
GPCRs (Civenni et al., 2003; Schlange et al., 2007). Furthermore, oestradiol (E2) binding to the 
plasma-membrane-associated oestrogen receptor (ER) has also been shown to transactivate 
ErbB1 (Razandi et al., 2003). Since many GPCR agonists activate PKC and Src, these kinases 
might also play a role in ErbB transactivation (Hynes and Lane, 2005). It has been shown that 
PKCδ phosphorylates ADAM9, resulting in HB-EGF processing (Izumi et al., 1998). The 
involvement of Src family members in ErbB transactivation through ectodomain shedding has 
not yet been shown. However, it is known that Src can phosphorylate ErbB1 intracellularly 
(Biscardi et al., 1999). Moreover, other kinases and receptors have been shown to 
phosphorylate ErbB receptors: Janus tyrosine kinase 2 (Jak2) was shown to phosphorylate 
ErbB1 and ErbB2 once activated (Yamauchi et al., 1997). Several studies have shown that 
integrins are capable of transactivating ErbB receptors: α6β4 integrin was shown to associate 
with ErbB2 at the cell surface and to regulate ErbB2 translation and ErbB1 transactivation in 
vitro (Yoon et al., 2006). Even more compelling was the finding that β4 integrin also regulates 
ErbB2 signaling in vivo. A knockdown of β4 integrin suppresses mammary tumor onset and 
invasive growth of ErbB2-expressing tumors (Guo and Giancotti, 2004).  
 




(Yarden and Sliwkowski, 2001) 
 
Figure 1-7 Crosstalk between the ErbB network and other signaling pathways  
G-protein-coupled receptors (GPCRs) such as those for lysophosphatidic acid (LPA), 
thrombin and endothelin (ET) can have positive effects on ErbB signaling through two 
mechanisms. First, through a poorly defined mechanism, they can activate matrix 
metalloproteinases (MMPs), which cleave membrane-tethered ErbB ligands (such as 
heparin binding EGF-like factor, HB-EGF), thereby freeing them to bind to ErbBs. 
Second, GPCRs indirectly activate Src (perhaps via PTyrk2), which phosphorylates the 
intracellular domains of ErbBs on tyrosine residues. Steroid hormones can have a 
positive effect on ErbB signaling by activating the transcription of genes encoding 
ErbB ligands. Finally, ErbB activation can activate a positive feedback loop through the 
Ras–MAPK (mitogen-activated protein kinase) pathway, which also activates 
transcription of ErbB ligand genes. 
 
 
In summary, the ErbB receptor/ligand system is a complex signaling network that has become 
more complex and specialized throughout evolution, with divergent signaling inputs and 
outcomes. Control mechanisms are installed in both a temporal and spatial manner i.e. 
through the regulation of ligand expression. However, the ErbB2 signaling network does not 
function on its own, but receives activating and repressing signals from other pathways itself.  
It has been shown that signaling through ErbBs is frequently impaired in development and 
disease and thus this network has become a major target for therapy. However, considering 
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1.3.4 Endocytosis, sorting and recycling of ErbBs 
 
Endocytosis and thus degradation of the ErbB receptors is a major negative regulatory 
feedback mechanism that controls the intensity and duration of receptor signaling. This is 
mostly true for ErbB1, since endocytosis and degradation of ErbB2, ErbB3 and Erbb4 is much 
less efficient (Sorkin and Goh, 2009). Yet, ligand induced internalization of all the ErbB 
receptors can also lead to their sorting into endosomal complexes were they remain in active 
signaling complexes. Thus, depending on the context, endocytosis can be regarded as both a 
negative and a positive feedback loop of ErbB signaling (Sorkin and Goh, 2009). In the absence 
of activation, ErbB1 is constitutively internalized at a rate comparable to the rate of basal 
membrane recycling. After internalization, inactive ErbB receptors are mainly recycled back to 
the surface. Additionally, it was proposed to that both ErbB1 and ErbB2 can be translocated 
from the cell surface to the nucleus. 
Activation of the receptor by ligand binding leads to an acceleration of receptor internalization. 
EGF-ErbB1 complexes are primarily internalized via clathrin coated pits. However, other 
mechanisms of ErbB1 internalization have been detected as well, including EGF-induced 
pinocytosis and internalization via the vesicular-tubular endocytosis compartment (Haigler et 
al., 1979; Orth et al., 2006).  Studying the endocytosis of ErbB2 is difficult, since ErbB2 has no 
natural ligand. Despite this, it was found that in some cases overexpression of ErbB2 prevented 
ErbB1 internalization and, in others, re-routed ErbB1 from degradation to the recycling 
pathway. Yet, ErbB2 clearly has a lower potency to be ubiquitinated and targeted to the 
lysosome than ErbB1 (Sorkin and Goh, 2009).  
Neuregulin induced internalization of ErbB3 and ErbB4 has been observed in many cell types, 
though their rates of degradation are much slower as compared to ErbB1. Trafficking of both 
receptors has been shown to be regulated by ubiquitination (Sorkin and Goh, 2009). 
The mechanism of internalization of ErbB2, ErbB3 and Erbb4 is poorly understood and not well 
studied. Additional research, perhaps following up on initial observations from the studies on 
ErbB1 endocytosis, needs to be done to further our knowledge of this complex, but important, 
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1.4 ErbB receptors in development and disease 
 
The ErbB network is a key developmental signaling pathway throughout evolution. Research 
using knockout and transgenic mice is helping to clarify the functions of individual ErbB 
receptors and specific ligands in mammalian development (Yarden and Sliwkowski, 2001).  
Null mutations of ErbB1 are lethal prenatally or shortly postnatally and it was suggested that 
ErbB1 is required fro the promotion of proliferation and differentiation of the epithelial 
component of skin, lung, pancreas and the gastrointestinal tract. Similarly, mice lacking the 
ErbB ligand TGFα show abnormal skin, hair and eye development. However, unlike ErbB1 
knockout mice, which undergo massive apoptosis in cortical and thalamic brain regions, these 
mice show no brain abnormalities (Olayioye et al., 2000; Yarden and Sliwkowski, 2001) 
ErbB2 null mice die midgestation, a phenotype shared by ErbB4 knockout mice (Gassmann et 
al., 1995, Olayioye, 2000 #7; Olayioye et al., 2000). This is due to trabecular malformations of the 
heart, implying that ErbB2 and Erbb4 are essential for embryonic heart development. The 
important role of ErbB2 in the heart will be discussed further when discussing ErbB-targeted 
therapies. 
Most ErbB3 knockout mice die by E13.5, displaying normal heart trabeculation, but defective 
valve formation. Moreover, these animals show a generalized neural crest defect and lack 
Schwann cell precursors (Olayioye et al., 2000). 
Since most ErbB receptor null mutations are lethal, it is difficult so study their role in adult 
development. In order to do this, conditional, organ-specific knockout mice have been 
generated. The most interesting organ, in which to study ErbB receptors in the adult, is the 
mammary gland as it undergoes most of its proliferation and differentiation postnatally 
(Olayioye et al., 2000). All four ErbB receptors are expressed in cell type- and developmental 
stage-specific patterns (Schroeder and Lee, 1998). ErbB1 is expressed through all mammary 
gland developmental stages, and a mutation in the kinase domain leads to defective ductal 
growth. Similarly, ErbB2 is expressed throughout all developmental stages, yet dominant-
negative (DN) ErbB2 mice display normal ductal growth. However, as with ErbB4 DN mice, 
these mice exhibit an impairment in lactation. 
Collectively, these studies reveal the importance of the ErbB network during development, 
especially in the mammary gland. It is perhaps not surprising, given their requirement for 
proper cellular growth and differentiation that deregulation of the ErbB network in the 
mammary gland results in cancer.  
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1.5 ErbB receptors in cancer – aberrant signaling, treatment 
and resistance 
 
The ErbB signaling network has been implicated in the development of many human cancers. 
In many cancer cell types the ErbB pathway becomes hyperactivated by a range of 
mechanisms such as kinase domain mutations, in-frame deletions, total deletion of the 
extracellular domain or  ligand or receptor overproduction, all of which lead to a constitutive 
activation of the system (Hynes and MacDonald, 2009; Yarden and Sliwkowski, 2001). Receptor 
overexpression is either due to gene amplification, increased transcription or increased 
translation.  
In-frame deletions in the extracellular domain of ErbB1, the most frequent being a deletion of 
the dimerization arm termed EGFR vIII, are often found in glioblastoma and lead to constitutive 
receptor activation and defective degradation (Jorissen et al., 2003). Up to 20% of glioblastoma 
show ErbB1 rearrangements and up to 40% of glioma tumours overexpress the receptor (Citri 
and Yarden, 2006). Furthermore, overexpression of ErbB1 is seen in squamous cell carcinomas 
of head and neck (SCCHN), non-small cell lung cancers (NSCLC), ovarian and other tumors 
(Holbro and Hynes, 2004). However, receptor overexpression on its own is insufficient to 
induce its constitutive activation and in most primary cancers, co-expression of a ligand is seen 
(Holbro and Hynes, 2004). Both receptor overexpression and ligand co-expression in breast and 
ovarian cancers have been associated with poor patient prognosis (Citri and Yarden, 2006). 
Thus, the parallel analysis of both ErbB1 and its ligands provides a strong predictive tool for 
patient survival in several types of human cancer (reviewed in Nicholson et al., 2001).  
ErbB2 has been shown to be upregulated in many cancers due to gene amplification and 
overexpression, which leads to constitutive signaling. Overexpression of ErbB2 is seen in 
breast, lung, pancreas, colon, endometrium and ovarian cancers. Furthermore, in breast cancer, 
where 15-30% of all cases exhibit an overexpression, and in ovarian cancer, ErbB2 is considered 
to be a negative prognostic marker (Ross and Fletcher, 1998).  
The catalytically inactive ErbB3 receptor is expressed in several cancer subtypes. However, 
there is no evidence to suggest that gene amplification or overexpression of ErbB3 plays a role 
in tumor progression. Rather, ErbB3 plays its pivotal role in cancer progression as the preferred 
dimerization partner of the other family members, especially ErbB2, and links to the pro-
survival PI3K pathway.  As with ErbB3, ErbB4 has been shown to be upregulated in different 
types of cancer, however, relatively little is known about the general or specific roles of ErbB4 
in the development of human tumors. 
Since the ErbB receptors have been shown to be aberrantly regulated in a wide range of 
human tumors, they are excellent targets for selective therapy (Hynes and Lane, 2005).  Two 
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major therapeutic strategies to target ErbB receptors are currently in the final stages of drug 
development or are being used in the clinic, namely small molecule tyrosine kinase inhibitors 
(TKIs) and monoclonal antibodies targeting the extracellular domain of the receptors (Strome 
et al., 2007) (Figure 1-8). TKIs usually bind to the ATP-binding pocket of the intracellular kinase 
domain thereby inhibiting kinase activity. In contrast to TKIs, targeted antibodies bind the 
extracellular domain of the receptor. Several mechanisms for their modes of action have been 
proposed, though why they are efficacious is not clearly understood. Several of these 
treatments, their proposed modes of action and their clinical status are discussed below.  
 
Cetuximab or Erbitux, a chimeric monoclonal antibody (mAb), targets the extracellular domain 
of EGFR thereby preventing ligand binding, receptor activation and subsequent signal 
transduction. Furthermore, there is evidence to suggest that Cetuximab promotes receptor 
internalization (Baselga, 2001). It is approved for the treatment of colorectal cancer and clinical 
trials are ongoing to test its efficacy in the treatment of pancreatic cancer, SCCHN and NSCLC 
(Hynes and Lane, 2005).  
Considering the phenotype observed in ErbB1 knockout mice, it is not surprising that the 
common side effects of ErbB1 targeted therapies include rash, acnetic skin reactions and 
diarrhea (Baselga et al., 2002).  Interestingly, cutanous skin rash has been proposed as a 
surrogate marker of clinical benefit for many EGFR-targeted agents (Hynes and Lane, 2005).  
Trastuzumab (Herceptin) and Pertuzumab (Omnitarg) are both humanized mAbs targeting the 
ErbB2 receptor, however, their mode of action is different: Trastuzumab, which is used for the 
treatment of ErbB2 overexpressing breast cancer, binds domain IV of ErbB2 resulting in 
downregulation of ErbB2 levels and thus ErbB2 mediated signaling pathways. In addition, it 
blocks MMP-mediated ErbB2 ectodomain shedding, which would otherwise mediate 
constitutive signaling.  It was observed in the clinic that some patients treated with 
Trastuzumab presented cardiac phenotypes, including cardiomyopathy, congestive heart 
failure and a decreased left vent ejection fraction (Hynes and Lane, 2005), most probably due to 
the  important role of ErbB2 in the heart. 
Pertuzumab on the other hand, binds domain II of ErbB2 thereby preventing ligand-induced 
receptor dimerization. This difference could explain why Pertuzumab is effective for the 
treatment of tumors expressing low levels of ErbB2, whereas Trastuzumab is not (Agus et al., 
2002). Clinical trials to test the efficacy of Pertuzumab in ovarian, breast, prostate and NSCL 
cancer are ongoing.  
 
It has been observed that only approximately one-third of all ErbB2-overexpressing breast 
cancer patients respond to Trastuzumab (reviewed in Hynes and Lane, 2005). This is an 
indication that many tumors acquire or have de novo resistance to Trastuzumab, an issue that 
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has been analyzed in several studies. Many of these provide evidence that modulation of other 
pathways compensates for the blockade of ErbB2, activating the PI3K pathway and 
contributing to resistance. For example, the Met receptor is rapidly upregulated in cells treated 
with Trastuzumab leading to activated PI3K signaling (Shattuck et al., 2008) and activation of 
the insulin-like growth factor 1 receptor (IGF-IR) renders Trastuzumab-sensitive cells resistant 
to the antibody, an effect which was again linked to the PI3K pathways (Lu et al., 2001, Lu, 2004 
#857). More importantly, it was shown that activating mutations of PIK3CA, the gene encoding 
the PI3K p110α catalytic subunit, as well as decreased expression of PTEN, the phosphatase 
that dephosphorylates PIP3,  thus attenuating PI3K signaling, are very frequent in breast cancer 
, and serve as markers for poor response to Trastuzumab. Encouragingly, a recent study 
showed that this resistance can be overcome by the addition of selective PI3K inhibitors 
targeting the p110 subunits. In vitro studies proved that Trastuzumab together with GDC-0941, 
a selective p110 inhibitor, produces a synergistic effect and cell death is increased (Junttila et 
al., 2009). 
Recently, it was demonstrated that the mechanism underlying therapeutic resistance depends 
on the nature of the ErbB2/ErbB3 complexes at the cells surface. Trastuzumab destabilizes 
constitutive ligand-independent ErbB2/ErbB3 complexes, which exists due to ErbB2 
overexpression, uncoupling ErbB3 from ErbB2 and thus blocking downstream PI3K signaling.  
However, these complexes are structurally distinct from the ligand-dependent Trastuzumab-
insensitive ErbB2/ErbB3 complexes, which signal even in the absence of ErbB2 overexpression. 
Whether these different complexes also activate distinct downstream signaling pathways has 










(Citri and Yarden, 2006) 
 
Figure 1-8 Targeting the ErbB signaling network in cancer 
Several monoclonal antibodies as well as small-molecule tyrosine kinase inhibitors 
(TKIs) have been developed to target the ErbB signaling network in cancer. They 
include the antibodies Erbitux (Cetuximab) targeting EFGR for treatment if colorectal 
cancer, Trastuzumab (Herceptin) targeting ErbB2 for treatment of breast cancer and 
Pertuzumab (Omnitarg), which prevents ErbB2 from dimerizing with another receptor.  
Small molecule TKIs include two EGFR specific drugs, Gefitinib (Iressa) and Erlotinib 
(Tarceva), which are effect against tumors with hyperactive ERBB1 mutants and are 
used for the treatment of non-small-cell-lung cancers. Furthermore, the dual-
specificity inhibitor Lapatinib targets both EGFR and ErbB2 and the HSP90 inhibitor 
17-AAG (17-N-allylamino-17-demetoxygeldamycin) aims at the dissociation of HSP90 
from the receptor thereby targeting the receptor for degradation.  
 
Apart from monoclonal antibodies, small-molecule tyrosine kinase inhibitors (TKIs) have been, 
and are still, under development for the targeted treatment of cancer. Both Gefitinib (Iressa) 
and Erlotinib (Traceva) are TKIs targeting ErbB1 that have been approved for use in NSCLC after 
failure on other available treatments. Both have been shown to be effective against tumors 
that express catalytically hyperactive ErbB1 mutants.  Even so, resistance to TKIs has also 
rapidly emerged as a significant clinical problem (Citri and Yarden, 2006). Similar to resistance 
to antibody therapies, tumors resistant to TKIs show an upregulation of other pathways or 
pathway components, leading to active signaling, mainly through the PI3K and MAPK pathway 
(Hynes and MacDonald, 2009). Compensatory signaling to PI3K via IGF-IR, as well as increased 
binding of the IRS-1 scaffold protein to the receptor, has been observed in Gefitinib-resistant 
NSCLC (Buck et al., 2008; Guix et al., 2008). 
Altogether, it seems that the PI3K pathway plays an important role in tumors with ErbB 
receptor mutation (Hynes and MacDonald, 2009). Furthermore, although many targeted 
approaches are being tested and are already approved for the clinic, resistance to these 
therapies is inevitable. Future approaches to cancer treatment will have to involve the accurate 
prediction of which patients will benefit from a given treatment and  to not only to develop 
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accurate predictors for the response to ErbB targeted therapies, but also to use combinations 
of known targeted therapies, like it was shown by the co-administration of  Trastuzumab and 
the p110α inhibitor GDC-0941 (Junttila et al., 2009).  
 
1.5.1 ErbB2 in breast cancer 
 
ErbB2 is amplified in 15-30% of all breast cancers and serves as a prognostic indicator of poor 
outcome (Slamon et al., 1987); (Ross and Fletcher, 1998). Although ErbB2 amplification is best 
studied in breast cancer, it has also been reported in other cancer types, including gastric, 
esophageal and endometrial cancers, where it is also associated with a poor prognosis. It has 
become increasingly apparent that ErbB2 plays a pivotal role within the family of ErbB 
receptors, as it is the preferred heterodimerization partner of all of the other receptors and 
when overexpressed, can become constitutively active. Thus it is not surprising that historically 
it has been the focus of attention for ErbB-directed targeted therapies. This chapter will focus 
on ErbB2 and its known functions in breast cancer.  
 
In 1985 two independent studies, performed in human and mouse systems, described EGFR-
related genes found to be amplified in breast cancer, namely HER2 and neu, a gene 
homologous to the v-ErbB (avian erythroblastosis virus) viral oncogene. It was quickly 
reconciled that these two genes were in fact homologues of one another (King et al., 1985; 
Schechter et al., 1985; Schechter et al., 1984; Slamon et al., 1987). Although the nomenclature 
was initially complex, with HER2 and neu used in the literature to refer to the human and 
rodent genes respectively, the field has slowly adopted the name ErbB2 for all species 
(Moasser, 2007).  
The ErbB2 receptor is widely expressed in normal human organs and tissues, including the 
ovarian epithelium, endometrium, heart, lung, prostate, kidney, pancreas, and liver. It encodes 
a 185 kDa orphan receptor tyrosine kinase for which no direct ligand has been identified. The 
ERBB2 oncogene is located on chromosome 17q12, a region frequently amplified in cancer. In 
breast cancer the amplified DNA fragment, or ErbB2 amplicon, covers a region of 
approximately 2Mb and includes 13 co-amplified genes, some or all of which may play a role in 
the phenotype and clinical characteristics of ERBB2-amplified tumors (Kauraniemi and 
Kallioniemi, 2006). 
The role of ErbB2 within the cellular network remained largely unknown until 1988, when for 
the first time ErbB1 heterodimerization with ErbB2 was shown to induce its transactivation 
(Stern and Kamps, 1988). The ErbB2 receptor can mediate the lateral signal transduction of all 
ErbB receptors (Hynes and Lane, 2005). Therefore, normal activation of ErbB2 is highly 
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dependent on the expression of other family members, for which it acts as the preferred 
heterodimeric partner (Graus-Porta et al., 1997). In fact, ErbB2 and ErbB3 have been established 
as obligate heterodimerization partners, since even chimeric kinase-active ErbB3 constructs fail 
to signal without hetero-partners suggesting that ErbB3 even lacks the ability to homodimerize 
(Moasser, 2007).  In this context the main function of ErbB3 is to couple active ErbB2 to the PI3K 
pathway (Holbro et al., 2003a).   Conversely, overexpression and/or mutation of ErbB2 lead to 
its constitutive activation as well as spontaneous dimerization and stabilization of the homo-
dimeric complex in a ligand-independent manner (Hynes and Stern, 1994).   
It is indisputable that both the human HER2 as well as the rodent neu have the ablility to 
transform cells (reviewed in Moasser, 2007). The transforming potential of the neu oncogene is 
due to a point mutation in the transmembrane domain (V664E), which promotes receptor 
dimerization and kinase activity.  Transgenic mouse models in which expression of the 
activated neu oncogene (neuT) is driven by the mouse mammary tumor virus promoter (MMTV-
neuT) exhibit multifocal adenocarcinoma formation (Muller et al., 1988).  The MMTV-neuT 
model has become the workhorse for the study of ErbB2 tumorigenesis in vivo (Moasser, 2007), 
however, direct translation of the information gained using this model to the human disease 
may be limited, as in contrast to rodent ErbB2, overexpression of human ErbB2 appears to be 
sufficient for transformation. Although mutations in human HER2 have been identified, human 
breast cancer is most often characterized by an overexpression of wildtype ErbB2.  
Amplification of ErbB2 appears to be an early event in human breast cancer as it is seen in 
nearly half of all in situ ductal carcinomas.  Its status is also maintained during the transition to 
invasive disease, as well as in nodal and distal metastases (Park et al., 2006).  Human ErbB2 
amplified breast cancers possess biological characteristics that distinguish them from other 
types of breast cancer. These include increased sensitivity to certain cytotoxic 
chemotherapeutic agents, resistance to endocrine therapies and an increased propensity to 
metastasize to the brain (Gabos et al., 2006; Ross et al., 2003). 
As discussed previously, of the four ErbB family members, ErbB2 is the least susceptible to 
inactivation and when recruited into heterodimers, prolongs the signaling activity of its 
dimerization partner as well. Thus, ErbB2 overexpressing cells sustain downstream signaling 
significantly longer than those that exhibit low ErbB2 expression (Karunagaran et al., 1996). 
Five major ErbB2 autophosphorylation sites have been identified and mapped (Hazan et al., 
1990): Tyr1023/1028, Tyr1139/1144, Tyr1196/1201, Tyr1222/1227 and Tyr1248/1253 
(human/rat) referred to herein as YA, YB, YC, YD and YE, respectively.   
Mutation of any single pTyr site had minimal effect on the transformation potential of ErbB2 in 
focus formation assays, however despite this, it was shown that the YA site single add-back 
interferes with the transforming potential and is putatively a negative regulatory site, and sites 
YB through YE independently drive transformation monitored by colony formation in soft agar 
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(Dankort et al., 1997). The transforming potential of YB, YD and YE single add-backs is 
susceptible to the Ras inhibitor Rap-1A a, whereas the YC single add-back mutant transforming 
potential is resistant. This is due to the binding of Crk to phosphorylated YC, which recruits the 
C3G exchange factor that in turn can activate Erk kinases in a Ras-independent fashion, hence 
making the receptor signaling Ras-independent (Dankort et al., 2001b). 
Through its five phosphorylation sites the ErbB2 receptor links to a plethora of signaling 
pathways including PLCγ, PI3K and MAPK.  Indeed, the MAPK pathway effectors Grb2 and Shc 
have both been shown to bind to various autophosphorylation sites of ErbB2. Moreover, 
recently a novel factor, which binds to the pTyrD site of ErbB2 and was given the name Memo 
for Mediator of ErbB2-driven cell motility, was identified.  Both Memo and PLCγ, which also 
binds to pTyrC, have been shown to play a role in ErbB2-dependent cell migration (Marone et 
al., 2004; Meira et al., 2009).  
 
Furthermore, it was demonstrated that the individual ErbB2 phosphorylation sites play distinct 
roles in tumorigenesis in vivo: Transgenic mice overexpressing the constitutively active Neu 
receptor carrying only a single phosphorylation site in the mammary gland develop metastatic 
mammary tumors when carrying the YB, YC, YD and YE sites, respectively. Out of these the YC-, 
YD-, and YE-derived tumors show similar pathologic and transcriptional features and both the 
YC and YE tumors activate the MAPK and the PI3K pathway. Furthermore, it was observed that 
YE-derived tumors show a decreased expression of MMPs (Schade et al., 2007). In contrast to 
that, both Neu-YB and-YD overexpressing lines developed lung metastases, however, the YB 
lines at a significantly higher rate.  
 
In summary, numerous studies have shown that the ErbB2 receptor is a key signaling molecule 
in both the development as well as the spread of breast cancer. ErbB2 amplification and/or 
overexpression have clearly become prognostic factors for this type of cancer. However, there 
are still pieces missing in understanding the full picture of ErbB2 in pathogenesis. A key 
question remains the downstream signaling of the receptor in cancer, neither have all ErbB2 
adaptor proteins been characterized, nor was their spatial and temporal binding and its effect 
on signaling determined, yet. 
Therefore, we set out to identify known or novel binding partners of ErbB2, especially of the 
phosphorylated YE site, and link them to a cancer phenotype. In the course of our studies we 
identified human Copine III as a binding partner of pTyr1248 of ErbB2. These findings and the 
experiments leading to them will be explained in the results part. However, prior to this, the 
Copines, a family of Ca2+-dependent phospholipid binding proteins, will be introduced. 
 




1.6 Copines – a conserved family of Ca2+-dependent,  
 phospholipid binding proteins 
1.6.1 General aspects, discovery, homology and conservation 
 
In search for Ca2+-dependent, phospholipid-binding proteins that might be involved in 
membrane trafficking in the ciliate protozoa Dictyostelium discoideum the group of Carl Creutz 
discovered a novel protein, which they named Copine. Its name arises from its property to bind 
the membrane like a friend (Copine = french noun for friend). This Paramecium protein was 
shown to bind phosphatidylserine (PS), but not phophatidylcholine dependent on Ca2+, but 
not Mg2+. Furthermore, the group also found and cloned a human Copine homolog and 
showed that this human Copine also possesses the ability to bind to phospholipids (Creutz et 
al., 1998). Thus, the authors for the first time, presented the Copines as a novel family of Ca2+-
dependent, phospholipid binding proteins, which might be involved in membrane trafficking 
(Creutz et al., 1998).  
Since their first discovery multiple copine homologs have been identified and studied in 
various organisms such as A. thaliana, D. discoideum, C. elegans and H. sapiens. Similar to other 
gene families, the number of copines genes increased throughout evolution: A. thaliana has 3 
copine genes, whereas there are 6 in D. discoideum and, up to now, 9 have been identified in H. 
sapiens. No copine gene has been found in yeast. The Copines show a high degree of sequence 
conservation between different species: Copine I shares 40, 40 and 33% sequence identity with 
copines from C.elegans, A. thaliana and P. tetraurelia, respectively. The widespread distribution 
of copines throughout different kingdoms as well as their high degree of conservation implies 















1.6.2 Domain architecture  
 
All copines share the same domain architecture: they contain two N-terminal C2 domains (C2A 
and C2B) followed by an von Willebrand  A  or A domain towards the C-terminus. 
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Figure 1-9 Domain architecture of Copine family members 
All Copine family members share the same domain architecture: Two C2-domains, 





C2 domains are Ca2+-dependent, phospholipid binding domains found in a growing number of 
membrane binding proteins involved in various cellular signaling pathways such as membrane 
trafficking, generation of lipid messengers, activation of GTPases and protein phosphorylation. 
C2 domains are characterized by adopting an eight-stranded antiparallel β-sandwich and are 
classified into two distinct topologies, which differ slightly in structural position and 
connectivity of the β-strands:  the first strand of topology I occupies the same structural 
position as the eighth β-strand of topology II (Figure 1-10) (Nalefski and Falke, 1996). Proteins, 
which contain only one C2 domain, such as protein kinase C (PKC), or phospholipase C (PLC), 
usually fall into the type II topology and proteins carrying two C2 domain, like synaptotagmin 












(Jimenez and Davletov, 2007) 
 
Figure 1-10 Two structurally different topologies of C2 domains  
Schematic representation of the β sandwich structure encompassing eight β strands 
that are aligned in two C2 domain topologies, type I and typeII. Strand 1 of topology I 
corresponds to strand 8 in topology II (both highlighted in red). Both of these strands 
are structurally equivalent but permutated in the linear sequence. The Calcium 
binding loop or regions (CBRs) are also shown and lie within the conserved six-
stranded core (boxed). 
 
C2 domains bind Ca2+ through conserved aspartate residues in the loops connecting the β-
strands. However, these Ca2+-binding sites are not conserved in all C2 domains and hence not 
all C2 domains are Ca2+-dependent. In the family of protein kinase C the diversity of Ca2+-
dependency of C2 domains is illustrated: the family is divided into different subgroups: 
conventional, novel and atypical PKCs: conventional or classical PKCs (PKCα, βI, βII, γ) carry a C2 
domain that is Ca2+- and diacylglycerol (DAG)-dependent for protein activity, whereas the C2 
domain of novel PKCs (PKCδ, ε, θ) is Ca2+-independent and only activated by DAG. For 
completeness it has to be mentioned that the family contains a third group, the atypical PKCs 
(PKCζ, λ/ι) that do not contain a C2 domain (Kheifets and Mochly-Rosen, 2007).  
Lipid selectivity is variable among the family of C2 domain containing proteins, yet, most C2 
domains bind phosphatidylserine (PS) with high affinity (Cho and Stahelin, 2006). Although not 
all C2 domains are Ca2+-dependent, for those which do bind Ca2+ a temporal specificity of 
membrane binding is achieved by transient increases of intracellular Ca2+. The membrane 
binding region of these C2 domains is often acidic in the absence of Ca2+. Ca2+-binding confers 
positive charges to this region thereby changing its electrostatic potential, making it able to 
bind negatively charged lipids. Additionally, the bound Ca2+-ions, usually two to three per 
binding region, form a “bridge” between the C2 domain and PS (Lemmon, 2008). Some C2 
domains can simultaneously engage multiple membrane components with both their Ca2+-
binding loops and the cationic β-groove (Cho and Stahelin, 2006). This has been modeled for 
the C2 domain of PKCα, which binds PS in a Ca2+-dependent manner and simultaneously binds 




phosphatidylinositol4,5diphosphate (PtdIns(4,5)P2) through a Lysine-rich cluster located on the 
β3 and β4 strands (Figure 1-11) (Guerrero-Valero et al., 2007).  
 
  
(Guerrero-Valero et al., 2007) 
 
Figure 1-11 Model of the membrane docked C2 domain of PKCα 
Structural representation of the PKCα C2 domain modeled to a membrane. The 
membrane is represented as a stick model with carbon in grey, nitrogen in blue and 
oxygen in red. The overall structure of the C2 domain of PKCα is represented as a 
cartoon model in green (PDB 1DSY). The four Lys residues located in the Lysine-rich 
cluster are represented by a stick model with carbon in grey and nitrogen in blue. The 
headgroup of the two interacting phospholipids, phosphatidylserine (PtdSer) and 
PtdIns(4,5)P2  are represented as spheres, Calcium ions as yellow spheres. The C2 
domain that binds one PS molecule through its Ca2+-binding region and one 
PtdIns(4,5)P2 molecule through its Lysine-rich cluster. 
 
 
Von Willebrand A-like or A domain 
The analysis of P. tetraurelia Copine1 showed that this copine carried a domain related to the 
von Willebrand A (VWA) or the Integrin A/I domain. Later on, this domain was found to be 
conserved in all copine family members. VWA domains are most widely distributed 
phylogentically: they can be found in all sequenced eukaryotic genomes (Whittaker and Hynes, 
2002). The VWA domain is present in many cell adhesion or extracellular matrix proteins, such 
as collagens and is most often found in integrins. Most proteins carry the VWA domain 
extracellularly. Only recently a group of intracellular VWA domain-containing proteins was 
discovered. Interestingly, these intracellular VWA domain-carrying proteins can be found in all 
eukaryotes, in contrast to extracellular VWA domains, which are only found in metazoa. 




Intracellular VWA domains are involved in fundamental cellular processes such as DNA repair 
and transcription and include the Rpn10-26S proteasome regulatory subunit (C. elegans), the 
TFIIHp44 multi protein complex transcription factor (A. thaliana), the Ku70/80 DNA helicase 
family (H. sapiens), the family of ATPases associated with diverse cellular activities (D. 
melanogaster), Sec-23 (S. cerevisiae), the uncharacterized protein Q9VPY0 (H. sapiens) and 
Copines.  This, as well as the fact that VWA domains are absent from bacterial genomes, 
suggests that intracellular VWA domains are the most ancient VWA domains (Whittaker and 
Hynes, 2002). 
The first structure of a VWA domain was solved in 1995 (the A domain of αMβ2 integrin 
(CD11b/CD18, CR3)) (Lee et al., 1995b). The domain adopts a classic alpha/beta Rossmann fold, 
a hydrophobic core of β-sheets surrounded by seven α helices, and contains an unusual metal 
ion coordination site at its surface (Figure 1-12). It has been suggested that this site represents 
a general metal ion-dependent adhesion site (MIDAS) for binding protein ligands (Lee et al., 
1995b). The integrin VWA domain plays a major role in ligand binding and undergoes 
conformational changes in response to receptor activation (Lee et al., 1995a). Furthermore, it 
was proposed from structural analyses of integrin VWA domains bound to different metal ions, 
that binding of Mn2+ to the VWA domain MIDAS motif renders the protein inactive 
(“unliganded”), whereas Mg2+ binding represents the active conformation (“liganded”) (Figure 
1-12) (Lee et al., 1995a).  It was suggested that this influences the ligand binding properties of 
integrins: the Mn2+-bound state is more stable without a ligand, whereas the Mg2+-bound form 
has a high affinity for ligand binding. These findings confirmed the common feature seen in 














(adapted from Lee et al., 1995a; Qu and Leahy, 1995) 
 
Figure 1-12 Structure of an integrin A domain  
a) the integrin CD11a A domain adopts a Rossmann fold with a hydrophobic core of β-
sheets encompassed by α-helices and contains a metal affinity metal ion-dependent 
adhesion site (MIDAS) here shown with a bound Mg2+ ion.  
b) and c) Solvent accessible surface of the Mn2+ and the Mg2+ bound A domain. 
Negatively charged regions are shown in red, positive in blue. Mg2+-binding allows 
acidic residues to be exposed to the surface, which increase the hydrophobicity and 
thus ligand binding. 
 
The A domain of human Copine I shows a distant relationship to the VWA domain with the 
highest homology in the C-terminal 2/3 of the domain (Creutz et al., 1998). The MIDAS motif 
and especially the residues involved in Mg2+ and Mn2+ binding are conserved and it was shown 
that human Copine I binds both Mg2+ and Mn2+ (Tomsig and Creutz, 2000). Evidence from 
yeast-two hybrid (YTH) screens supports the idea that also Copine A domains are involved in 
protein-protein binding: The purified A domains of  human Copine I, II and IV bind various 
substrates  such as protein phosphatase 5, myc binding protein, apoptosis linker-gene 2 or β-
actin (Tomsig et al., 2003). For the majority of these proteins the copines bound to regions 
predicted to form a coiled-coil and a consensus sequence was determined as a predictor for 
novel copine targets (Tomsig et al., 2003). The potential binders identified are involved in many 
divergent cellular processes such as protein phosphorylation, transcription, or ubiquitination. 
Furthermore, it was shown that Copines and their associated proteins can be recruited to 
immobilized lipids in vitro in a Ca2+-dependent manner. Theses findings led to the hypothesis 
that a function of Copines is to recruit target proteins to the plasma membrane or intracellular 
membrane that contain acidic lipids. However, due to the divergence of copine-associated 
proteins identified, the biological function of each Copine, although highly homologous, 
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1.7 Biological roles of Copine family members 
 
Since the discovery of the copine proteins in 1998 the question about their biological function 
has remained intriguing. The widespread distribution of copine family members, as well as 
their high degree of conservation suggests that copines might have an important biological 
function. The presence of C2 domains and the A domain led to the hypothesis that the function 
of copines involves Ca2+-dependent phospholipid binding and protein-protein interactions.   
Copine family members have been studied to different degrees in various organisms and in 
particular the work in A. thaliana, C. elegans and D. discoideum has yielded valuable insights. 
Biochemically, human Copine I is by far the most extensively studied protein of the family and 
recently the function of human copines has also been addressed. These results on biological 
roles of copine are summarized in the following section. 
 
1.7.1 Copine in Arabidopsis thaliana 
 
In A. thaliana mutants of the two copine genes BON1 and CPN1 were analyzed (Hua et al., 2001; 
Jambunathan et al., 2001). These genes were analyzed in different studies and were found to 
exhibit different phenotypes, however, they are both orthologues of human Copine III and 
therefore, in fact, the same gene.  
Plants are anchored organisms and therefore need to regulate homeostasis in response to 
environmental factors. Usually Arabidopsis sustain a relatively constant size at a variety of 
temperatures. Deletion of the BONZAI1 (BON1) gene gives rise to miniature plants at 22°C, 
whereas the growth is normal at 28°C (Hua et al., 2001). Additionally, it was shown that the 
expression of BON1 RNA is high in young, growing plants and downregulated with increasing 
temperature, thus BON1 might have a direct role in regulating cell expansion and cell division 
at lower temperatures. One known mechanism in plants for the adaptation to temperature 
changes is adjusting their membrane composition, in particular their lipid content, in order to 
remain fluid even at low temperatures. Yet, BON1 null mutants do not show a significant 
difference in overall lipid composition to wild type plants. Furthermore, purified BON1 protein 
was shown to possess Ca2+-dependent activity and to be associated with PS in vitro. From these 
observations the authors conclude that BON1 is important in plant homeostasis possibly by 
either catalyzing membrane fusion or preserving membrane function at low temperatures (Hua 
et al., 2001).  
CPN1 mutants were shown to have multiple phenotypes in response to humidity changes. 
They show an aberrant regulation of cell death as well as morphological abnormalities. 




Furthermore, these mutants have an increased susceptibility to infection by Pseudomonas 
syringae and Peronospora parasitica by repression of a disease resistance gene (R gene). BON1 
or CPN1 RNA levels are increased under low humidity conditions and the expression is 
decreased with increasing humidity. Therefore, CPN1 might be a regulator of plant responses 
to humidity and the effects on disease resistance are indirect or CPN1 might be a direct 
regulator of Arabidopsis defense responses (Jambunathan et al., 2001). 
Following these studies, more copine family members were discovered in Arabidopsis (BON1-
3). BON1 and BON2 share 82% sequence identity and 91% similarity, whereas BON3 is more 
distantly related and shares 62% identity and 75% similarity with BON1. The Ca2+-binding 
aspartates are conserved in both C2 domains of all three proteins.  Single loss-of-function 
mutants of BON2 and BON3 display a wild-type (wt) phenotype, in contrast to the BON1 
mutant that, when analyzed in the same experiment, showed again a growth phenotype. 
However, BON3, but not BON2 was found to rescue the BON1 growth phenotype. Furthermore, 
BON2/BON3 double mutants do not show any phenotype, whereas the other double mutants 
(BON1/BON2 and BON1/BON3) show an even more severe phenotype than BON1 single 
mutants and are seedling-lethal at 22°C.  Triple mutants show a severe seedling-lethal 
phenotype at 22°C and 28°C. 
These studies show that the Arabidopsis copine family members have both distinct and 
overlapping functions and BON1 seems to play a dominant role among the three proteins, 
exhibiting growth defects and precocious cell death under low temperature or low humidity 
conditions (Yang et al., 2006). 
 
1.7.2 Copines in Caenorhabditis elegans 
 
Several putative members of the copine family have been identified in the nematode 
Caenorhabditis elegans. Most of these genes were classed as copine family members based on 
their homology to human copines (cpna1 to cpna5). However, only the function of two family 
members has been studied in some detail:  GEM-4 and T28F3.1. 
The gonad of C. elegans is derived from four postembryonic blast cells that initiate divisions 
several hours after the larva hatches from the egg. These divisions require the activity of GON-
2, a predicted cation channel that is likely to mediate Ca2+ and Mg2+ influx. Gem-4 encodes a 
Ca2+-dependent PS binding protein that is highly similar to three human proteins, copine I, 
copine III, and KIAA1599 (40% identity over 590 residues). Gem-4 (gon-2 extragenic modifier) 
mutation results in suppression of loss-of-function alleles of gon-2. Gem-4 antagonizes gon-2 in 
gonadal development. Both gem-4 mutants as well as gem-4(RNAi) efficiently suppress the  




gon-2 phenotype. It is speculated that this is mediated by a direct interaction of the two 
proteins, since both proteins are predicted to localize to the plasma membrane. Another 
possibility is that the two proteins act in parallel functioning pathways.  
The expression of GFP-GEM-4 is brightest at the plasma membrane and in some cases a 
punctuate staining is detectable in the cytoplasm, which could be due to an association of 
GEM-4 with vesicular structures. Yet, the localization of GEM-4 to the plasma membrane is not 
dependent on gon-2 function, which could implicate that GEM-4 localization to the membrane 
in not Ca2+- dependent. In a wild-type background gem-4 mutants do not show an apparent 
phenotype (Church and Lambie, 2003). 
T28F3.1 also encodes a putative calcium-dependent phospholipid binding protein of the 
copine family, sharing a high degree of homology with human Copine V.  It was identified in a 
screen for proteins associated with the levamisole sensitive nicotinic acetlycholin receptor 
(nAChR). nAChRs are pentameric, ligand-gated ion channels of which the levamisole-sensitive 
receptor is the best studied. They mediate excitatory neurotransmission in neurons and 
muscles.  A good read-out for the function of the levamisole nACHR is nicotine resistance in a 
paralysis assay, since its depletion causes nicotine resistance. T28F3.1(RNAi) and T28F3.1 
mutants showed moderate resistance to nicotine as well as moderate levamisole resistance (a 
specific nAChR agonist).  Moreover, T28F3.1 mutants showed reduced synaptic nAChR 
expression.  
T28F3.1 is expressed in many cell types including neurons in the head and tail as well as in 
body muscle. Importantly, it localizes to plasma membranes and co-localizes with nAChR. 
This study implies that T28F3.1 specifically affects cell surface expression of the levamisole 
nAChRs and could therefore be a general membrane organizer (Gottschalk et al., 2005). 
In another study, T28F3.1 was found to be required for sperm migration towards a 
polyunsaturated fatty acid (PUFA)-based signal exuded by oocytes. In search for genes 
encoding proteins synthesizing PUFA-derived signal, T28F3.1 was identified as one of 35 target 
genes.  T28F3.1(RNAi) hermaphrodites are infertile, both through aberrant loss of their own 
sperm and through failure of males to effectively inseminate them due to defects in directional 
sperm motility. Thus, T28F3.1 is involved in directional cell migration by somehow influencing 









1.7.3 Copines in Dictyostelium discoideum 
 
Dictyostelium discoideum lives as a single-celled amoeba, is very motile and possesses 
phagocytic cells, processing organelles and membrane trafficking pathways similar to 
mammalian cells. These features make Dictyostelium an ideal model organism to study copine 
function.  
The Dictyostelium genome contains six copine genes encoding copine proteins named CpnA to 
CpnF. They share between 26% (CpnA and CpnF) and 80% (CpnB and CpnE) sequence 
homology. All six copines are expressed throughout D. discoideum development showing an 
upregulation at one or two developmental stages. Only CpnF shows a decreasing RNA 
expression level throughout development (Damer et al., 2005). 
The best-studied copine protein in Dictyostelium is CpnA.  The recombinant C2A domain of 
CpnA binds lipids in a Ca2+-dependent manner and endogenous CpnA was found to be 
associated with Dictyostelium membranes in the presence of Ca2+.  Furthermore, GFP-CpnA 
localized to the cytoplasm of vegetative cells, but was shown to transiently translocate to the 
plasma membrane in an oscillating manner as a result of peaks in intracellular Ca2+ 
concentrations. Moreover, GFP-CpnA localized to contractile vacuoles, endosomal organelles 
and phagosomes (Damer et al., 2005).  
Knock-out strains for cpnA (cpnA-) show only mild phenotypes: they exhibit a normal growth 
rate with few multinucleated cells, suggesting a defect in cytokinesis. Additionally, they are 
delayed or arrested in finger state development. When placed under starvation conditions 
Dictyostelium cells undergo cell differentiation and morphogenesis to form multicellular 
structures: after 14 – 16h of starvation the cells have accumulated and form a finger-like 
structure (finger state) and at 19 – 20h, during the final stage of development, the cells 
terminally differentiate into spore or stalk cell. The requirement for CpnA in fruiting body 
formation correlated with increased CpnA gene expression during development. 
In line with previous findings that CpnA localized to contractile vacuoles, it was discovered that 
cpnA- cells exhibited unusually large contractile vacuoles when put into H2O. However, no 
effect on the growth rate of cpnA- cells in H2O was observed, nor swelling or bursting of cpnA- 
cells, as well as no upregulation of any of the Cpn genes upon osmotic pressure (Damer et al., 
2007). 
The hypothesis for the major function of copines in D. discoideum is similar to that in A. thaliana 
and C. elegans (Gem-4): the phenotypes seen in the CpnA,  such as the defective cytokinesis or 
the delayed or arrested finger state development mutants could originate from changes in 
membrane properties or defective membrane trafficking.  
 




Interestingly, in a proteomics study performed to identify proteins involved in mouse embryo 
development, Copine I was identified as being upregulated during embryonic day E8.5 – 10.5. 
During this time, major developmental events occur, including axonal rotation, formation of 
differentiated somites, extensive remodeling of the heart with onset of regular contractions 
and formation of the neural tube. Thus, this is the first indication that a copine family member 
plays a role in mouse development (Greene et al., 2002).   
The temporal expression of Copine family members as well as studies in Dictyostelium (CpnA) 
and mouse (Copine I) imply that they play a role during development. 
 
In summary, the studies of copine family members in Arabidopsis, C. elegans and Dictyostelium 
show that they have distinct roles. The observed mutant phenotypes e could be classified as 
rather “mild”, occurring only under special environmental conditions (temperature or humidity 
in Arabidopsis or osmotic pressure in Dictyostelium). In most of the cases it was speculated that 
the role of copines lies in signal transduction from the membrane, membrane trafficking or 
that copines are general membrane organizers.  
This is underscored by the fact that they all are Ca2+-dependent (when tested) membrane 
binding proteins.   
 
1.8 Human Copines 
 
Nine genes belonging to the copine family have been identified in H. sapiens. Human copines 
are a relatively novel family of proteins, with the first discovery of copine I in 1998 (Creutz et al., 
1998). Much of what we now about human copines emerged from in vitro studies, but 
increasingly in vivo functions are being assigned to members of the human copine family. 
Human copines are highly homologous: copine I shares 60, 78, 53 and 56 % homology to 
copines II to V, respectively (Figure 1-13). Copines I, II and III are expressed ubiquitously, the 
others being tissue specific. Copine IV is only expressed in the brain, heart and prostate, 
whereas the expression of Copine VI is restricted to the brain and it is therefore also referred to 
as N-copine (neuronal-copine).  





(Tomsig and Creutz, 2002) 
 
Figure 1-13 Dendrogram showing the relationship of seven human Copines  
Multiple sequence alignment of seven human copine proteins. Copine I and Copine III 
share the highest sequence homology (78%), whereas Copine I shared 60%, 53 and 
58% sequence homology with Copines II, IV and V. 
 
1.8.1 Phenotypes, biological roles 
 
Copine VI or N-Copine has been studied to some extend. It was shown that N-Copine 
expression is truly restricted to the brain and that it is expressed throughout development with 
a drastic increase of expression after birth. Further studies demonstrated that N-Copine mRNA 
is expressed exclusively in neurons of the hippocampus and in the main and accessory 
olfactory bulb. These are brain areas, where various forms of synaptic plasticity and memory 
formation occur. There N-Copine is found mainly in the cell bodies and dendrites in the 
neurons.  
Moreover, N-Copine was shown to exhibit Ca2+-dependent phospholipid binding similar to 
other family members. Thus, the function of N-Copine, although not known yet, seems to differ 
from other neuronal proteins carrying two C2 domains and might be to act as a Ca2+ sensor in a 
postsynaptic event (Nakayama et al., 1999a; Nakayama et al., 1999b; Nakayama et al., 1998). 
 
The best studied among the human copines is Copine I. The group of Carl Creutz, who was the 
first to identify copines, published several articles focusing on the biochemistry of copine I. 
Already in their early studies they showed that copine I binds PS in a Ca2+-dependent, but 
Mg2+-independent manner (Creutz et al., 1998). They also showed that Ca2+ changes the 
aggregation state of Copine I.  Addition of Ca2+ to purified monomeric copine induces copine 
aggregation into multimers as observed by measuring dynamic light scattering. According to 




these measurements aggregates of 17 copine molecules can exist in the presence of Ca2+. 
Moreover, the aggregation was reversible by the addition of EDTA. 
Copine I binds to PS containing lipid vesicles as well as to those containing phosphoinositides 
(PI), phosphoglycerides (PG) and phosphatidic acid (PA). Copine binding to PA is Ca2+-
independent, and its affinity for PI is less than for the other phospholipids.  
Furthermore, the biochemical analysis of copine 1 also showed that it can bind both Mn2+ and 
Mg2+ suggesting that  the conserved MIDAS motif within the A domain is functional (Tomsig 
and Creutz, 2000).  
These biochemical studies confirmed that human copines exhibited the same features (e.g. 
Ca2+-dependent phospholipid binding) as other copines family members. Yet, the question 
about a function of human copines still remained unanswered. Therefore putative binding 
partners of purified recombinant A domains of human Copines I, II and IV were used as baits in 
a yeast-two-hybrid assay with the aim to find the function or functional pathways copines are 
involved in. It was found that copine A domains can bind a variety of proteins involved in 
different cellular processes such as protein phosphorylation (MEK1), transcriptional regulation 
(Myc binding proteins) or regulators of ubiquituination (E2-230K). A common structural feature 
was a sequence predicted to fold into a coiled-coil domain: E…. R..R.L.E..EQ.RK.LELR..KQR… 
EL.QLD.E.E. This has been designated as the Copine-binding motif. Furthermore, it was 
demonstrated that full length copines can recruit their binding partner to immobilized lipids in 
a Ca2+-dependent manner. Importantly, the purified A domain alone is not enough to recruit 
proteins to lipid bilayers.  
This was the first evidence that Copines might have a transporter function, between the 
cytoplasm and the plasma membrane and so regulate signaling processes at the membrane 
(Tomsig and Creutz, 2000; Tomsig et al., 2003).   
 
Since two of the identified binding partners of Copine I were proteins regulating NFκB activity 
and Copine I was shown to posses a cis-κB-binding element in the promoter region (Tomsig et 
al., 2003), two follow-up studies analyzed the effect of Copine I on NFκB. In the first study the 
purified A domain of Copine I was used as a dominant negative construct based on the 
assumption that it binds to putative target proteins. Using this construct it was shown that 
Copine I regulates TNFα-induced NFκB activation. Moreover, Ca2+ acts in synergy with TNFα 
and the effect of Ca2+ on NFκB activation was also blocked by the Copine A domain. 
Furthermore, a feedback loop was found between TNFα and Copine I, where stimulation with 
TNFα increases Copine I expression levels significantly (Tomsig et al., 2004). 
These findings were revised in a later publication on Copine I and its role in the NFκB pathway: 
it was illustrated that copine I represses NFκB-mediated transcription by recruiting a mediator, 




which endoproteolytically cleaves the p65 subunit.  The authors claimed that the different 
results to their previous study, which showed that Copine I activated NFκB, was due to the fact, 
that in this first study, a GFP-tagged Copine was used, that was excluded from the nucleus. 
Since the phenotype that is reported in the later publication occurs mainly in the nucleus this 
would explain why the results seem contradictory.  
In the later study it was shown that Copine I represses NFκB activation at a common point in 
the cytokine pathway, since the cells could be stimulated with different cytokines and the 
result on NFκB activity was the same.  In the inverse experiment, the KD of Copine I increased 
NFκB activity. The authors could show that Copine I binds to the N-terminus of p65 and 
initiates the endoproteolytic cleavage of p65.  Moreover, Copine I was found to cleave other Rel 
family members such as p50, p52, RelB and cRel.   
Copine I cleaves p65 at its DNA binding domain and in that way inhibits p65 binding to DNA 
and therefore represses NFκB activity. It is important to note that the authors specifically stated 
that Copine I has not been shown to possess endoproteolytic activity itself, but rather recruits 
another protein with enzymatic activity. Even more convincing for this hypothesis is the fact 
that immunopurified Copine I was not able to stimulate proteolysis of p65. (Ramsey et al., 2008) 
 
Another family member that has been studied to some extent is Copine III. In primary rat 
hippocampal cultures loss of Copine III reduces dendritic protrusions and causes a collapse of 
the dendritic tree during synapse formation. Furthermore, Copine III was shown to interact 
with Copine VI and the actin-modulating small-GTPases Rac1 and Pak1 in vitro (M. Galic, 
Inaugurladissertation 2006; Biozentrum Basel).  
In another study, it has been claimed that Copine III is a phosphoprotein that possesses kinase 
activity. This evidence is based on studies in which partially purified Copine III was used. It 
phosphorylated myelin basic protein in vitro and in an in-gel kinase assay a band with the size 
of Copine III was detected. Copine III carries no known kinase motif and it is therefore very 
plausible that this kinase activity resulted from a co-purified enzyme, rather than from Copine 
III itself (Caudell et al., 2000). No evidence for kinase activity or ATP-binding has been found for 
any other Copine either (Tomsig and Creutz, 2002) 
Thus, the collective biochemical results on Copine I and Copine III suggest that these proteins 
could function by interacting with specific enzymes, possibly through their A domains. 
However, the functional consequences of such associations yet remain unclear. To bridge the 
gap between the intriguing biological and biochemical properties of this protein family, 
functional studies are needed to place its members in a cellular context. 
 




Human Copines have not been studied extensively since their discovery in 1998. There are 
some good biochemical studies, especially on Copine I, but apart from that the number of 
publications on human Copines is limited. This is probably due to the fact that no real function 
has been assigned to any human Copine family member so far. Two publications argue for a 
function for Copine I and Copine III, yet, as illustrated above, the evidence that these are indeed 
the functions of Copines and not rather those of associated proteins is weak. In summary, in 
addition to the biochemical data available for human Copines, functional data needs to be 








































2 RESEARCH OBJECTIVE 
 
It is a matter of fact that the ErbB2 receptor plays a pivotal role in the initiation and progression 
of breast cancer. Up to 30% of all breast cancers show an ErbB2 overexpression, a property 
correlated with poor prognosis for these patients. Therefore, it is of uttermost importance to 
study signaling pathways initiated by ErbB2 in more detail.  
Recently, Memo (Mediator of ErbB2-mediated cell motility) was identified as a novel ErbB2 
interacting protein and was shown to be important for ErbB2-mediated cell motility, a trait 
important in cancer metastasis. This illustrates that there are still “blind spots” in our 
knowledge of the ErbB2 signaling cascade. Therefore, a better understanding of these pathway 
could provide more specific targets for the treatment of cancer. 
 
In line with these previous findings we set out: 
 
(I)        To identify novel interacting proteins of the phosphorylated Tyr1248 (YE) site of  the 
 ErbB2 receptor 
 
We addressed this question using a combination of SILAC (stable isotope labeling of amino 
acids in cell culture), a peptide affinity pull-down and quantitative mass spectrometry.  
 
(II)         To place the ErbB2-binding protein into the signaling pathways downstream of the  
              receptor and find an associated cancer phenotype 
 
This aim was addressed using RNAi in culture cells, which were subjected to assays 





















































3 IDENTIFICATION OF COPINE III AS A BINDING PARTNER 
 OF ERBB2 
3.1 Introduction 
Members of the ErbB family of receptors are expressed in multiple tissues and play a crucial 
role in initiating diverse signaling cascades. Out of these receptors, ErbB plays a pivotal role, 
since it is the preferred heterodimerization partner of the other receptors. Signal transduction 
through ErbB2 is mediated by tyrosine phosphorylation on specific residues in the C-terminal 
regulatory region of the receptor, which leads to the binding of specific adapter proteins and 
the initiation of signaling cascades. As mentioned before, the five major pTyr sites of ErbB2 
receptor have been mapped and several interacting proteins to each site have been identified 
since. In the area of high throughput genomics and proteomics studies have aimed at 
identifying a whole “interactome” of putative binding partners of the ErbB family of receptors 
(Jones et al., 2006; Schulze et al., 2005). These studies have, without doubt, elucidated the 
variety of signaling molecules able to bind to the receptors and they have greatly deepened 
our understanding of ErbB signaling. However, although these studies aimed at identifying 
protein-protein interactions at the resolution of a single tyrosine phosphorylation site, the 
question about the temporal and spatial binding of each adaptor protein to the receptor and 
hence its impact on downstream signaling remains unanswered. Therefore, the aim of our 
study was to use state-of-the-art quantitative mass spectrometry at the resolution of a single 
modification to identify binding partners of a single pTyr site of ErbB2 and, furthermore, to 
place this identified protein within a pathway and thus a function downstream of ErbB2. For 
our analysis we chose pTyr1248, because, although some binding partners to this site have 
already been identified (Dankort et al., 2001a; Jones et al., 2006; Schulze et al., 2005), a link 
between a specific binder and a signaling effect downstream of ErbB2 has not been shown yet. 
In order to identify interaction partners of specific pTyr residues of the ErbB2 receptor we used 
a combination of SILAC (stable isotope labeling by amino acids in cell culture) (Ong et al., 2003) 
together with a peptide affinity pull-down purification (Schulze et al., 2005), followed by 
quantitative mass spectrometry. It has been shown previously in the lab that the use of 
synthetic peptides mimicking the C-terminal region of ErbB2, including a specific pTyr residue, 
can be used as baits to identify binding proteins of the receptor in vitro (Marone et al., 2004). 
Furthermore, at the time of our experiments, the use of quantitative mass spectrometry 
emerged as a major topic in proteomic studies, allowing for a robust and highly sensitive 
determination of binding partners.  
 




Quantitative mass spectrometry 
Quantitative mass spectrometry has emerged as a highly accurate, sensitive and reliable 
technique to measure relative and absolute amounts of given proteins within a complex 
mixture. Several techniques for quantitation by mass spectrometry have been established: 
Most of these techniques employ differential stable isotope labeling to create a specific mass 
tag, which can be recognized by the mass spectrometer. Special mass tags can be introduced 
into proteins or peptides metabolically, by chemical means, enzymatically or provided by 
spiking with synthetic peptide standards (Bantscheff et al., 2007) (Figure 3-1).  Stable isotope 
labeling was introduced as a tool in protein analysis by MS in 1999 by three independent 
groups (Gygi et al., 1999; Oda et al., 1999; Pasa-Tolic, 1999) and has since then been widely 
accepted, modified and advanced in the field.  The earliest possible point for introducing a 
stable isotope tag into proteins is by metabolically labeling proteins during cell growth and 
division. Metabolic labeling has been performed in cell culture, which is used widely in the 
field, and in whole animals (Wu et al., 2004), a method that has been shown to work, but still 
remains difficult and is far from being standardized. Metabolic labeling in the form of SILAC 
was introduced in 2002 (Ong et al., 2002). In the most common implementation of this method 
the medium used for culturing cells contains 13C6-Arginine and 13C6-Lysine ensuring that all 
tryptic peptides carry at least one labeled amino acid resulting in a constant mass increment 
over their non-labeled counterpart (Bantscheff et al., 2007). First the peptides and proteins are 
identified followed by a relative quantification by comparing the intensities of isotope clusters 
of the intact peptide in the survey spectrum.  
Another way of labeling, which happens later on in the experiment, is done by post-
biosynthetic labeling of proteins and peptides either by chemical or enzymatic derivatization in 
vitro. Enzymatic labeling can be performed either during proteolytic digestion or as a second 
independent enzymatic step afterwards. In principal, every reactive amino acid side chain can 
be used to chemically incorporate isotope-coded mass tags, however, in practice, mostly 
Lysine and cysteine side chains are used for this purpose (Bantscheff et al., 2007). One specific 
application of this category uses the isotope-coded affinity tag (ICAT) reagents (Gygi et al., 
1999), where cysteine residues are specifically derivatized with a reagent that not only 
introduces zero or eight deuterium atoms, but also a biotin group for affinity purification. Since 
the initial description of ICAT, several variations of this method have emerged to improve e.g. 
the recovery of labeled peptides (Hansen et al., 2003). One drawback of ICAT is certainly the fact 
that this method is not suitable to quantify proteins containing few or none cysteine residues 
and it is of limited use to analyze post-translational modifications and splice variants.  
A prominent example of another group of labeling reagents, which targets the peptide N-
terminus and the epsilon amino group of lysine residues, are the isotope tags for relative and 




absolute quantification (iTRAQ). The iTRAQ reagents are a set of isobaric reagents which are 
amine specific and allow for the identification and quantitation of up to eight different samples 
simultaneously. They are designed as an isobaric tag consisting of a charged reporter group, a 
peptide reactive group, and a neutral balance portion to maintain an overall mass of 145. 
Isobaric, by definition, implies that any two or more species have the same atomic mass but 
different atomic arrangements (Zieske, 2006). Currently, there are two mainly reagents used: 4-
plex and 8-plex, which can be used to label all peptides, in theory, from different 
samples/treatments. 
However, in contrast to metabolic labeling techniques, with both ICAT and iTRAQ the labeling 
occurs at a later step in the experimental protocol, meaning that samples with different 
treatments/conditions need to be handled in parallel for longer and thus this increases the 




(Bantscheff et al., 2007) 
 
Figure 3-1 Common quantitative mass spectrometry workflows 
Boxes in blue and yellow represent two experimental conditions. Horizontal lines 
indicate when samples are combined. Dashed lines indicate points at which 
experimental variation and thus quantification errors can occur. 
 
The use of isotope-labeled synthetic standards for use in absolute quantification is becoming 
more and more broadly applied using a technique called AQUA (absolute quantification of 
proteins).  In a simple set-up the addition of a known quantity of a stable isotope-labeled 




peptide to a protein digest and subsequent comparison of the intensity of the mass 
spectrometric signal to that of the endogenous peptides can yield absolute quantification of 
protein amounts.  Since the amount of sample and spiked peptides must be similar, and most 
of the times the amount of peptides from each endogenous protein varies with its expression 
level (protein abundance) and digestibility, which may differ greatly in-between samples, 
“guessing” the right amount of peptide to be spiked in, is a major drawback of this method 
 
Another technique for quantification, not involving stable isotope tags, is label-free 
quantification, which aims at correlating the mass spectrometric signal of intact polypeptides 
or the number of peptide sequencing events with the relative or absolute protein quantity 
directly (Bantscheff et al., 2007)(Figure 3-1). Currently, there are two widely used, but 
fundamentally different techniques for label-free quantitation: measuring and comparing the 
spectrometric signal intensity of peptide precursor ions belonging to a particular protein or 
counting and comparing the number of fragment spectra identifying peptides of a given 
protein. Label-free approaches are certainly the least accurate among the mass spectrometric 
quantification techniques when considering the overall experimental process, because all the 
systematic and non-systematic variations between experiments are reflected in the obtained 
data (Bantscheff et al., 2007). 
Although each of the discussed methods has drawbacks depending on the question addressed 
and the accuracy required, each has its specific virtues as well. In summary, the ability of mass 
spectrometry to identify and, increasingly precisely quantify thousands of proteins from 
complex samples can be expected to impact broadly on biology and medicine (Aebersold and 



















General aspects of mass spectrometers and protein identification on the 4000QTrap 
Mass spectrometers consist of a few simple modules: an ionization mechanism; a section to 
separate, select and fragment peptides (analyzer); and a detector (de Hoog and Mann, 2004). In 
general, mass spectrometers are named or classified by the type of ionization mechanism and 
analyzer they contain (e.g. MALDI-TOF or ESI-Quad). 
By definition, a mass spectrometer consists of an ion source, a mass analyzer that measures the 
mass-to-charge ratio (m/z) of the ionized analytes, and a detector that registers the number of 
ions at each m/z value. Electrospray ionization (ESI) and matrix-assisted laser 
desorption/ionization (MALDI) are the two most commonly used techniques to volatize and 
ionize proteins or peptides for mass spectrometric analysis (Aebersold and Mann, 2003). In 
contrast to MALDI, which ionizes samples out of a dry matrix using laser pulses, ESI ionizes the 
analytes out of solutions. Therefore, ESI-MS is mostly coupled to a liquid chromatography 
system (LC) and, due to the pre-separation step, used for the analysis of complex samples. 
MALDI-MS is routinely used to measure relatively simple mixtures, however, recent advantages 
allow also for MALDI-MS to be coupled (off-line) to a chromatography system and thus to 
analyze far more complex samples. 
 
For our quantitative analysis we used nano-LC-ESI-MS/MS using a triple quadrupole mass 
spectrometer (4000QTrap, from Applied Biosystems).  
In a triple quadrupole instrument the linear set-up of the modules is: Q1, a quadrupole, 
followed by q2, which can be used as either an ion trap or a collision cell and Q3, another 
quadrupole (Figure 3-2).  In a standard experiment the samples are treated and/or 
prefractionated to reduce the complexity. Afterwards the proteins are separated by SDS PAGE, 
individual bands are cut and proteins are digested for mass spectrometry. The resulting 
peptide mixture is then separated in the LC system that is directly coupled to the mass 
spectrometer. The amino acids sequences of the individual peptides can be deduced and thus 
proteins in the mixture can be identified (Figure 3-2) 
 





(Aebersold and Mann, 2003) 
 
Figure 3-2 Generic mass spectrometry-based proteomics experiment  
The proteins to be analyzed are isolated from cell lysate or tissues by biochemical 
fractionation or affinity selection (1). This often includes a final step of one-
dimensional gel electrophoresis, and defines the ‘sub-proteome’ to be analyzed. 
Proteins are degraded enzymatically to peptides, usually by trypsin, leading to 
peptides with C-terminally protonated amino acids, providing an advantage in 
subsequent peptide sequencing (2). The peptides are separated by one or more steps 
of high-pressure liquid chromatography in very fine capillaries and eluted into an 
electrospray ion source where they are nebulized in small, highly charged droplets. (3) 
After evaporation, multiply protonated peptides enter the mass spectrometer and a 
mass spectrum of the peptides eluting at this time point is taken (MS1 spectrum, or 
‘normal mass spectrum’) (4). The computer generates a prioritized list of these 
peptides for fragmentation and a series of tandem mass spectrometric or ‘MS/MS’ 
experiments ensues (5).  
 
In our set-up proteins were metabolically labeled with Lysine and Arginine residues containing 
stable isotopes (SILAC) leading to mass shift of 6 and 10Da, respectively, between the labeled 
amino acids and their non-labeled counterparts. By definition these peptides behave similarly 
in LC-MS and are therefore eluted and analyzed at the same time.  
Tandem mass spectrometry was used (MS/MS) and the peptides were analyzed in the following 
way: first an overall elution chromatogram of all peptides eluting from the LC system was 
monitored (total ion chromatogram - TIC). At any timepoint the m/z value of the eluted ions is 
monitored. This yields a low resolution survey scan. The ion with the most intense m/z ratio in 
this spectrum is further analyzed. First a survey scan is performed, from which the ionization 
state of the ion can be deduced (MS1). Next, the selected ion is further fragmented in q2 and all 
resulting fragments are analyzed in Q3 and measured by the detector (MS/MS). This enhanced 




product ion (EPI) scan is used in a database search. In principal the EPI spectrum is searched 
against a database (Mascot database) of known spectra and thus the peptide sequence is 
elucidated. Furthermore, peptides identified from the same protein are grouped and thus 
proteins are identified (Figure 3-3).   
 
MS/MS of 421.7
Enhanced Product Ion scan (EPI)
MS : survey scan
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Figure 3-3 Peptide and Protein identification on the 4000QTrap 
All eluted peptides are ionized in the source and monitored in a first elution 
chromatogram (TIC). A more detailed low resolution scan identifies the ion with the 
most intense m/z at the specific timepoint. This ion is then selected for further 
analysis: first, in an enhanced resolution scan, the charge of the ion is determined. 
Next, it is fragmented in q2 and the resulting fragments are analyzed in Q3 and 
measured in the detector. From this fragmentation patter the peptide sequence can 
be deduced using database searched. Hence peptides and proteins are identified. The 
4000QTrap is a cycling instrument; many ions are selected, fragmented and analyzed 
at a given timepoint. Each ion is only selected twice within a timeframe of 1 minute, 
which allows also the analysis of less intense ions. 
 
Each ion can only be selected for MS/MS fragmentation twice within a timeframe of 1 minute 
(by default setting). Thus also less intense ions are selected for fragmentation making the 
analysis more sensitive and comprehensive. After the identification run, the identified peptide 
sequences are searched versus the UniProt data base (version 6.4) restricted to homo sapiens 
using Mascot (version 2.1, Matrix Science, London, UK) and the proteins they belong to are 
identified. The proteins that have been reliably identified (with at least 2 peptides and a protein 
score ≥ 20) are selected and their identified peptides chosen for quantification in a second run 
in the multiple reaction monitoring (MRM) mode. 




Multiple reaction monitoring - MRM 
In principle, multiple reaction monitoring describes a method, which allows for the monitoring 
of many transitions in a cycling fashion. A transition is defined as the combination of a 
precursor ion and one of its fragment ions. Using MRM, relative amounts of peptides and hence 
proteins can be quantified, by measuring the intensity of a given transition over time during 
the chromatographic elution. The term “multiple” implies that many such transitions can be 
measured sequentially in one experiment. The relative amounts of each peptide are calculated 
from the area under the peak resulting from the measurement.   
To extract the required peptide information for quantification (precursor ion mass, fragment 
ion mass, retention time, etc.) from Mascot we use a program called MRM buddy (developed at 
the FMI in Basel, Switzerland. The MRM buddy interface allows the user to select peptides for 
quantification. The user can decide, whether peptides are suitable for quantification or rather 
not, depending on their modification and amino acid composition and charge state. 
MRM buddy contains a function so that it automatically calculates the labeled or endogenous 
counterpart for any measured peptide, in case this has not been measured during the 
identification run. MRM buddy then generates a list of transitions to be quantified, which can 
be directly used in setting up the MRM run on the 4000QTrap. In the second run, the MRM run, 
these selected transitions are then monitored over time during the chromatographic elution. 
After the analysis of the sample in the MRM mode, the peak areas for each measured transition 
have to be integrated manually. Then MRM buddy incorporates the measured areas for each 
peptide into the previously established transition list and calculates peptide ratios (e.g. labeled 
over endogenous AA). It also takes into account the correction factor for the purity of the stable 
isotope labeled amino acids and a factor for normalization. From the resulting peptide ratios 
overall protein ratios are calculated. Therefore, each protein needs to be quantified by at least 3 
peptides. 
In such an experiment, the user has to make sure, not only to quantify proteins that are 
interesting in the experiment, but also proteins that are known to be unchanged by the kind of 
treatment or purification performed. These proteins will yield a quantification ratio around one 
and thus make it easier to determine proteins, whose ratio is significantly decreased or 
increased in the sample. All protein ratios are plotted and, assuming normal distribution, a cut-
off is determined at ± 2σ from the mean. In this way proteins, which are regulated (e.g. by some 
treatment prior to the MS experiment) can be identified through the quantification of their 
relative amounts within the sample. 
 




3.2 Materials and methods 
A description of the Materials and Methods used in these experiments is found in section 4.3. 
 
3.3 Results 
Metabolic labeling of T47D beast cancer cells using SILAC 
In order to identify proteins that specifically bind to pTyr1248 of the ErbB2 receptor we used a 
combination of a peptide affinity pull-down and SILAC, followed by quantitative mass 
spectrometry. For SILAC, one set of T47D cell was kept in normal growth medium with 
endogenous non-labeled amino acids. The other set was cultured in SILAC medium for at least 
five passages. This medium contained 400x excess of 13C614N4- Lysine (Lys6) and 13C615N4- 
Arginine (Arg10). The cells were lysed and the percentage of incorporation of the isotopically 
labeled amino acids was monitored by MALDI-TOF MS. We found an incorporation of                  
≥ 90-95 % after five passages. Additionally, we monitored the T47D breast cancer cells grown 
in SILAC medium and compared their growth and morphology to the cells grown in parallel in 
normal medium. We could not detect any obvious differences in cell proliferation rate or the 
morphology of the cells due to the metabolic labeling with Lysine and Arginine. Therefore, 
these cells were used for the pull-down experiments. 
 
Peptide affinity purification, protein identification and quantification by MRM 
Peptides mimicking the C-terminal regulatory region of ErbB2 were synthesized with an N-
terminal desthiobiotin group connected by an SGSG linker to a 15mer peptide sequence with 
the specific tyrosine residue in the middle (desthiobiotin-SGSGPTAENPEYLGLDVPV-NH2). 
Peptides were synthesized as pairs of a non-phosphorylated and a tyrosine phosphorylated 
version. Desthiobiotin was used as affinity tag, and biotin, as the specific eluant.  
The peptides were bound to strepatavidin attached to magnetic beads and incubated with 
equal amounts of cell extract from HRG-stimulated non-labeled and labeled T47D cells (Figure 
3-4). After binding the beads were washed to remove unbound proteins, then the peptides and 
their bound proteins were eluted using biotin or by boiling the samples in SDS buffer. The 
eluted proteins were separated by SDS-PAGE and digested with trypsin. Trypsin cleaves after 
Lysine and Arginine residues ensuring that all resulting peptides are labeled except the very C-
terminal one. The eluted proteins were analyzed by the two-step MS method described above. 
We were especially interested in peptides that were enriched by the affinity purification as 
indicated by an increased intensity for the isotopically labeled form (Figure 3-4). 
 
 





















Figure 3-4 Identification of binding partners of pTyr1248 of ErbB2 
T47D breast cancer cells were either grown in normal medium (grey) or in medium 
containing stable isotope labeled Lysine and Arginine (red). The cells were starved 
overnight and stimulated with 1 nM HRG for 20min. Then the cells were lysed and 
equal amount of whole cell extract (WCE) were incubated with the respective peptide 
linked to magnetic beads. After binding the beads were washed and the peptides and 
bound proteins were eluted using biotin. The proteins were separated by SDS PAGE, 
digested by trypsin and identified by MS. Quantification was done by multiple 
reaction monitoring. Peptides with a higher intensity of the labeled peptide were of 




Figure 3-5 shows an example of an MRM run from one sample of a pull-down experiment. The 
chromatographic traces of all transitions monitored are shown in the upperpanel. Since all 
individual transitions are monitored over time their traces occur as curves, of which the area 
can be taken for quantitation analysis. The chromatographic traces from peptide pairs (e.g. 
Arg0 or Arg10 labeled) are overlaying curves since both peptides behave similar during the 
chromatography and the MS. The two lower panels of Figure 3-5 depict transitions for 2 
peptide pairs that are either non-regulated (left) or show an increased intensity for the labeled 
peptide (right). This means that the peptide pair on the left bound to the Tyr1248 and 
pTyr1248 peptides equally well, whereas the peptide on the right bound to the pTyr1248 with 
a much higher affinity that to the Tyr1248 peptide. Presumably, this peptide belongs to a 
protein that specifically binds to the phosphorylated Tyr1248 site. However, it is important to 
note, that from each protein at least 3 peptides with a Mascot peptide score ≥ 20 need to be 
quantified to draw any reliable conclusion about the binding preference of the protein. 
Therefore, an observed regulation of a single peptide pair does not necessarily lead to the right 
conclusion. 
 




Chromatographic traces of all transitions in 1 run
Specifically enriched




Figure 3-5 Example of an MRM run for one sample 
All chromatographic traces from one MRM experiment are shown in the top column; 
transitions of peptide pairs that have been monitored are shown as overlaying curves. 
The lower panels show two examples of transitions of peptide pairs that can be used 
for quantification. On the left side the area under both peak, from the non-labeled and 
the labeled peptide, are about equal, meaning that this peptide was binding to both 
Tyr1248 and pTyr1248 with the same affinity. On the right side the area under the 
curve for the labeled peptide is much larger than that of the non-labeled peptide 
suggesting that this peptide preferentially bound to pTyr1248. 
 
For each of the monitored transitions a peak integration needs to be performed (Figure 3-6). 
This can be done automatically using Analyst1.4 peak integrator. However, it is advisable to 
check all integrations manually and to correct them if necessary. The integrated peak areas can 
then be exported into Excel, from which they can be either imported into MRMbuddy or 
analyzed manually. 
 






Figure 3-6 Peak integration in Analyst 1.4 
For each peptide pair measured during the MRM run peak integration has to be done 
using Analyst peak integrator. The peak areas are integrated manually to avoid false 
integration. All integrated areas are calculated by Analyst and can be exported into 
Excel. 
 
For one pull-down experiment we usually cut the SDS gel into 24 pieces that were all analyzed 
individually. For all proteins in one samples the chosen transitions were monitored, the peaks 
integrated and the ratios (labeled AA/ endogenous AA) were calculated. Then all these data 
were pooled for all 24 samples and overall proteins ratios were calculated. These ratios were 
then grouped and plotted for the frequency of their occurrence (Figure 3-7). Since we also 
quantified many proteins of which we were assuming that they bound to both the Tyr1248 and 
the pTyr1248 peptide in the same ratio we expected to find most of the protein ratios around 
1. This was indeed true as seen in the example shown in Figure 3-7. Additionally, the 
distribution of all protein ratios adopted a normal distribution. This assures a more reliable 
distinction between background and specific binding proteins.  
Therefore, we determined the mean of this curve and set the cut-off for specific binding at ± 2σ 
from the mean. Since we were mainly interested in proteins binding specifically to the 
phosphorylated Tyr1248 site we only considered proteins with a ratio ≥ 1.5. In this first 













































































































Figure 3-7 Distribution of all quantified protein ratios from one experiment 
From the quantification ratios for each peptide pair to overall ratios for the identified 
proteins were calculated. These ratios were grouped as above and plotted versus the 
number of proteins falling in this group. As expected, the distribution assumes a 
Gaussian or normal distribution with most of the ratios around 1. This means that the 
majority of the protein quantified bind to Tyr1248 and pTyr1248 with the same 
affinity. We set the cut of for significant binders at ± 2σ from the mean (red line). All 
proteins above this cut-off are of potential interest since they bind pTyr1248 
preferentially.  
 
The complete experiment was repeated three times with fresh cell extracts to verify specific 
binders.  
In this way, we identified Copine III as a specific binding partner of pTyr1248 of the ErbB2 
receptor. In the above experiment, the first full pull-down experiment performed, we identified 
Copine III with 4 peptides. 3 of these were taken for quantification and yielded an overall 
protein ratio (Arg10 over Arg0 and/or Lys6 over Lys0) of 1.76, thereby being clearly above the 
cut-off. In two other full experiments we quantified Copine III with ratios of 1.76 (5 peptides 
identified, 4 quantified) and 1.78 (9 peptides identified, 6 quantified) confirming that, at least in 
vitro, Copine III interacts with pTyr1248 of the ErbB2 receptor. 
3.4 Discussion 
We could show, by using a combination of a peptide affinity pull-down and quantitative mass 
spectrometry, that Copine III is a putative interaction partner of the ErbB2 receptor. Using set of 
non-phosphorylated and phosphorylated peptides mimicking different areas of the C-terminal 
regulatory domain of ErbB2 (Tyr1196/pTyr1196 and Tyr1248/pTyr1248), we were also able to 
show that Copine III binds specifically to pTyr1248 of the receptor.   




Although we used a previously published method for the peptide affinity pull-down, some 
optimization had to be done to achieve optimal binding. Prior to the full scale experiments the 
binding capacity of the magnetic beads used was tested with the Tyr and pTyr-peptides. Using 
a titration approach and by monitoring the amount of bound peptide by HPLC, we determined 
the individual binding capacity for each peptide on the beads. In this way, we wanted to 
minimize background protein binding by occupying all binding spaces on the beads with 
peptide.  
Nevertheless, we still observed a large amount of background proteins eluting from the beads. 
Since we were using streptavidin beads we tried solutions like binding the dethiobiontinylated 
peptide to the beads and then incubating the beads with biotin to block empty streptavidin 
binding sites. Yet, this did not markedly decrease the amount of background proteins bound 
and eluted from the beads. Therefore, the sample was far too complex to be run on the MS 
from solution and had to be pre-separated by SDS PAGE. Even though the MS approach used is 
a highly sensitive approach, we had to start out with relatively large amounts of input protein 
samples and beads. A reason for this could have been that after binding the sample was 
separated by SDS PAGE and peptides were eluted from the gel pieces, a technique, which is 
known to cause a large decrease in sensitivity.  
 
We identified up to 300 proteins in one experiment, showing on the one hand the amount of 
background binding in the experiment and, on the other hand, the sensitivity of the mass 
spectrometry approach. Although the background proteins result in poor signal to noise ratios, 
their identification was also desired in order to clearly distinguish specific and non-specific 
binders. In different experiments we always found more than one protein binding specifically 
to the pTyr1248-containing peptide. However, Copine III was the only one found in all full scale 
experiments. This, and the fact that the ratios obtained for Copine III binding to pTyr1248 in all 
experiments are very similar, made us confident to have identified a true interaction partner of 
the receptor. 
 
One curious observation of our mass spectrometry experiments was the absence of Shc 
amongst the identified. Shc has been shown to bind pTyr1248 in vitro using the same peptide 
affinity pull-down approach (Schulze et al., 2005). In western blots done in parallel to the MS 
identification, we detected Shc in the elution fraction. This is rather curious, since MS is much 
more sensitive in terms of amounts of proteins than western blotting. One explanation for this 
phenomenon could be that in our studies a different type of mass spectrometer was used than 
in the other study, in which Shc was identified. We used a nano-LC-ESI-triple quadrupole 




instrument, whereas Schulze et al. worked on an ESI-quadrupole TOF hybrid mass 
spectrometer and on a LTQ-FT (ion trap Fourier transform ultra hybrid MS). 
In a quadrupole TOF hybrid mass spectrometer the final quadrupole is replaced by a time-of-
flight device. Therefore, this hybrid MS contains two mass analyzers, which provides a much 
higher mass accuracy in the measurements that in instruments with only one kind of mass 
analyzer. Similarly, Fourier transform ion cyclotron resonance (FTICR) mass spectrometers have 
a very high resolution and mass accuracy. FTICR-MS is useful is for dealing with complex 
mixtures since the resolution allows the signals of two ions of similar m/z to be detected as 
distinct ions. Therefore, it might be possible that Shc was not detected using out triple 
quadrupole instrument, because the ions it produced were overlaid by other ions at the same 
m/z ratio that were measured with a higher intensity. We tried to circumvent this by specifically 
monitoring Shc peptide transitions in the MRM run. However, since Shc had not been identified 
in any identification run, the transitions used fro the MRM run were produced in silico. This 
could be a reason why also in such a directed MRM experiment we did not identify Shc in the 
sample. 
 
Even though it would have been a good internal control to identify Shc with the pTyr1248 
peptide in the MS approach, we are still very confident that Copine III is indeed binding to 
pY1248 of ErbB2 specifically. To further confirm this data, we were able to show this interaction 











































4 IN SILICO ANALYSIS OF COPINE III 
 
After the identification of Copine III as a putative binding partner of the ErbB2 receptor, we 
searched the literature for publications on Copine III. We found that it belongs to a recently 
identified family of proteins, on which not many studies have been published. We therefore 
started to investigate Copine III using bioinformatic tools. This was done in order to gain 
information about Copine III from the in silico analyses to help us to place it within a framework 
of proteins or a specific network.  
First we performed sequence alignments of all human Copines identified to date. This 
alignment showed that the human Copines are indeed a highly conserved family of proteins. 
Overall, there are two stretches, one being the N-terminus and the other being the C-terminus, 
that are not as conserved as the rest of the sequence. Copine V has an insertion of 19 amino 
acids (AAs) that is not seen in any of the other sequences (Figure 4-1). 
 
In order to retrieve more information about Copine III we analyzed its domain structure in more 
detail. From the literature it was known that all Copines carry two C2 domains (C2A and C2B) 
and a Copine-specific A domain (Creutz et al., 1998). We performed sequence alignments of 
Copine III with other proteins carrying a C2 domain, mainly of the PKCs and synaptotagmin 
family of proteins. Furthermore, 3D modeling of the putative regions forming each domain was 
preformed to define to boarders of the domains. A similar analysis was done for the A domain 
by aligning and modeling it to an integrin A domain. According to these results the domain 
architecture of human Copine III was determined as follows: C2A: 7 – 104, C2B: 143 – 270, A 
domain: 375 – 498 (Figure 4-1). 
.  
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Figure 4-1 Sequence alignment of nine human Copine proteins 
The amino acid sequences from nine human Copine proteins were extracted from the 
SwissProt database and aligned using ClustalW. Domains, as characterized in our lab 
by sequence aligments and modeling, were annotated as follows: grey – C2A, blue – 
C2B, light red – Lysine –rich cluster and green – A domain. The domain boarders were 
set for human Copine III. Stars denote amino acids conserved in all proteins, points 
those that are  conserved in all but one sequence and colons those that are conserved 
in tall but two of the aligned sequences. 
 
Moreover, the AA sequence of both C2 domains hints to a secondary structure, in which the β-
strands fold occurs in an order as seen in other type II C2 domains, which was already claimed 
(Creutz et al., 1998). This is an intriguing result, since in other proteins that carry two C2 
domains, like annexins or synaptotagmin, these domains fall into the type I topology. 
Furthermore, our sequence alignment demonstrated that the six aspartate residues, which 
have been shown to confer Ca2+-binding in other proteins, are conserved throughout the 




Copine family (Figure 4-2). This result strongly suggests that the Copines will exhibit Ca2+-
dependent functions in the cell. 
When further analyzing the alignments we found that all copine family members have a 5-6 AA 
stretch rich in lysine residues, which we, therefore, termed “Lysine-rich motif”. This motif is 
found at the C-terminus of the C2B domain. Interestingly, it has been hypothesized, since other 
C2 domain containing proteins also carry such a motif, that it helps targeting the protein to the 
membrane by binding to PIP2 (Guerrero-Valero et al., 2007). 
Moreover, we found that all copines have a conserved MIDAS (metal ion-dependent adhesion 
site) motif in their A domain (Figure 4-3). 
 
** * * * *  
 
Figure 4-2 Alignment of the Copine IIIC2B domain to C2 domains of PKCδ and 
other Copines 
Residues 1-156 of human Copine III were aligned to the C2 domains of other human 
Copines and those of PKCδ. Five aspartate residues were conserved in all Copines 
(marked with an asterisk) and a probably required for Ca2+- binding. The alignment 
was performed using HHPred (M. Rebhan, FMI) 
 
 






Figure 4-3 Alignment of Copine III to other Copine family members 
Residues 1 – 573 of human Copine III were aligned to AA sequences of Copine family 
members from different species. A Lysine-rich cluster, which is conserved throughout 
the whole family, is depicted in blue with a black bar underneath. Moreover, all 
Copine family members carry a conserved MIDA motif, denoted in black, within their A 
domain. The alignment was performed using HHPred (M. Rebhan, FMI) 
 
 
Therefore, these in silico analyses of human Copine III support the hypothesis that it exhibits 
Ca2+-dependent phospholipid binding activity within the cell. Furthermore, since it shows the 
conserve MIDAS motif it probably binds Mg2+ and/or Mn2+, which might influence its 
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ErbB2 amplification and overexpression in breast cancer correlates with aggressive disease and 
poor prognosis. To find novel ErbB2 interacting proteins, we employed SILAC followed by 
peptide affinity pull-downs and identified specific binders using relative quantification by mass 
spectrometry. Copine III, a member of a Ca2+-dependent phospholipid binding protein family, 
was identified as binding to phosphorylated Tyr1248 of ErbB2. In breast cancer cells, Copine III 
requires Ca2+ for binding to the plasma membrane, where it interacts with ErbB2 upon receptor 
stimulation, an interaction that is dependent on receptor activity. Copine III also binds RACK1 
(receptor of activated C kinase 1) and co-localizes with phosphorylated focal adhesion kinase at 
the leading edge of migrating cells. Importantly, knockdown of Copine III in T47D breast cancer 
cells causes a decrease in Src kinase activation and ErbB2-dependent wound healing. Our data 
suggest that Copine III is a novel player in the regulation of ErbB2-dependent cancer cell 
motility. In primary breast tumors, high CPNE3 RNA levels significantly correlate with ERBB2 
amplification. Moreover, in an in situ tissue microarray analysis, we detected differential protein 
expression of Copine III in normal versus breast, prostate and ovarian tumors suggesting a 
more general role for Copine III in carcinogenesis.  
 
 
Keywords: quantitative mass spectrometry, ErbB2, HRG, Copine III, FRET acceptor 
photobleaching, cell migration 
 
 






The ErbB2/Her-2/Neu receptor belongs to the type I receptor tyrosine kinase (RTK) family also 
including EGFR, ErbB3 and ErbB4 (Schlessinger, 2000). Alterations in EGFR or ErbB2 promoting 
constitutive receptor activation have been implicated in development of many human cancers. 
Patients whose tumors show ErbB receptor alterations tend to have an aggressive disease and 
poor prognosis (Slamon et al., 1987); (Holbro and Hynes, 2004; Hynes and Lane, 2005; Ross and 
Fletcher, 1998). Upon binding of EGF-related ligands to ErbBs, receptor homo- and 
heterodimers form, leading to kinase activation and phosphorylation of specific tyrosine 
residues in the cytoplasmic tail (Hazan et al., 1990; Hynes and Lane, 2005.). ErbB2 has no ligand, 
but is the favored dimerization partner of the other family members (Graus-Porta et al., 1997). 
ErbB3, although able to bind ligands, has impaired kinase activity.  ErbB2 is the preferred 
heterodimerization partner of ErbB3, thereby coupling ErbB2 to the PI3K pathway (Holbro et al., 
2003a). ErbB2, via activation of signaling pathways including Erk and PI3K/Akt mediates 
numerous cellular processes important for tumorigenesis including proliferation, survival and 
migration, (Citri and Yarden, 2006; Keely et al., 1997; Klemke et al., 1997; Schlessinger, 2000; 
Yarden and Sliwkowski, 2001).  
 
The five major tyrosine phosphorylation sites, Tyr1023/1028, Tyr1139/1144, Tyr1196/1201, 
Tyr1222/1227 and Tyr1248/1253 (human/rat) and their role in ErbB2 signaling has been studied 
by various means. Tyr1028 couples to a pathway implicated in negative regulation of NeuT 
transforming potential, whereas the four other sites have a potentiating effect. Tyr1144, 
Tyr1201 and Tyr1227 signal through the Ras/Erk pathway by binding Grb2, Crk and Shc 
(Akiyama et al., 1991; Dankort et al., 2001b; Dankort et al., 1997), which also binds Tyr1253 
(Schulze et al., 2005). The role of pTyr residues has also been examined in migration assays. In 
T47D breast tumor cells, Tyr1196 and Tyr1222 have each been linked to ErbB2-mediated cell 
migration via PLCγ and Memo, respectively (Marone et al., 2004; Meira et al., 2009)  
 
We set out to identify novel binding proteins for Tyr1248 and to link them to an ErbB2-
mediated phenotype. Using a  pTyr1248 encompassing peptide in an affinity pull-down 
approach followed by relative quantification by mass spectrometry, we identified Copine III, 
which belongs to a family of Ca2+-dependent phospholipid binding proteins first found in the 
ciliate protozoan Paramecium tetraurelia. Copines are conserved from plants to humans, where 
nine CPNE genes have been identified (CPNE I - IX) (Tomsig and Creutz, 2002). All copines 
possess two N-terminal C2 domains (C2Ds) followed by a von Willebrand A-like or A domain. 
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C2Ds were originally identified in conventional protein kinase C isoforms and have been found 
in a growing number of eukaryotic proteins (Nalefski and Falke, 1996). The copine A domain, 
while similar to the extracellular A domain of integrins, is cytoplasmic and thought to mediate 
protein-protein interactions (Tomsig and Creutz, 2002). 
 
Although widely expressed throughout the eukaryotes, indeed, most cells express multiple 
copines, relatively little is known about their specific roles. Interestingly, Copine III was shown 
to be up-regulated in tumor cells in response to ErbB2 overexpression (Gharbi et al., 2002; 
White et al., 2004). We examined the role of Copine III downstream of ErbB2 receptor signaling 
and show here that Copine III is a Ca2+-dependent, phospholipid-binding protein that interacts 
with activated ErbB2 at the plasma membrane of tumor cells. Moreover, we identified the focal 
adhesion (FA) associated scaffold protein RACK1 as a Copine III binding partner. Importantly, 
we show that Copine III is required for ErbB2-dependent cell migration. 
 
5.3 Materials and Methods 
 
Antibodies and Reagents 
Recombinant heregulin β-1 (HRG) was purchased from R&D Systems (Minneapolis, MN, USA) 
and solubilized in PBS + 0.1% BSA.  
The following antibodies were used: The serum for the polyconal antibody against a 17- amino 
acid peptide of Copine III was provided by Elisabeth A. Grimm (MD Anderson, Houston, TX, 
USA) (Caudell et al., 2000). The monoclonal Copine III antibody was generated against the 
recombinant C2B domain of human Copine III (AA132 to 278) (for antibody specificity see 
supplementary figure 1). This antibody was used for all immunofluoresecence (IF) studies. For 
ErbB2, the 21N polyclonal antiserum was used in western blot analysis (Hynes et al., 1989). A 
polyclonal antibody (sc-284) purchased from Santa Cruz (Santa Cruz, CA) was used in IF studies. 
For pY1248-ErbB2 the 06-229 antibody from Upstate (Millipore, Billerica, MA) was used in both 
WB and IF. 
Other antibodies used in western blot analyses included rabbit anti-GAPDH (ab9385) and 
rabbit anti-Calnexin (ab10286) from Abcam (Cambridge, CA,USA), rabbit anti-p42/44 Erk 
(#9102), rabbit anti-phosphorylated p42/44 Erk (#9101), rabbit anti-Akt (#9272), rabbit anti-
phosphorylated Akt (#9271), rabbit anti-phosphorylated pY925 FAK (#3284) all from Cell 
Signaling (Danvers, MA, USA), the anti-mouse Src (0-5184) antibody from Upstate, the rabbit 
anti-phosphorylated Src (44-660G), the rabbit anti-phosphorylated pY861FAK (07-832)  and the 
rabbit anti-phosphorylated pY397FAK (44-624G) were from Biosource (Invitrogen) and rabbit 




anti-FAK (sc-932) from Santa Cruz (Santa Cruz Biotechnology Inc., Santa Cruz, USA). The rabbit 
anti Copine-I antibody (10126-2-AP) was from PTGLabs (Chicago, IL). PTyr was detected with 
the 4G10 monoclonal antibody (a gift from Juergen Mestan, NIBR, Basel, Switzerland). For the 
transferrin receptor, cells were stained with the Ber-T9 antibody (sc-19675) from Santa Cruz. 
The following secondary antibodies were used: An alexa488-conjugated goat anti-mouse 
antibody, an alexa568-conjugated goat anti-rabbit antibody (both Molecular Probes, Eugene, 
OR, USA) and a Cy3-conjugated donkey anti-rabbit antibody (Jackson ImmunoReasearch 
Laboratories, Inc., West Grove, PA, USA) 
DMSO was purchased from Sigma, Ionomycin from Calbiochem (Merck, Germany). The small 
molecule inhibitor AEE788 is a Novartis compound (Basel, Switzerland) (Traxler et al., 2004). 
 
Cell Culture 
T47D and SKBr3 breast tumor cells were cultured in Dulbecco`s modified Eagle`s medium 
supplemented with 10% fetal bovine serum (FBS) (GIBCO Invitrogen, Basel, Switzerland) and     
2 mM glutamine at 37 °C, 5 % CO2.  
 
SILAC 
Cells were cultured in medium without arginine (Arg) and lysine (Lys), which was 
supplemented with a 400-fold excess of 12C614N4 (Arg0) or 13C615N4 (Arg10) and 12C614N2 (Lys0) or 
13C614N2 (Lys6) (Sigma and Cambridge Isotope Laboratories, Andover, MA, USA). Cells were 
cultured for at least 5 passages. The level of incorporation was measured by MALDI mass 
spectrometry (Ultraflex II, Bruker, Bremen, Germany).  
 
Peptide synthesis and affinity pull-down 
Peptides were synthesized as 15mers carrying an N-terminal desthiobiotin group followed by a 
four amino acid linker (Ward et al., 1996) by JPT Peptide Technologies GmbH (Berlin, Germany) 
in the non-phosphorylated and Tyr-phosphorylated form (sequence: desthiobiotin-
SGSGPTAENPEYLGLDVPV-NH2) 
For affinity pull-downs, 2 mg Dynabeads MyOne Streptavidin C1 (Invitrogen) were incubated 
with 150 pmol peptide for 30 min at room temperature (RT). Heregulin β-1 (HRG) stimulated 
T47D cells were lysed in 50 mM Tris–HCl pH 7.5, 150 mM sodium chloride, 1 % (v/v) Nonident P-
40, protease inhibitors (Complete Tablets, Roche), and 1 mM sodium orthovanadate. 12 mg of 
protein lysate were added and incubated for 4 hours at 4 °C, afterwards beads were washed 
and samples pooled (see Figure 1a). Proteins were eluted in biotin for 30 min at 30 °C or in SDS 
buffer at 95 °C for 10 min, subjected to SDS-polyacrylamide gel electrophoresis (SDS PAGE) and 
visualized using the Colloidal Blue Staining Kit (Invitrogen). 
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Mass Spectrometry and Quantification 
The Coomassie stained bands were processed by reduction and alkylation of the cysteines 
followed by tryptic digestion. Peptides were analyzed by nano-HPLC (Agilent 1100 nanoLC 
system, Agilent Technologies, Santa Clara, USA) coupled to a 4000QTRAP mass spectrometer 
(Applied Biosystems, Foster City, USA). Peptides were identified searching UniProt data base 
(version 6.4) restricted to Homo sapiens using Mascot (version 2.1, Matrix Science, London, 
UK)(Perkins et al., 1999). 
 
For relative quantification, the required peptide information (e.g. m/z values of the precursor 
and fragment ions, retention time) was extracted from the Mascot dta file using “MRM buddy” 
(unpublished, developed at the FMI, Basel, Switzerland by Alessandro di Cara and Reto 
Portman). Proteins identified with ≥ 2 peptides and with a Mascot protein score ≥ 20 were 
quantified. For quantification, samples were re-injected and analyzed in the multiple reaction 
monitoring (MRM) mode. Relative quantification was performed by comparing the peak areas 
that were extracted using Analyst Classic in Analyst 1.4.1.  
 
Quantification correction and normalization 
Ratios (heavy/light) of peak areas for each individual light and heavy form of each peptide were 
calculated using Excel. Individual peptide ratios were corrected for the purity (given by the 
manufacturer) and incorporation (measured) of the labeled isotopes. From the corrected and 
normalized peptide ratios overall protein ratios were determined. Assuming a normal 
distribution we determined the mean of all protein ratios and set the cut-off for specific 
binding proteins at 2σ below and above the mean. 
 
Immunofluorescence microscopy 
Preparation of cells was performed as described previously (Meira et al., 2009). Images were 
recorded with an Axioskop Zeiss Microscope coupled to a Sony 3 CDD camera. For inhibitor 
studies, cultures were starved overnight, then preincubated 1.5 h with 0.5 μM AEE788 (DMSO 
for controls) then 1 nM HRG (PBS for controls) was added for 20 min. Cells were fixed and 
stained as described (Meira et al., 2009). 
 
Subcellular fractionation 
The cells were washed and detached by scraping in PBS, then homogenized and fractionated 
following the Membrane Preparation by Homogenization protocol from Current Protocols in 
Cell Biology online (Unit 7.10, support protocol 1; Wiley Interscience, John Wiley & Sons Inc, 
Malden, MA).  All buffers were supplemented with either 10 μM CaCl2 or 1 mM EGTA. Equal 




volumes of each fraction were used for subsequent SDS-PAGE and western blotting with 
specific antibodies.  
 
Preparation of cell lysates, IP and immunoblotting 
For assaying the effect of stimulation, cells were starved in DMEM + 0.1 % FBS overnight and 
subsequently stimulated with 10 ng ml-1 HRG for 20 minutes, unless indicated otherwise. 
Control cells were treated with PBS + 0.1 % BSA for the same time. Whole cell extracts (WCEs) 
were prepared in lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 1 % Triton X-100, 1x 
complete EDTA-free, 1 mM sodium orthovanadate) and total protein content was determined 
using the Bradford Protein Assay (Bio-Rad, Hercules, CA, USA). Immunoprecipitations (IPs) were 
performed as described previously (Meira et al., 2009)  
 
FRET acceptor photobleaching 
SKBr3 cells were grown on glass coverslips (BD Biosciences, San Diego, CA) coated with 25 ug 
ml-1 rat-tail Collagen I (Roche Diagnostics, Indianapolis, IN) and stimulated 20 min with 1 nM 
HRG as described (Meira et al., 2009), except that slides were mounted using Mowiol 
(Calbiochem, EMD Chemicals, Gibbstown, NJ). Copine III was visualized using a secondary anti-
mouse Alexa488-conjugated antibody. ErbB2 and transferrin receptor were visualized using a 
secondary anti-rabbit Cy3-conjugated antibody. Acceptor photobleaching was used to assess 
FRET efficiency on a Zeiss LSM510 confocal microscope equipped with a 63x/1.4 oil immersion 
objective. Alexa488 was excited with a 488nm laser line, emission measured with a BP505-530 
filter. Cy3 was excited with a 543nm laser line, emission measured with a LP560 filter. For each 
measure Cy3 bleaching had to be over 90 % and FRET efficiency (E) was calculated after 
background subtraction and Alexa488 bleaching correction as follows: E = (ID-IDA)/ID, where ID 
and IDA are Alexa488 intensities in the bleached region after and before photobleaching of Cy3, 
respectively. For each condition, 4 to 10 cells were assessed. 
 
Copine III knockdown 
Transient: Copine III siRNA was obtained from Qiagen (Germantown, MD). Cells were 
transfected in Optimem medium with the HiPerfect Transfection reagent (Qiagen) according to 
the protocol, using 2 μM siRNA. Successful KD was obtained using the following siRNA 
sequences: Optimal down-regulation occurred 96 h post transfection with the following siRNA 
sequences: siRNA1 5`-CCAGUUAUCUGUUAAUCAA-3`, siRNA2 5`-GGCAAUCUUUCCAAAGUAA-
3`. LacZ: 5`-GCGGCUGCCGGAAUUUACC-3`. 
Stable: Bacterial glycerol stocks of pLKO.1-puro vectors containing different shRNA sequences 
targeting Copine III were purchased from Sigma (MISSION shRNA library, TCRN_NM_00390S). 
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Infections were done as described in Section III: Lentiviral Infection Protocol from the RNAi 
Consortium (Cambridge, MA). Copine III knock-down (KD) was confirmed by western blotting. 
The shLacZ vector was produced by cloning the 5`-CCGGGCGGCTGCCG 
GAATTTACCTTCTCGAGGGTAAATTCCGGCAGCCGCTTTTTAATT-3` sequence into the pLKO.1-
puro plasmid.  Bacterial glycerol stocks of pLKO.1-puro vectors containing different shRNA 
sequences targeting Copine III were purchased from Sigma (MISSION shRNA library, 
TCRN_NM_00390S). Successful knockdown was achieved with: shRNA1: 5`-
CCGGCCCTACTGCAATGGAATCCAACTCGAGTTGGATTCCA TTGCAGTAGGGTTTTT-3`, shRNA2: 5`-
CCGGGCACAGAAAGGATTAAGAATTC TCGAGAATTCTTAATCCTTTCTGTGCTTTTT-3`.   
HEK293 packaging cells were transiently transfected with polyethylenimine (PEI) (Polysciences 
Inc.) at a PEI:DNA ratio of 4:1.  PEI was added to DNA diluted in serum-free media (8 μg pLKO.1-
puro backbone with shLacZ or shCopine III, 0.4 μg HDM-tat16, 0.4 μg HDM-HgPM2, 0.4 μg pRC-
CMV-RaII and 0.8 μg HDM-VSV-G), vortexed and incubated at RT for 15 min.  The PEI/DNA mix 
was added to the cells and incubated for 16h at 37°C, at which point the media was changed.  
Media containing viruses was collected 72h post-transfection, filter sterilized, aliquoted and 
stored at -80 °C. 
T47D and SKBr3 cells were infected by incubation in media containing 8μg/mL polybrene 
(Sigma) and 600 μl of viral supernatant for 24 h at 37 °C.  The media was then changed and the 
cells were incubated another 24 h at 37 °C. Cells infected with lentivirus for shRNA expression 
were cultured in medium supplemented with 0.5 ug ml-1 puromycin (BD Bioscience, Palo Alto, 
CA, USA).  Successfully infected cells were then maintained using 0.2 μg ml-1 puromycin and 
knock-down of Copine III was confirmed by western blotting. 
 
Wound healing assay 
Wound healing capability was analyzed using scratch assays. Cells were grown to confluency 
and starved for 8h in phenol red-free DMEM + 0.1 % FBS. Monolayers were scratched and 
stimulated with 1 nM HRG. Wound healing was monitored using a Widefield TILL5, LONG RUN, 
Axiovert 200M (5 % CO2 and 37 °C chamber). Time-lapse images were digitally captured every 
20 min with a CCD camera over 12 h. The area recovered by the migrating cells was calculated 
using ImageJ and plotted in Excel. For IF, cells were stimulated, scratched and allowed to 
migrate for 1.5 h, afterwards cells were treated as described previously (Meira et al., 2009). 
 
Tïssue microarray (TMA) design and immunohistochemistry analysis 
Cancer specific TMAs were prepared (Kononen et al., 1998) and analyzed as described (Capra et 
al., 2006; Confalonieri et al., 2009). 2 μm sections of the TMA block were cut, mounted on glass 
slides and processed for immunohistochemistry (IHC). Immunostaining for Copine III was 
performed using mouse monoclonal antibody (1:600 dilution) followed by detection with the 




EnVision Plus/HRP detection system (DAKO, Glostrup, Denmark). A semiquantitative approach 
was used to evaluate Copine III expression, which was scored as follows: 0, negative staining; 1, 
weak; 2, moderate; 3, intense. Samples showing IHC scores ≥ 1.0 were assigned to the Copine 
III-positive expression group (or high expression group), whereas those with IHC scores < 1.0 




Identification of Copine III as an ErbB2 binding partner by quantitative mass spectrometry 
To identify proteins that specifically bind to pTyr1248 of ErbB2, we used stable isotope labeling 
of amino acids in cell culture (SILAC) (Blagoev et al., 2003) in combination with an in-vitro 
peptide affinity pull-down approach (Schulze and Mann, 2004), followed by relative 
quantification by mass spectrometry (Figure 5-1a). Endogenous amino acids in the T47D breast 
cancer cell line were substituted by their light (Lys0 and Arg0) and heavy (Lys6 and Arg10) 
forms. Extracts from both populations were subjected to an affinity pull-down using peptides 
(Tyr and pTyr) encompassing Tyr1248 of the C-terminal tail of ErbB2. Bound proteins were 
eluted, subjected to SDS-polyacrylamide electrophoresis (PAGE), digested with trypsin and 
identified by LC-MS/MS.  
 
Over 100 proteins were identified in each individual pull-down experiment, however, only 
proteins identified by ≥ 2 peptides and with a Mascot protein score ≥ 20 were selected. For 
quantification, specific transitions for the light and heavy form of each peptide were measured 
over time using multiple reaction monitoring (MRM). The ratio of the peak area for the heavy 
form over that of the light form was calculated. The majority of the proteins yielded a 
quantification ratio of around 1, reflecting equal binding to the Tyr and the pTyr peptide 
(Figure 5-1b). A protein was considered as a specific binder if the mean ratio of all its quantified 
peptides was ≥ 1.5. Copine III (acc. AAH07017) was quantified with ratio of 1.8 in three 
independent experiments (Figure 5-1c). 
 
The selective binding of Copine III was confirmed using western blot analysis with a Copine III 
specific antibody. Tyr1248 and pTyr1248-containing peptides were incubated with T47D cell 
lysates and used as affinity reagents. Shc, which has been identified as a pTyr1248-binding 
protein (Dankort et al., 2001b; Schulze et al., 2005) was also examined as a control. These results 
confirmed the specific binding of Copine III to the pTyr1248-containing peptide (Figure 5-1d).   
 




Figure 5-1 Copine III preferentially binds to pTyr1248 of ErbB2 
(a) Schematic illustration of the peptide affinity method used to identify proteins 
binding to the pTyr1248 of ErbB2. 15-mer peptides encompassing the Tyr1248 of 
ErbB2, either phosphorylated or not, were bound to magnetic beads and incubated 
with protein extract from isotopically lysine (Lys6) and arginine (Arg10) labeled T47D 
cells (SILAC). Identification and relative quantification of proteins was done by mass 
spectrometry.  
(b and c) Multiple reaction monitoring of single peptide pairs. One transition for each 
form of a peptide (Lys0/Arg0 and Lys6/Arg10) was measured over time. Peak areas 
were compared using Analyst 1.4.1 (for details see supplementary Material and 
Methods) Representative spectra for a peptide pair from a background protein 
(Heterogeneous nuclear ribonucleoprotein K) and a specific binding protein (Copine 
III) are shown. 
 (d) Western blot analysis of Shc and Copine III binding to Tyr/pTyr1248.  Peptide 
pulldowns using HRG stimulated T47D cell extracts were performed and the bound 
proteins (elution) were monitored by western blot. As a control for equal loading, 
fractions of the input cell lysate were also loaded on the gel (input). 
 
 
Copine III is a Ca2+-dependent, membrane-binding protein 
Copine III belongs to a family of proteins, which have been shown to be Ca2+-dependent, 
phospholipid binders (Creutz et al., 1998; Tomsig et al., 2003). Copine III is ubiquitously 
expressed in human tissues (HUGE data base); however, essentially nothing is known about its 
role in normal or cancer tissue. It was shown that Copine III mRNA and protein are upregulated 
in response to ErbB2 expression levels and activation (Gharbi et al., 2002; White et al., 2004). 
Therefore we examined Copine III in more detail using the breast cancer cell lines T47D, with 




moderate ErbB2 levels, and SKBr3, which has ERBB2 amplification and very high levels of the 
receptor (Lane et al., 2000).  
 
The effect of Ca2+ on Copine III’s cellular location was first assessed by subcellular fractionation 
experiments. Cells were lysed in buffer containing CaCl2 or EGTA and crudely fractionated into 
cytoplasmic (C) and membrane (M) fractions. In both cell lines Copine III was enriched in the 
membrane fraction in the presence of Ca2+ and shifted to the GAPDH-containing cytoplasmic 
fraction after the addition of EGTA (Figure 5-2a). These results demonstrate that Ca2+ is required 
for Copine III localization to membranes. Calnexin, an integral membrane protein of the 
endoplasmic reticulum (ER), was detected in the crude membrane fraction. Thus, we used 
immunofluorescence microscopy (IF) to see whether Copine III bound to the ER or to the 
plasma membrane (PM) in response to Ca2+, by treating the cells with the Ca2+-ionophore 
ionomycin. Copine III was detected using a monoclonal antibody directed against its C2B 
domain. The specificity of the antibody was verified using Copine III knock-down (KD) cells (5-
3).  
 
Interestingly, for both cell lines, Copine III was detected in the nucleus upon treatment with 
ionomycin. However, the role of Copine III in the nucleus was not further pursued in this study. 
In control DMSO treated cells, Copine III was found mainly in the cytoplasm; treatment with 
ionomycin caused its re-localization to the PM (Figure 5-2b). In T47D cells, Copine III staining 
was enriched at cell-cell adhesion membranes (Figure 5-2b left), while in SKBr3 cells Copine III 
localized to specific regions at the PM (Figure 5-2b, right). Thus, Copine III is a Ca2+-dependent 
membrane-binding protein.  




Figure 5-2 Copine III localizes to membranes in a Ca2+-dependent manner 
(a) T47D and SKBr3 cells were incubated in buffer containing either CaCl2 or EGTA, 
disrupted by glass-glass homogenization (Dounce) and fractionated into cytoplasmic 
(C) and membrane (M) fractions. Equal volumes were subjected to SDS-PAGE and 
subsequent immunoblotting. Calnexin was used as a marker for the membrane and 
GAPDH for the cytoplasmic fraction.  
(b), Immunofluorescence microscopy (IF) of T47D and SKBr3 breast cancer cells. Cells 
were starved overnight and subsequently treated for 1.5min with 1μM ionomycin or 
DMSO in control cells. Copine III was visualized with a specific monoclonal antibody. 
Representative images are shown (scale bar: 20 μm). Inserts show 2x zooms of boxed 
regions. 
 





Figure 5-3 Specificity of the α-Copine III monoclonal antibody 
(a) Copine III was visualized with the monoclonal antibody using immunofluorescence 
microscopy in T47D wt and T47D Copine III KD cells. Excitation time and picture 
processing was the same for both images (scale bar: 20 μm). 
(b) T47D wt and Copine III KD cells were subjected to SDS PAGE and levels of Copine III 
were analyzed using the polyclonal peptide antibody (pAb) and the new monoclonal 
antibody against the C2B domain of Copine III (mAb).  
(c) T47D wt and Copine III KD cells were blottet for expression of Copine III and 
Copine-I, its closest homolog. Copine-I expression was unaltered in Copine III KD cells. 
(d) LacZ transduced and stable Copine III KD SKBr3 cell pools were embedded in 
paraffin blocks and IHC was performed using the Copine III specific monoclonal 
antibody. 
 
Copine III and ErbB2 co-localize and interact at the PM   
We explored the localization of Copine III and ErbB2 in the breast cancer cell lines using IF. In 
control T47D cells, Copine III was diffusely distributed throughout the cytoplasm. In response 
to HRG, Copine III re-localized to the PM, where it co-localized with activated ErbB2 (Figure 5-
4a). In control SKBr3 cells, most of Copine III was diffusely distributed throughout the 
cytoplasm, however, a portion also co-localized with the receptor at the PM. In SKBr3 cells 
ErbB2 has high levels of pTyr, even in the absence of ligands. HRG treatment caused ErbB2 to 
distribute along the PM, and increased Copine III at the membrane, where it co-localized with 
total ErbB2 (Figure 5-4b) and pTyr1248-ErbB2 (Figure 5-5). 




Figure 5-4 Co-localization of Copine III and ErbB2 at the plasma membrane 
T47D (a) and SKBr3 (b) cells were starved overnight and stimulated with HRG for 
20min, control cells were treated with PBS in parallel. Copine III and ErbB2 were 
visualized with their respective antibodies. The bottom panels are merged images, 
where yellow represents regions of Copine III and ErbB2 co-localization (scale bar:      
10 μm). Inserts show 2x zooms of boxed regions showing the co-localization of Copine 




Figure 5-5 IF staining of Copine III and pTyr1248-ErbB2 in T47D and SKBr3 cells 
T47D (a) and SKBr3 (b) cells were starved overnight and stimulated with HRG for 
20min, control cells were treated with PBS in parallel. Copine III and pTyr1248-ErbB2 
were visualized with their respective antibodies. The bottom panels are merged 
images, where yellow represents regions of co-localization of Copine III and pTyr1248-
ErbB2 (scale bar: 10 μm).  
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Next we used fluorescence resonance electron transfer (FRET) acceptor photobleaching 
(Kenworthy, 2001) to examine the interaction of Copine III and ErbB2 in fixed, HRG treated 
SKBR3 cells. Copine III and ErbB2 were labeled with specific primary antibodies and with a 
donor (Alexa488) and acceptor (Cy3) fluorophore-conjugated secondary antibody, respectively. 
Acceptor photobleaching was performed and FRET efficiency was measured at three regions: 
(1) at the membrane where both proteins co-localize, (2) in the cytoplasm where there is no co-
localization and (3) outside the cell to measure background fluorescence (Figure 5-6a). FRET 
efficiency (E) was calculated by comparing the Alexa488 intensities of region 1, after and before 
photobleaching of Cy3 (Figure 5-6b). Donor intensities were corrected for background 
fluorescence (region 3) as well as bleaching due to imaging (region 2).  
FRET efficiency was measured between ErbB2 and transferrin receptor (TR) and ErbB2 and 
Copine III. ErbB2 co-localized with both TR and Copine III at the PM, however, no FRET 
efficiency was measured between ErbB2 and TR (E = 0.6 ± 1), showing that these receptors co-
localize but do not interact (Figure 5-17b, left). Importantly, a significant FRET efficiency was 
found for ErbB2 and Copine III (E = 8.3 ± 1.3) (Figure 5-6b, middle). As a control, no FRET 
efficiency was measured for only Alexa488 labeling of Copine III (Figure 5-6b, right).  These 















Figure 5-6 FRET acceptor photobleaching shows the interaction of Copine III and 
ErbB2 at the plasma membrane 
SKBr3 cells were starved overnight and stimulated with HRG for 20min. Copine III and 
ErbB2 were labeled with their respective primary antibodies and visualized with an 
Alexa488-labeled anti-mouse and a Cy3-labeled anti-rabbit secondary antibody, 
respectively. 
(a) Representative images of a single cell before and after acceptor bleaching are 
shown. Three regions of interest (boxes 1-3) were taken for FRET efficiency 
calculations (see Materials and Methods) (scale bar: 5 μm). (b) Quantification of the 
FRET acceptor photobleaching experiments (ErbB2/Copine III, middle). In each 
experiment 4-10 individual cells were measured. As a control transferrin receptor (TR) 
was visualized with an Alexa488- and ErbB2 with Cy3-labeled secondary antibody and 
FRET efficiency was measured after acceptor photobleaching (ErbB2/TR, left). As an 
experimental control, Copine III only was visualized with an Alexa488-labeled 
secondary antibody and FRET efficiency was measured after photobleaching (Copine 




















Copine III interacts with the active ErbB2 receptor at the PM 
To test directly if Copine III interacts with active ErbB2, SKBr3 cells were pretreated with the 
ErbB tyrosine kinase inhibitor (TKI) AEE788 (Traxler et al., 2004) before stimulating with HRG. In 
TKI-treated cells there was a dramatic decrease in the pTyr content of ErbB2 as shown by 
immunoprecipitating the receptor and probing the immunoprecipitates (IP) with a pTyr 
specific antibody (Figure 3-7a, left). Additionally, the activity of the Akt and Erk pathways were 
also reduced (Figure 3-7a, right). IF revealed that the intense regions of ErbB2-membrane 
staining in control cells were lost in TKI-treated cells and the receptor re-localized to specific 
intracellular regions (Figure 3-7b). Strikingly, in AEE788 treated cells there was little or no 
Copine III at the PM in comparison to control cells, where there was intense membrane 
staining. Taken together, these results show that Copine III requires active ErbB2 signaling at 
the PM for its localization there. 
 
We examined complexes of Copine III and ErbB2 using co-IP experiments. ErbB2 was found in 
IPs of Copine III from lysates of T47D and SKBr3 cells (Figure 5-18c & e). In control cells an 
association of ErbB2 and Copine III was detected, reflecting autocrine receptor activity in T47D 
cells (Meira et al., 2009) and ErbB2 overexpression in SKBr3 cells (Lane et al., 2000). In Copine III 
IPs from lysates of HRG-treated cells there was an increase in complexed, active pTyr-
containing ErbB2 (Figure 5-7c & e). Copine III does not possess an SH2- or a PTB-pTyr binding 
domain. Shc has both domains and has also been found associated with pTyr1248 (Dankort et 
al., 1997; Schulze et al., 2005) (Figure 5-1).  Shc was detected in Copine III IPs from lysates of 
T47D cells, and Shc levels increased in response to HRG (Figure 5-18d). Together, these data 
provide evidence that Copine III is found in complexes with ErbB2 and with Shc, the latter 
perhaps mediating Copine III binding to the receptor. 
 
 




Figure 5-7 The localization of Copine III depends on activity of the ErbB2 
receptor 
SKBr3 cells were starved overnight, treated for 1.5 h with 0.5 μM AEE788 or DMSO, for 
controls, and stimulated for 20 min with HRG or PBS, for controls. 
(a) Extracts of control and treated cells were taken for western blot analysis. ErbB2 was 
immunoprecipitated and its phosphorylation status was monitoring using a pTyr-
specific antibody (a, left panel). Inhibition of downstream signaling pathways was 
monitored by western blotting of total lysates for Erk1/2, Akt and their 
phosphorylated forms.   
(b) The localization of Copine III and ErbB2 in HRG treated SKBr3 control- and AEE788 
treated cells was visualized by IF using their respective antibodies. Images of 
representative cells are shown (scale bar: 10μm). Inserts show 2x zooms of boxed 
regions focusing on the plasma membrane. 
(c, d and e) Co-immunoprecipitation of Copine III, ErbB2 and Shc. Copine III was 
immunoprecipitated from lysates of control and HRG-stimulated T47D (c, d) or SKBr3 
(e) cells using a specific monoclonal antibody. The co-IPs were probed for ErbB2 and 
overall pTyr on ErbB2 (pY in c, e) or for Shc (d). Whole cell extracts (WCE) are shown on 












Copine III interacts with RACK1 and both proteins complex with ErbB2   
To gain more insight into the role of Copine III in ErbB2-mediated cellular signaling, we sought 
to identify Copine III binding partners. For this, SKBr3 cells with incorporated light or heavy 
isotopes of lysine and arginine (SILAC) were transfected with an empty control vector or a Flag- 
tagged Copine III, respectively. After stimulation with HRG, anti-Flag affinity purification was 
performed and Copine III binding partners were identified by MRM (Figure 5-8a). The analysis 
yielded several putative binding partners (Table 5-1), one of these being RACK1, receptor of 
activated C kinase (Ron et al., 1994)(Figure 5-8a). In an independent experiment we quantified 
the relative amounts of RACK1 in Copine III IPs from SKBr3 lysates by MRM. We found a 1.5-fold 
enrichment of RACK1 in Copine III IPs vs. control IPs (data not shown), confirming the 
interaction. An examination of ErbB2 IPs from SKBr3 and T47D cells showed that ErbB2 is 









Figure 5-8  Copine III binds RACK1 and localizes to focal adhesions 
(a) Identification of Copine III binding partners. SKBr3 labeled with SILAC (light 
(Lys0/Arg0) or heavy (Lys6/Arg10) isoforms) were transiently transfected with an 
empty vector or a vector expressing Flag-Copine III, respectively. Proteins were 
extracted and subjected to an affinity purification using anti-Flag columns. Specific 
binders to Flag-Copine III were identified by LC-MS/MS and quantified using MRM. The 
protein ratios (heavy/light) of all quantified proteins were plotted. The cut-off for 
specific binders was determined by assuming a normal distribution and setting the 
cut-off to ±2σ from the mean. 
(b + c) Co-IP of Copine III, Shc and RACK1 with ErbB2 in HRG-stimulated cells. In IPs of 
ErbB2 from HRG-treated SKBR3 (b) and T47D (c) cells ErbB2 Tyr1248  phosphorylation 
was monitored with  a specific antibody. In a further experiment ErbB2 co-IPs were 
monitored for Shc, Copine III and RACK1 by western blotting. ErbB2 phosphorylation 
was monitored using a total phospho-tyrosine (pY) antibody. In parallel IgG IPs were 












Copine III localizes to focal adhesions and is required for ErbB2-dependent tumor cell migration 
The adaptor protein RACK1 acts as a scaffold in numerous signaling events including cell 
migration, where it has been shown to localize to nascent focal adhesions (FAs) (Cox et al., 
2003). Our finding that Copine III interacts with RACK1 prompted us to examine whether 
Copine III might also have a role in cell migration. First, we used IF to examine Copine III 
localization. Copine III and phosphorylated focal adhesion kinase (pTyr397FAK) were both 
diffusely present in the cytoplasm of control T47D cells and upon HRG treatment co-localized 
at the PM (Figure 3-9a), suggesting that Copine III is a FA-associated protein.  
 
Next we examined the role of Copine III in cell migration using a KD approach.  Two pools of 
Copine III KD cells and a pool expressing the control (LacZ) vector were generated in T47D cells. 
Copine III KD was almost complete in pool 2, while it was approximately 50 % in pool 1 (Figure 
5-9b, insert). The effect of Copine III KD on migratory ability of T47D cells was examined using a 
wound healing assay. Wound closure of control and Copine III KD cultures left untreated or 
stimulated with HRG was monitored over 12h (Figure 5-9b). Basal migration of control cells was 
low and not affected by Copine III KD.  Importantly, compared to control cells, HRG-stimulated 
Copine III KD cells were significantly impaired in their ability to migrate into the wound 
(p<0.005) (Figure 5-9b).  
 
The localization of Copine III, pTyr397FAK and ErbB2 was also examined in wounded 
monolayers. In untreated cells none of these proteins strongly localized to the cell membrane 
(Figure 5-9c and d, PBS). In contrast, in HRG-treated cultures, Copine III, pTyr397FAK and ErbB2 
were each present in membrane protrusions at the edge of the wounded area. Moreover, a 
high degree of overlap between Copine III and pTyr397FAK staining (Figure 5-9c) and Copine III 
and ErbB2 staining (Figure 5-9d) was evident. In Copine III KD cells, pTyr397FAK and ErbB2 were 
localized to membrane protrusions in response to HRG (data not shown), showing that these 
events are not dependent upon Copine III.  
 
Src and FAK, two proteins with important roles in cell migration were further analyzed. Src, but 
not FAK, was found in complex with ErbB2 after HRG stimulation (Figure 5-9e). 
A western analysis revealed that Src activity increased in control HRG treated cells, as shown by 
the increase in pTyr418Src levels. In contrast, there was little or no increase in pTyr418Src levels 
in the two Copine III KD pools (Figure 3-9f). Moreover, the level of pTyr925FAK, a site that has 
been shown to require Src kinase activity to become phosphorylated (Brunton et al., 2005), also 
increased in HRG-treated control cultures, while little or no increase was observed in Copine III 
KD pools (Figure 5-9f), attesting to the decrease in Src activity.  In contrast to the effects on Src 
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kinase activity, activation of the Akt and Erk pathways was similar in response to HRG-
treatment in the Copine III KD cultures and the control cells (Figure 5-9f). These findings imply 
that Copine III might be a component of focal adhesions that is required for Src activity and 
thus for regulating focal adhesion turnover and ErbB2-mediated migration in response to HRG.  
 
 
Figure 5-9 Copine III has a role in HRG-mediated T47D cell migration. 





               Figure 5-9  
(a) Co-localization of Copine III and phosphorylated focal adhesion kinase (pFAK). 
T47D cells were starved overnight and stimulated with 5 nM HRG for 20min. Control 
cells were treated with PBS in parallel. Copine III and pTyr397FAK were visualized 
using their respective antibodies. Merged images in the bottom panel include 
Hoechst staining for the nucleus in blue (scale bar: 10 μm). The arrows indicate areas 
of co-localization.  
(b) Wound healing assay in T47D Copine III KD pools. Two pools of Copine III KD T47D 
cells were generated with different shRNA targeting vectors (KD1 and 2). A control 
LacZ pool was also prepared. Expression levels of Copine III in the KD1 and KD2 and 
the LacZ pools is shown; GAPDH is the loading control (insert). T47D cells were grown 
to confluency, starved in DMEM for 8 h, then stimulated with 1 nM HRG and 
subsequently scratched. Cell migration into the wound was monitored for 12 h in 4-6 
regions of the scratch. The recovered area of the wound is shown by the mean ± SEM. 
* P < 0.005 
(c and d) Localization of Copine III and pTyr397FAK (c) and Copine III and ErbB2 (d) in 
migrating T47D cells. Cells were grown to confluency, starved overnight, then 
stimulated with 5 nM HRG, scratched and allowed to migrate for 1.5 h before they 
were fixed and stained. Copine III, pTyr397FAK and ErbB2 were visualized by IF using 
their respective antibodies. The direction of migration into the wound is indicated by 
the arrow. Merged images in the bottom panel include Hoechst staining for the 
nucleus in blue (scale bar: 10 μm). Inserts show 2x zooms of boxed regions focusing 
on the leading edge of the migrating monolayer. 
(e) Co-IP of Src with ErbB2 in HRG-stimulated T47D cells. IPs of ErbB2 from HRG-
treated T47D cells were monitored for Src and pY418 Src by western blotting. ErbB2 
was monitored using a total ErbB2 antibody and its phosphorylation was analyzed 
using a pTyr1248 specific antibody. In parallel IgG IPs were probed as controls. Whole 
cell extracts (WCE) are shown on the left. 
(f) The two pools of Copine III KD T47D cells, the control LacZ pool and the parental 
cells were treated or not with HRG for 20min. Cell lysates were prepared and western 
blots were probed for the level of FAK, pTyr925FAK, Src, pTyr481Src, Akt, pAKT, Erk1/2, 
pErk1/2 and Copine III.   
 
 
Copine III expression in human cancer 
We examined Copine III and ErbB2 expression levels in breast tumor cell lines and primary 
tumors. Copine III was expressed to varying degrees in the breast cancer cells lines, with the 
highest levels in SKBr3 and BT474, both having ERBB2 amplification (Figure 5-10a). These data 
correlate with previous publications showing Copine III upregulation in response to ErbB2 
overexpression (Gharbi et al., 2002; White et al., 2004).  We also examined Copine III RNA 
expression in 49 primary breast tumors (Farmer et al., 2005). Plotting log gene expression 
values of ERBB2 against expression values for CPNE3 revealed that high levels of CPNE3 were 
significantly correlated with ERBB2 amplification; 10 of 11 tumors with the highest level of 
Copine III also possessed the amplicon (Figure 5-10b).   
 




Figure 5-10 Copine III expression correlates with ErbB2 amplification in breast 
cancer 
(a) Protein expression levels of Copine III and ErbB2 were analyzed in different breast 
cancer cell lines by western blotting. WCEs for each cell line were subjected to western 
blotting and probed for ErbB2, Copine III and Erk1/2 as loading control. The ErbB2 
amplification status is indicated by +/-. 
(b) Evaluation of CPNE3 expression values  in 49 primary breast tumor samples (Farmer 
et al., 2005). Log expression of CPNE3 is plotted on the y-axis and ERBB2 log expression 
values on the x-axis. Axes are plotted through the median expression levels of CPNE3 
and ERBB2, respectively. The different subtypes of the analyzed breast tumors are 
denoted: Basal ( ), apocrine ( ) and luminal ( ). ERBB2 amplified tumors are 
















We also performed an analysis of Copine III expression in different human tumors, initially 
examining data from published transcriptome studies (www.oncomine.org) (Rhodes et al., 
2004). We found that CPNE3 expression increased significantly in metastatic prostate cancer in 
comparison to normal prostate and non-metastatic tumors (data from (Yu et al., 2004)) (Figure 
5-11a). Moreover, in comparison to normal ovary, there were significantly higher levels of 
CPNE3 in ovarian endometrioid adenocarcinoma (OEA), the second most common type of 
ovarian cancer (data from (Hendrix et al., 2006)) (Figure 5-11b).  
 
Based on these findings we performed IHC staining of Copine III in breast, prostate and ovarian 
TMAs. There was a tendency for Copine III to be up-regulated in the epithelial component of 
cancer tissue compared to normal tissue (Figure 5-11c). Some Copine III staining was evident in 
normal breast, while normal prostate and ovarian tissues have very low levels of Copine III 
(Figure 5-11d). Tumors of all three types showed higher Copine III levels. These finding suggest 
that the up-regulation trend revealed by the Oncomine analysis is retained at the protein level, 
implying a potential biological function of Copine III in human cancer. 




Figure 5-11 Expression of Copine III in breast, prostate and ovarian cancer 
samples 
(a and b) CPNE3 expression analysis in different microarray datasets from the 
Oncomine database (www.oncomine.org) (Rhodes et al., 2004). CPNE3 RNA expression 
levels in samples from normal prostate tissue, carcinoma and metastatic prostate 
carcinoma are shown (Yu et al., 2004)(a) as well as in normal ovary and ovarian 
endometrioid adenocarcinoma samples from the Hendrix et al. dataset (Hendrix et al., 
2006)(b).  
(c) Analysis of Copine III expression in a human breast, prostate and ovarian tissue 
microarray (TMA). The table shows the number of samples analyzed for normal (N) 
and tumor tissue (T) for the respective cancer type. The number of Copine III positive 
samples is annotated as well as their percentage from all analyzed samples using a 
cut-off of > 1.0 for breast and ≥ 1.0 for prostate and ovarian tissue samples. 
(d) Examples of IHC staining for Copine III using the monoclonal antibody in breast, 
prostate and ovarian normal and cancer tissue samples. The magnification is 20x. The 
arrow heads indicate nuclear Copine III staining.  
 






ErbB2 has been shown to play a pivotal role in various types of human cancer.  In breast cancer, 
ErbB2 overexpression correlates with aggressive disease and a metastatic phenotype (Hynes 
and Lane, 2005). In search of novel ErbB2 effector proteins, we identified Copine III via its ability 
to specifically bind an ErbB2 pTyr1248-containing peptide. Our results show that Copine III 
interacts with ErbB2 at the plasma membrane of breast tumor cells in response to HRG 
treatment. Moreover, we show that Copine III binds the focal adhesion-associated protein 
RACK1 and is also present in focal adhesions in cells with active ErbB2. Importantly, KD of 
Copine III in T47D breast tumor cells causes a decrease in HRG-induced migration. Our results 
suggest that Copine III is a novel ErbB2-interacting protein that might link ErbB2 to focal 
adhesions, thereby contributing to HRG induced cell motility.  
 
Copines are a conserved family of ubiquitously expressed proteins found in many eukaryotic 
organisms (Tomsig and Creutz, 2002). Copines possess two C2 domains (C2D-A and C2D-B) and 
an A domain; C2Ds are responsible for Ca2+-dependent membrane-binding properties and A 
domains bind proteins (Tomsig et al., 2003). Copine family members from various organisms 
have been shown to bind membranes (Church and Lambie, 2003; Gottschalk et al., 2005; Hua et 
al., 2001). Bioinformatic analysis showed that aspartate residues required for Ca2+-binding are 
conserved in both Copine III C2Ds. Additionally, between the C2D-B and the A domain of 
Copine III there is a Lys-rich cluster, which, in PKCs, has been shown to bind 
phosphatidylinositol(4,5)P2 thereby strengthening membrane affinity (Guerrero-Valero et al., 
2007). Using IF we show that Copine III and ErbB2 co-localize to the PM after HRG stimulation. 
Moreover, in FRET acceptor photobleaching experiments we measured a FRET efficiency of 8 ± 
3 between ErbB2 and Copine III, which agrees well with the FRET efficiency of 14 ± 3 between 
ErbB2 receptors (Nagy et al., 1998). Taken together, our analysis of Copine III suggests that it is a 
Ca2+-dependent membrane-binding copine that responds to ErbB2 activation and localizes to 
the PM in close proximity to the receptor.  
 
How does Copine III interact with ErbB2? C2Ds have been classified as Type I and Type II 
(Nalefski and Falke, 1996) and the Type II C2D of PKCδ has been shown to directly bind specific 
pTyr-containing peptides (Benes et al., 2005). However, we consider it unlikely that Copine III 
directly binds ErbB2 since a bioinformatic analysis suggested that Copine III’s C2Ds are both 
likely to be Type I. Moreover, the residues in PKCδ that have been shown to be essential for 
pTyr binding are not conserved in Copine III.  We favor the hypothesis that Shc, which 
possesses both an SH2 and a PTB domain, mediates Copine III’s interaction with ErbB2. Indeed, 
5. Copine III and ErbB2-mediated migration 
 
90 
complexed Shc was identified in Copine III co-IPs (Figure 5-7d). Although copines have been 
linked to other membrane receptors, including the nicotinic acetylcholine receptor in C. 
elegans and the TNFα receptor in HEKs (Gottschalk et al., 2005; Tomsig et al., 2004), this is the 
first description of a copine interaction with ErbB2 or any other RTK.   
 
Copine A domains have been shown to selectivity bind various proteins (Tomsig et al., 2003), 
which suggests that different copines respond to Ca2+ signals by transporting selectively bound 
proteins to phospholipid-containing membranes, where they influence activity of signaling 
pathways. Using mass spectrometry we identified seven Copine III interacting proteins, RACK1 
(Figure 5-8) and six other cytoplasmic and nuclear proteins (Table 5-1). This is interesting since 
we also observed enhanced Copine III nuclear staining following Ca2+ stimulation or HRG 
treatment (Figure 3-13b and 3-15) and Copine III nuclear staining was observed on breast and 
prostate TMAs (Figure 3-11d, arrows). However, this was not pursued further in our studies, 
which were focused on the Copine III binding partner RACK1.  
 
 
Table 5-1  Putative Copine III binding partners 
Candidates found to specifically bind to Flag-Copine III are listed with their accession 
number, protein name and ratio of quantification. For the ratio peak areas for the 




The adaptor protein RACK1 acts as a scaffold in numerous signaling events including cell 
migration, where it has been shown to localize to nascent focal adhesions (FAs) (Cox et al., 
2003). RACK1 was recently shown to associate with, and be required for FAK activation (Kiely et 
al., 2009). We provide evidence that Copine III binds RACK1 and co-localizes with pFAK at focal 
adhesions in the migrating front of breast cancer cells. Moreover, in Copine III KD cells we 
observe decreased Src-activity and decreased FAK-phosphorylation at the Src site (pY925). 
Phosphorylation of Tyr925FAK by Src is required for proper focal adhesion turnover and cell 
migration (Brunton et al., 2005). A RACK1-Src association has been described (Miller et al., 2004). 
Thus, we postulate that Copine III is a ErbB2- and Ca2+-dependent membrane binding protein 
that functions at focal adhesions, where it contributes to Src activity and tumor cell migration. 
The exact mechanism by which Copine III influences cell migration still remains to be 




elucidated in future studies. Since other cellular read-outs, such as proliferation and anchorage-
independent growth were unaltered in Copine III KD T47D cells, Copine III’s influence in 
response to HRG appears to be specific to migration (Figure 5-12). 
 
 
Figure 5-12  Analysis of Copine III KD cells 
 (a) The relative proliferation of control and Copine III KD T47D cell pools was 
monitored using the methylene blue assay as shown previously (Boulay et al., 2008). 
Cell proliferation was measured in DMEM + 10 % FBS for 4 days. The relative 
proliferation is shown by the absorbance at 650nm. 
(b) The potential for anchorage-independent growth was measured in T47D control 
and Copine III KD (siRNA) cells. Cells were plated on polyhema-coated plates and 
allowed to grow without and in the presence of HRG (Boulay et al., 2008). The fold 
induction of growth compared to the unstimulated cells is shown. The KD of Copine III 
was verified by western blotting at the end of the experiment. 
 
 
By performing pull-down assays with ErbB2 pTyr-containing peptides we have identified 
multiple proteins with roles in migration (Marone et al., 2004). PLCγ1 and Memo were shown to 
interact with pTyr1996 and 1222, respectively, and cells with KD of either protein were 
impaired in HRG-induced directional migration (Meira et al., 2009). Using a KD approach, we 
show here that Copine III is also required for HRG-induced T47D cell migration. It is tempting to 
speculate that in cells with low Copine III, ErbB2 loses its ability to couple to proteins and 
pathways involved in motility. Considering these and other proteins that interact with ErbB2, 
we propose the following model: In response to ligand activation, ErbB2 binds and activates 
PLCγ1 (Meira et al., 2009), which causes an increase in diacylglycerol (DAG) levels and initiates 
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Ca2+ influx from the ER and through store-operated channels into the cytoplasm (Kheifets and 
Mochly-Rosen, 2007); (Patterson et al., 2005). Interestingly, specific residues that have been 
mapped in the C2D of PKCα as being essential for RACK1 binding (McCahill et al., 2002), are 
conserved in Copine III C2D-B. Therefore, it might be possible that RACK1, which is thought to 
direct PKCs to specific membrane locations (Kheifets and Mochly-Rosen, 2007), might also 
direct Copine III to the plasma membrane in close proximity to ErbB2. This enables Copine III to 
interact with the receptor and influence Src activity and cell migration (Figure 5-13). 
 
 
Figure 5-13 Hypothetical model for the role of Copine III in ErbB2-dependent cell 
migration. 
Upon stimulation of ErbB2/ErbB3 heterodimers with HRG (1), PLCγ1 binds pTyr1996 of 
ErbB2 and, once activated, cleaves PIP2 into DAG and IP3 (2), which binds IP3R (3) 
leading to the release of Ca2+ from intracellular stores and through store-operated 
channels (4). Ca2+ influx allows Copine III to re-locate to the nucleus or the plasma 
membrane (5). The elucidation of a putative role for Copine III in the nucleus awaits 
further investigation. At the PM, RACK1 directs it to a specific membrane location in 
close proximity to ErbB2. It is possible that Copine III interacts with RACK1 via a 
conserved motif in the C2D domain (McCahill et al., 2002). Copine III associates with 
pTyr1248, very likely via Shc, and influences Src activation (6), thereby influencing 
ErbB2-induced cell migration (7). We have seen a direct interaction of Src with ErbB2 
in our experiments, which we have shown here. We have drawn a direct Shc-Copine III 
interaction, however, as indicated by the dots, it is possible that another protein 
mediates the interaction. 
 
In primary human tumors there was some evidence for a functional relationship between 
Copine III and ErbB2, since Copine III mRNA and protein levels were shown to correlate with 
ErbB2 expression (Gharbi et al., 2002; White et al., 2004). We have extended these studies by 
examining a panel of 49 breast tumors (Farmer et al., 2005) and showing that there is a 
significant correlation between CPNE3 RNA levels, and ERBB2 gene amplification and 




expression,. Furthermore, data mining (Oncomine) and data from our own TMAs provide 
evidence that Copine III levels are increased in prostate and ovarian tumors. Taken together, 
these results suggest that Copine III function might be important in multiple cancer types. Our 
results implicate Copine III as an important player in ErbB2-mediated cancer cell motility 
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6 COPINE III IN VIVO 
6.1 Introduction 
 
In the previous section we showed how Copine III was identified as an ErbB2-interactor and 
illustrated its role in cell migration. Cell migration is a key trait of both unicellular as well as 
multicellular organisms. Cells are required to migrate during embryogenesis and in the adult, 
for example during wound healing. In cancer, cell migration plays a pivotal role, since cancer 
cell migration is an initial step of tumor metastasis. Tumor cells migrate from the initial tumor 
to invade the surrounding tissue and the lymphatic or blood vasculature, which they 
subsequently leave again to form metastasis. In breast cancer, metastatic tumors often spread 
to the brain, which correlates with a very poor prognosis for the patients. Therefore, it is 
important to elucidate the mechanisms underlying cancer cell migration. 
Since we detected a migration phenotype (scratch assay, section 5.3) for Copine III KD cells, we 
wanted to follow-up on this studying the effect of a Copine III KD in vivo. The idea was to first 
assess the in vivo tumor growth of Copine III KD cells and later on analyze their metastasis 
potential. However, in this section only the in vivo tumor growth assays will be discussed, as the 
metastasis analysis has not been performed up to date. 
 
6.2 Materials and Methods 
 
Generation of Copine III rescue cell pools 
For each rescue construct three synonymous (silent) mutations were introduced into the DNA 
sequence of Copine III in such a way that the shRNA can no longer recognize the mRNA. Thus 
Copine III will be expressed and not silenced in cells expression these constructs. Furthermore, 
due to the silent mutations introduced the amino acid sequence of Copine III will stay intact. 
These rescue constructs were cloned into pLNCX2, a plasmid carrying a CMV promoter and a 
Hygromycin resistance that is often used for retroviral infections.  
Two days after seeding the packaging cell line HEK293 was transfected by adding 15 μl Fugene 
directly to 185 μl Optimem. Six μl DNA were added to this mix and incubated for 30 min at RT. 
The mixture was added dropwise to the cells. One day after transfection the medium was 
changed to fresh and after another it was harvested. The medium was filtered through a       
0.45 μm cellulose acetate filter, 30 μl of 4 mg/ml polybrene were added and the mixture was 
used to infect the Copine III KD cells. Fresh medium was added to the packaging cell line, and 
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virus harvested 24 h later for a second infection. Two days after the initial infection the 
selection was started using 500 μg/ml Hygromycin B. After selection the cells were maintained 
in 200 μg/ml Hygromycin B. 
 
Proliferation assay –methylene blue 
Cells (2500/well) were seeded in 100 μl DMEM + 10 % FCS into a 96-well plate and allowed to 
attach for 24 h. At day 0 the cells were treated or not with 1 nM HRG. Cells were analyzed at day 
0, 2 and 4. For this the cells were fixed by adding 25 μl 20 % glutaraldehyde solution to the 
medium for 10 min. Afterwards, the cells were washed 3x in H2O and stained with 50 μl 0.05 % 
methylene blue for 10 min. Again, the cells were washed 3x with H2O and then lysed in 3 % HCl 
for 30 min. The absorbance was read at 650nm and plotted as a measure for the relative 
proliferation of the cells.  
 
PolyHema assay 
Six cm plates were coated with poly(2-hydroxyethylmethacrylate) (PolyHema) to prevent cells 
from attaching to the surface. Cells (1x106) were seeded at day 0 and stimulated or not with 1 
nM HRG. Cells were left to grow for 4 days and afterwards counted. The total viable cell number 
was plotted as a read-out for the ability of the cells to grow in anchorage-independent 
conditions. 
 
Migration assay – Boyden chamber 
The ability of the cells to migrate in a ligand gradient was assayed in Boyden chambers. The 
bottom membrane was coated with 25 μl/ml collagen I. Cells were starved overnight in DMEM 
+ 0.1 % FCS, harvested and counted. Cells (1x105) were seeded in serum-free medium in the 
upper chamber. 600 μl medium with or without 1 nM HRG were put into the lower chamber. 
The cells were allowed to migrate through the membrane in a ligand gradient for 3 h. 
Afterwards the non-migrating cells were removed with a cotton swab and the migrated cells 
were fixed with 4 % paraformaldehyde for 30 min. The nuclei were stained with Hoechst and 
the number of migrated cells was counted.  
 
Adhesion assay 
Nunclon Surface plates were coated with collagen (10 μg/ml), laminin (10 μg/ml) or fibronectin 
(10 μg/ml).  After that the wells were blocked with 10 μl 10 mg/ml BSA for 1 h at RT. Cells 
(1.5x105 / ml) were seeded in 10 μl in triplicate per condition +/- 1 nM HRG and allowed to 
adhere for 1 or 2 h. Then the plate was flooded with PBS to remove non-adherent cells. 
Adherent cells were fixed in 4 % paraformaldehyde and stained using crystal violet. Cells were 
counted and the mean of the triplicate +/- SD was plotted. 





Injection of cells into the mammary fat pad and tumor measurements 
Cells (1x106) were injected into the 4rth mammary fat pad of 4-6 week old nude mice.  
Tumor growth in vivo was measured twice a week following the injections. Mice were sacrificed 
once tumors reached a size close to 2 cm3. Tumor length and width was determined and the 







Dissection of tumors, preservation and cutting 
Tumors were excised and their final weight measured. The tumor was fixed in freshly prepared 
4 % paraformaldehyde in PBS. Half of the material was stored in 70 % ethanol until embedding 
in paraffin. The other half was put into 30 % sucrose and frozen embedded into O.C.T.. 




Stainings were carried out with the Discovery XT Staining Module (Ventana Medical Systems). 
Images were acquired with a Leica DFC420 camera on a Nikon Eclipse E600 microscope using 
Plan Fluor 10x/0.3 and 20x/0.5 lenses.  
Sections were stained for KI-67 (proliferating cells), cleaved caspase 3 (apoptotic cells), CD31 
(vessels) and Copine III.  
 
Protein and RNA extraction 
Snap frozen tumors were resuspended in 500-1000 μl lysis buffer and homogenized using a 
tissue homogenizer. Extracts were spun at 13200 rpm for 30 min to remove debris. Total 
protein content in the supernatant was measured using Bradford. 
RNA was extracted using TRIzol reagent and washed using the RNAeasy Mini kit according to 
the manufacturer’s instructions.  
 
Microarray 
Total RNA was isolated from 3 individual tumors per group (Parental, Copine-III shRNA1, 
Copine-III shRNA-2). All RNAs were individually amplified and labeled using the Ambion 
MessageAMP III RNA amplification kit. Biotinylated, fragmented cRNA was hybridized to 
Affymetrix U133 plus 2.0 human GeneChipsTM (Affiymetrix). Expression values were estimated 
using the GC-RMA implementation found in Gendata’s Refiner 4.5 software.  
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The data analysis and gene filtering was performed using R/Bioconductor (Gentleman, 2004 
#58). Signal condensation was performed using only the RMA from the Bioconductor Affy 
package. Differentially expressed genes were identified using the empirical Bayes method (F-
test) implemented in the LIMMA package and adjusted with the False Discovery Rate (FDR) 
method (Wettenhall, 2004 #59). Hierarchical clustering and visualization was performed in R. 
Gene lists from the resulting contrasts were further classified into regulatory networks and 
pathways with Ingenuity Pathways Analysis (Ingenuity® Systems). A data set containing gene 
identifiers and corresponding expression values was uploaded into in the application. 
Each gene identifier was mapped to its corresponding gene object in the Ingenuity Pathways 
Knowledge Base. These genes, called focus genes, were overlaid into a global molecular 
network developed from information contained in the Ingenuity Pathways Knowledge Base. 
Networks of these focus genes were then algorithmically generated based on their 
connectivity. Functional analyses associated with biological functions and/or diseases in the 
Ingenuity Pathways Knowledge Base were considered and Fischer’s exact test was used to 
calculate a p-value determining the probability that each biological function and/or disease 
assigned to that data set is due to chance and chance alone. The networks/pathways shown 




Stable downregulation of Copine III in MDA-MB-231 cells 
For these experiments we used the MDA-MB-231 breast cancer cell line, which is regularly used 
to monitor tumor growth and tumor metastasis in vivo. Using the same shRNA sequences as 
described in Section 5.3, the protein expression of Copine-III was stably downregulated in 
these cells. In parallel, control cells were transduced with a LacZ-shRNA construct. After 
selection of cell pools carrying the shRNA-vectors, KD levels of Copine III were assessed by 
western blotting with specific antibodies. Furthermore, the cell pools were screened for 
differences in their ability to activate several signaling pathways downstream of ErbB2 as well 
as in their proliferation, adhesion and transformation potential.  
 
Western blots of cell extracts from control cells and cells that were treated with 1 nM HRG for 
10 minutes showed that there was a clear downregulation of Copine III in the KD cell pools. 
However, the major signaling pathways downstream of the ErbB2 receptor, such as the MAPK 
or PI3K pathways (data not shown), were not affected from the KD of Copine III (Figure 6-1).  
 




It is important to mention, that the MDA-MB-231 cell line is not dependent on ErbB2 signaling. 
It has an activating Ras mutation and an autocrine loop of HRG production. Therefore, 
stimulation with HRG is not expected to show changes as it would do in ErbB2-dependent cell 






Figure 6-1 Analysis of major signaling pathways in Copine III MDA-MB-231 KD 
cells 
MDA-MB-231 cells were starved in DMEM + 0.1 % FCS overnight and stimulated with 
1nM HRG for 10 minutes. 10 μg WCE were used for the analysis. Protein expression 
levels of Copine III, pFAK (Y397), pFAK (Y861), pMAPK (T202/Y204), pTyr (ErbB2) and 
GAPDH as loading control were assessed. 
 
Analysis of Copine III KD MDA-MB-231 cells 
After confirming that the KD of Copine III was efficient in these cell pools we analyzed them in 
several assays prior to the in vivo experiment. First we assessed their proliferation potential 
using the methylene blue assay for various stable pools of cells resulting from different 
infections. No significant difference in rate of proliferation upon the KD of Copine III was 
observed (Figure 6-2). 
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Figure 6-2 Proliferation of MDA-MB-231 Copine III wt and KD cells 
The relative proliferation of the cells was measured using the methylene blue assay. 
Cell were treated or not with 1 nM HRG for the entire duration of the assay (-/+).The 
relative proliferation is plotted as the absorbance at 650 nm. 
 
In addition, the migration of the MDA-MB-231 Copine III KD pools was assessed using the 
Boyden chamber assay (Figure 6-3). The first observation in this assay was that there was no 
difference between starved and HRG-stimulated cells for any cell line. The cells of the shRNA1 
pool seemed to migrate a lot more that all the other cells. But then again the 2nd KD pool was 
similar in its migration rate to the wt and LacZ pool arguing for no difference in Boyden 
chamber migration upon KD of Copine III in these cells (Figure 6-3). However, at this point no 






Figure 6-3 Migration assay (Boyden chamber) of MDA-MB-231 Copine III wt and 
KD cells 
Parental and KD cell pools of MDA-MB-231 cells were seeded in Boyden chambers and 
allowed to migrate in a gradient of PBS (ctrl) or HRG for 3 h. Afterwards the nuclei of 
the migrated cells were stained with Hoechst and the number of migrated cells was 
counted. The average number of cell from triplicate is plotted as the mean and 
standard deviation of the mean. 




To find out whether Copine III plays a role in cell adhesion we assessed the adhesive properties 
of wt and Copine III KD MDA-MB-231 cells on different coatings. For this, plates were coated 
with fibronectin, collagen or laminin. Each of these is a component of the extracellular matrix 
that surrounds the cells and binds to specific integrins. It has been shown that the ErbB2 
receptor can cross-talk with integrins to initiate downstream signaling. Therefore, we wanted 
to identify whether Copine III, as a interactor of ErbB2 has an effect on cell adhesion. 
Furthermore, we found in previous experiments (see section 5.3) that Copine III associates with 
and influences components of focal adhesions, such as focal adhesion kinase, which are 
important mediators of cell adhesion to a substrate. However, all previous experiments were 
performed  in ErbB2-dependent cell lines and the cell lines used in this experiments, MDA-MB-
231, carries other mutations making it a transformed cell line (e.g. constitutively active Ras) and 
is therefore not dependent of ErbB2 signaling. 
We found that a KD of Copine III had no effect on cell adhesion on either substrate (Figure 6-4).  
 
Adhesion in 0.1% FBS 
Adhesion in 10% FBS 
 
 
Figure 6-4 Adhesion of MDA-MB-231 Copine III wt and KD cells to fibronectin and 
collagen 
Wt, LacZ and Copine III KD cell pools were plated on plates coated with fibronectin, 
collage or laminin and allowed to adhere for 1 h or 2 h, respectively. The cells were 
plated either in medium containing 10 % FCS or containing 0.1 % FCS. Non-adherent 
cells were washed off the plates and the remaining cells were fixed, stained with 
crystal violet and counted. Plotted is the mean of adherent cells from three wells with 
the stand deviation of the mean. 




In summary, we successfully reduced the protein expression levels of Copine III in MDA-MB-231 
cell. Yet, in vitro, this did not have an effect on the tested phenotypes, such as proliferation, 
migration (Boyden chamber), anchorage-independent growth or adhesion. 
Considering the fact that we saw a strong reduction in migration in T47D cells (section 5.3), the 
next step clearly was to analyze migration of MDA-MB-231 cells in wound healing. Therefore, 
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Figure 6-5 Migration assay (scratch) of wt and Copine III KD MDA-MB-231 cells 
MDA-MB-231 wt, LacZ and KD cells were seeded in medium containing 10 % FCS and 
grown to confluency. Then the cells were stimulated, or not, with HRG and scratched. 
Migration into the wound was measured and plotted as the area recovered by the 
cells as the mean of 6 to 8 specific points of the scratch. The standard error of the 
mean in also plotted.  
 
Both Copine III KD cell pools were analyzed in separate experiments and compared to wt MDA-
MB-231 cells. Both wt and KD cells did not show an increase in migration upon stimulation with 
HRG. Yet, for both shRNA1 and shRNA2 we saw a significant reduction in wound healing 
compared to wt cells. For shRNA2 a problem occurred with the wt ctrl and HRG cells and the 
values could only be measured for the ctrl cells up to 8 hours into the experiment. Already in 
this timeframe a clear reduction of migration in Copine III KD cells compared to wt cells was 
observed. 
 
In summary, given the role of Copine III in tumor cell migration, this suggests that Copine III 
most probably might play a role in tumor metastasis. Further experiments exploring this 
possibility are necessary to evaluate Copine III as a potential new candidate in ErbB2-driven 
cancer metastasis. However, prior to this, we investigated the role of Copine III in in vivo tumor 
growth. 




Copine III KD in in vivo tumor growth 
Therefore, we planned to inject these cells into the mammary fat pad of nude mice to analyze 
their potential in xenograft tumor growth. In a later stage we also planned to analyze their 
potential in metastasis both from the primary tumor and when injecting the cells directly into 
the blood stream of the mice (tail vein injection). In this thesis, only the primary tumor growth 
experiments will be discussed. 
MDA-MB-231 cells are a well studied model for assessing in vivo tumor growth (Matsuda et al., 
2009). Cells (1x106) of each Parental (wt), LacZ, shRNA1 KD and shRNA2 KD were injected into 
the 4th mammary fat pad of 4-6 week old female nude mice. Eight mice were injected per 
group. Tumor growth was monitored twice a week and tumors were allowed to grow to a 
maximum size of 2 cm3. Then the mice were sacrificed and the tumors were excised and 
weighted. Samples of each tumor were taken for protein and RNA extraction and 
immunohistochemistry (IHC) stainings. The tumor volume was calculated as the area of a 
cylinder. Cells that did not grow into solid tumors were incorporated with a value of 0 into the 
calculations of average tumor volumes. These calculated volumes were plotted versus the time 
of the measurement to evaluate the growth rate of the different cell pools. Furthermore the 
endpoint tumor weight was measured, after the tumor was excised and an average of all 
tumors from one group was determined (Figure 6-6). 









Figure 6-6 In  vivo tumor growth of MDA-MB-231 Copine III wt and KD cells 
Cells (1x106) of each wt, LacZ, shRNA1 KD and shRNA2 KD were injected into female 
nude mice. The cells were injected into the 4th mammary fat pad of 4-6 week old mice. 
Eight mice were injected per group. The tumor size was measured twice week until 
tumors reached a maximum size of 2 cm3. Either when the tumors reached the 
maximum size or after 65 days the mice were scarified and the tumors were excised.  
 
Right after the injection the remaining cells were lysed and analyzed for the protein expression 
levels of Copine III by western blotting (insert in Figure 6-6). This confirmed that the KD of 
Copine III was efficient in both KD cell pools compared to the wt and LacZ cells. The 
measurement of the in vivo tumor growth showed, that both KD cells pools tend to have a 
reduced growth rate compared to the wt MDA-MB-231 cells. Yet, a major problem of this 
particular experiment was, that the control LacZ infected cells did not give rise to any tumors at 
all. This meant missing a very important control, since the effects seen with the shRNA cell 




pools could still come from the treatment and selection process the cells went through after 
the infection. Interestingly, the reduction of tumor growth correlated with the level of KD of 
Copine III: shRNA2 infected cells, which show a stronger KD efficiency as the cells infected with 
shRNA1, also showed a greater reduction in tumor growth (Figure 6-6). This observation 
strongly suggests that the growth reduction observed was actually due to the KD of Copine III 
rather than the selection process of the cells. 
Similarly, the endpoint tumor weights measured for the two KD cell pools were smaller that 
those measured for the tumors coming from wt MDA-MB-231 cells. Yet, due to mice in each 
group, which did not take tumors and were therefore counted as 0, these differences were not 
statistically significant. 
 
Analysis of signaling pathways in Copine III wild-type and KD tumors 
To further confirm that a KD of Copine III was the cause of the growth reduction, we extracted 
proteins from all tumor samples and analyzed them by western blotting for Copine III 
expression levels and other downstream signaling pathways of ErbB2. These analyses 
confirmed, that after several weeks of in vivo growth, Copine III protein levels were still reduced 
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Figure 6-7 Western blot analysis of tumor lysates 
Proteins were extracted from snap frozen tumor samples using a cell homogenizer 
(Polytron). Total protein concentrations as determined by Bradford and 50 μg of total 
protein were loaded per lane. Proteins were separated by SDS PAGE and transferred 
onto PVDF membrane. Extract were monitored for protein levels of Copine III, ErbB2 
(total), pErk, Erk, pAkt, Akt, Cyclin D1, Cyclin D3, p-p38 and p38. 
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When we analyzed signaling activity of the tumor cells, such as pErk, p38 or pAkt, we saw that, 
as for the in vitro results, there was no change in the activation of these signaling pathways 
upon KD of Copine III. Furthermore, cell cycle checkpoint protein, like Cyclin D1 and Cyclin D3, 
were also unchanged, indicating that Copine III does not influence cell cycle progression.  
Thus, from this analysis, we concluded that the decreased tumor growth rates seen in Copine III 
KD cells are neither due to changes in major ErbB2 downstream signaling pathways (Erk, PI3K), 
nor to changes in cell cycle progression (Cyclins). 
 
Analysis of proliferation, apoptosis and vascularization in Copine III wild-type and KD tumors 
Other properties that could be the cause for the growth delay seen in Copine III KDs were 
analyzed by IHC stainings of tumor sections. We found that cell proliferation (Ki-67) and 
apoptosis (cleaved caspase 3) were both unchanged between wt and Copine III KD cells.  IHC 
stainings for Copine III confirmed the western blot analysis showing a clear reduction of  
Copine III protein levels in sections from Copine III KD tumors (Figure 6-8). 
 
 
Figure 6-8 Immunohistochemistry analysis of tumor sections 
Paraffin embedded (for Copine III) and fixed frozen (for CD31) tumors were cut and 
stained for human Copine III (pAb) and mouse CD31. For the quantification of the 
CD31 staining pictures of the complete section were taken and analyzed. The ratio of 
the area covered with vessels (CD31 staining) over the total area of the section was 
calculated for each tumor. The mean of all these analysis for one group of tumors is 
plotted as a percentage with the standard error of the mean. 




Interestingly, when we stained the sections for CD31, a marker for blood vessels, we found that 
the vessel density was clearly reduced in Copine III KD tumors. A growing tumor needs blood 
vessels to secure its supply for oxygen and nutrients. Therefore, a reduction in blood vessel 
density could well be the reason for the reduction of tumor growth observed. In order to 
quantify these initial observations pictures from whole tumor sections were analyzed and the 
area covered by blood vessels as a percentage of the total area of each section was calculated 
(Figure 6-8). 
In this experiment it was important to correlate the area covered by vessels to the total area of 
the section, since some tumors were much smaller than others. For example, all tumors from 
the shRNA2 cells were smaller than those from the wt cells. Small tumors are usually densely 
vasicularized, however, once they grow bigger, more oxygen supply is required. Therefore, 
factors initiating new vessel formation (angiogenesis), such as VEGFs, are secreted from the 
tumor cells to the surrounding tissue to supply them with new blood vessels. This means, that 
in very small tumors, one might still see full vascularization, because this vascularization is not 
due to a new-formation of vessels. Only in larger tumors the difference between a tumor that 
can initiate vascularization and one that cannot will become obvious.  
In the analyzed tumor samples we found that the area covered by vessels was much smaller in 
the Copine III KD tumors than in the tumors originating from wt MDA-MB-231 cells. This was 
more striking for tumors originating from shRNA1 than those originating from shRNA2. This 
might mainly be due to the fact, that nearly all tumors excised from shRNA1 injected mice were 
larger than those from shRNA2 injected mice. We tried to analyze this by classifying the tumors 
as larger or smaller than 0.2 cm3. From the shRNA1 tumors one was smaller that 0.2 cm3 and 
already showed less vascularization than wt tumors of this size. However, for the shRNA2 
tumors, two fell into that category and these two showed a high vessel density similar to that 
of wt tumors. The vessel density in these tumors decreased rapidly in larger tumors that fell 
into the second category ( > 0.2 cm3). These results explain the large error bar seen for the 
shRNA2 KD tumors (Figure 6-8).  
Altogether, the analysis of the tumors from Copine III wt and KD cells lead to the conclusion, 
that Copine III is most likely required for in vivo tumor growth. The reduction in tumor growth 
seen in Copine III KD cells is derived from a lack in the recruitment of new blood vessels to the 
tumor. 
 
Microarray analysis of Copine III wild-type versus Copine III KD tumors 
To further elucidate the underlying mechanisms in the reduced tumor growth upon Copine III 
KD, we extracted total RNA from the tumor samples and analyzed changes in the tumor RNA 
using microarrays. Design and evaluation of microarrays was done as described in Materials 
6. Copine III in vivo 
 
108 
and Methods (section 6.2). From triplicate analysis of tumors from each wt, shRNA1 and 
shRNA2 tumors, we selected those probe sets with a Log2 average contrast signal of at least 5, 
an adjusted p-value < 0.05 and an absolute Log2 fold change of > 0.585 (1.5-fold in linear 
space).  
Figure 6-9 shows the Venn diagram for all genes that were found to be differentially regulated, 
either decreased or increased, in between the different groups. We compared each KD to the 
wt tumor RNA and the two KD to one another. For comparing the two KD samples to one 
another we compared the stronger KD, shRNA2, to the less effective KD, shRNA1.  
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Figure 6-9 Number of genes changed between the tumor samples analyzed by 
microarray 
 
We found that many genes were changed within the analyzed groups and therefore we tried to 
further group them. For this we used the software ingenuity pathways, which groups the 
differentially regulated genes into signaling pathways and networks. To confirm our 
hypothesis, we determined that the major pathways these genes could be grouped into were 
associated with cancer and the top hit included cellular movement.  
When analyzing the list of the top 10 up or downregulated genes, we found that most of the 
genes upregulated were genes coding for proteins that are components of the extracellular 
matrix (ECM), like Teneurin-3, Testican-1 or Elastin. On the other hand, most of the top 10 
downregulated genes encoded for proteins involved in the degradation of the ECM, like 









A- top ten upregulated genes 










cell-cell interaction 2.476 
ODZ3 Teneurin-3; Tenascin 
M3 
membrane cellular signal transducer 2.424 
SPOCK1 Testican-1 secreted cell-cell interaction 2.418 
LRRC17 Leucin-rich repeat containing protein 17   2.263 
MYLK 
Myosin light chain 
kinase  
regulation of endothelial and 
vascular permeability 2.192 
MMP2 Matrix 
metalloproteinase 2 
  2.092 
KIAA1199  secreted  2.026 
DCLK1 Serine/threonine-
protein kinase DCLK1 
 Ca2+ signaling 1.985 
ELN Elastin secreted  1.941 
TFCP2L1 
Transcription factor 
CP2-lik protein 2 nucleus 
transcriptional sipressor, may 
supress UBP-1 mediated 
transcriptional activation 1.794 
 
B- top ten downregulated genes 
Molecule Name Cellular localization   Function 
Expression 
value 
PRSS2 Serine protease 2 isoform B  secreted Serine protease, peptidase -4.196 
AGR2 Anterior gradient protein 2 homolog secreted  -3.713 
TFPI2 




mediated matrix remodeling 
-3.481 
TCN1 Transcobalamin-1 secreted Vitamin B12-binding protein. Transports cobalamin into cells -2.924 
SLC7A11 
Cystein 7 Glutamate 
transporter / solute 












family member 3  
secreted  -2.707 
PRSS1 Serine protease 1 (Trypsin-19 secreted Proteolytic ativity -2.645 
QPCT Glutaminyl-peptide 
cyclotransferase 
  -2.524 
TM4SF18 Transmembrane 426 family member 18 
membrane, 
multi-pass  -2.293 
SPINT2 Kunitz type protease inhibitor 2 membrane Inhibitor of HGF activator -2.285 
 Table 6-1 Top ten upregulated and downregulated genes 
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Interestingly, there were two genes that were downregulated in all groups and none that were 
commonly unregulated in all groups (Figure 6-9). These two downregulated genes are fermitin 
family homolog 1 (FERMT1), a protein claimed to be involved in cell adhesion, possibly via its 
interaction with integrins that may mediate TGFβ 1 signaling in tumor progression and insulin-
like growth factor 2 mRNA binding protein 3 (IGF2BP3), RNA-binding protein that acts as a 
regulator of mRNA translation and stability and that is found in lamellipodia of the leading 
edge, in the perinuclear region, and beneath the plasma membrane. This is intriguing since 
both proteins that these genes code for are expressed in regions of the cells were Copine III is 
supposed to be active (for example the plasma membrane). Furthermore, fermitin is involved 
in mediating integrin signaling and we have shown in section 0 that Copine III also plays a part 
in integrin signaling, since it influences Src and focal adhesion kinase, which are also influenced 
by integrin signaling. 
However, how a KD of Copine III influences the regulation of these genes or how the proteins 
might work together remains to be speculative.  
 
In vivo tumor growth of Copine III rescue cell lines 
Yet, before analyzing the data from this first in vivo experiment in too much detail, we wanted 
to ascertain that the changes in tumor growth were really due to a KD of Copine III. Rescue cell 
lines re-expressing Copine III in the Copine III shRNA KD background, were generated and 
tested in vivo (Figure 3-35 insert). The experiment was carried out in the same manner as the 
first in vivo experiment. Similarly, the proliferation of the cells was tested in vitro prior to 
starting the in vivo experiment. As seen in Figure 6-11, the proliferation rate of the cell pools 
did not change upon deletion or rescue of Copine III expression. 
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In vivo tumor growth
 
Figure 6-10 Copine III rescue cell lines- expression, proliferation and in vivo 
tumor growth analysis 
Parental, shRNA1 KD + empty vector, shRNA1 + rescue vector, shRNA2 KD + empty 
vector and shRNA2 + rescue  vector cell pools were analyzed for Copine III protein 
expression levels (upper panel) and their proliferation potential by methylene blue 
(middle panel). 
Cells (1x106) of each cell pool were injected into female nude mice. The cells were 
injected into the 4th mammary fat pad of 4-6 week old mice. Eight mice were injected 
per group. The tumor size was measured twice week until tumors reached a maximum 
size of 2 cm3. The last mice were scarified and the tumors were excised either when 
the tumors reached the maximum size or after 65 days. 
 
The first observation from this experiment was that similar as before, the shRNA2 + empty 
vector cells gave rise to much slower growing tumors than any of the other cells (Figure 6-11 
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light pink triangles). However, apart from that, the results from this experiment were quite 
different to those seen in the first experiment. The main observation was that the parental cells 
did not give rise to the fast growing tumors seen in the first experiment. Hence, there was no 
difference in tumor growth between the parental tumors and the shRNA1+ empty vector 
tumors. Additionally, both rescue cell pools did not yield tumors growing faster than the KD 
tumors.  Therefore, this second experiment makes the interpretation of the role of Copine III in 
in vivo tumor growth very difficult. 
6.4 Outlook 
Overall, the interpretation of the results obtained from the in vivo experiments is difficult. On 
the one hand, both experiments taken together suggest that Copine III is not involved in tumor 
growth and the effects that were seen in the first experiment were plainly due to the selection 
of the cell pools and the treatment prior to the experiment. On the other hand, one could 
argue that, in the second experiment, due to various reasons, the rescue constructs just were 
not able to compensate for the functional loss of Copine III and therefore these cell pools 
should have no influence on the conclusion drawn. Moreover, the parental cells yielded much 
slower growing tumors in the second experiment, compared to the first experiment. The 
growth kinetics of parental MDA-MB-231 cell injected into the fat pad of nude mice is well 
known and well studied (for example see Matsuda et al., 2009). If one would superimpose the 
growth curve of the parental tumors in experiment one onto experiment two, the tendency of 
the experiment would remain: both Copine III KD cell pools yield tumors with slower growth 
kinetics that the parental cells. Moreover, the stronger KD leads to a stronger decrease on 
tumor growth. Therefore, the argument for a role of Copine III could be that the parental cells 
did just not grow into tumors as well as in the first experiment. In summary, no clear conclusion 
can be drawn from these experiments.  
To validate the role of Copine III in in vivo tumor growth the experiment needs to be repeated 
thoroughly. First, the rescue cell pools need to be tested as the KD cell pools were initially 
(activation of signaling pathways, migration, anchorage-independent-growth, etc), to rule out 
any impairment in these cell pools, which could have led to the results seen in the second 
tumor growth experiment. Secondly, one has to make sure, that a large enough group of 
animals is taken for the experiment to be statistically significant and, even more importantly, 
the cells have to be in the growth phase to ensure proper growth. One major change to 
improve the outcome of the experiment could be to inject the cells into the 2nd and 3rd 
mammary fad pads instead of the 4th, as experiments from our laboratory suggest that this site 
is more conducive to tumor growth and metastasis. 




7 DISCUSSION AND OUTLOOK 
The ErbB receptor signaling network plays a pivotal role in breast cancer development and 
progression. Up to 25% of all breast cancer patients show an overexpression of the ErbB2 
receptor; this is correlated with a more aggressive disease and a poor prognosis. Therefore, the 
ErbB receptor signaling network is one of the most extensively studied areas in signal 
transduction. Our knowledge about this system, especially ErbB2, and its role in breast cancer, 
has continuously increased in the past years. However, in spite of extensive research, many 
question, about the signaling cascades initiated by ErbB2 and their downstream effects, 
remain. One of these is the determination of the individual roles of ErbB2 binding partners in 
breast cancer. Several proteins binding to specific tyrosine residues in the C-terminal 
regulatory region of the receptor have been identified and, to some extend, associated with 
downstream effects. One of these is Memo, mediator of ErbB2-dependent cell migration that 
binds to pTyr1222 and is important for tumor cell migration (Marone et al., 2004; Meira et al., 
2009). 
In this study we identified Copine III as a novel binding partner of pTyr1248 of ErbB2. We 
showed that Copine III interacts with the active ErbB2 receptor at the plasma membrane of 
breast cancer cells upon receptor stimulation. Moreover, Copine III localizes to focal adhesions 
and binds to the focal adhesion-associated protein RACK1. Copine III is required for tumor cell 
migration and influences Src activity. Therefore Copine III might provide a link between ErbB2 
and focal adhesions thereby mediating cell migration. 
 
The interaction of Copine III and ErbB2 through Shc 
Copine III belongs to a conserved family of Ca2+-dependent phospholipid binding proteins. All 
human Copines contain two C2 domains (C2A and C2B) followed by a Copine-specific A 
domain at the C-terminus. Furthermore, they have a conserved lysine-rich cluster within their 
C2B domain. C2 domains are Ca2+- and membrane-binding domains that are found in various 
intracellular proteins (e.g. members of the PKC or synaptotagmin family). It was shown recently 
that the C2 domain of PKCδ is able to bind pTyr (Benes et al., 2005). C2 domains can be 
subdivided into two groups depending on the arrangement of the β-strands in their secondary 
structure. The order of the 1st and the 8th β-strand determines whether the domain is classified 
as type I or type II topology. Most type I C2 domains bind Ca2+ whereas the majority of the type 
II C2Ds is Ca2+-independent. The C2 domain described by Benes et al. is classified as type II 
topology and does not bind Ca2+. Using bioinformatic tools we modeled the secondary 
structure of the Copine III C2 domains and came to the conclusion that both domains should 
be classified as type I topology. Both Copine III C2 domains carry 6 conserved aspartate 
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residues that should mediate Ca2+-binding. To further support this in silico evidence, we 
experimentally showed that Copine III is Ca2+-dependent in the cell (section 5.3). Therefore, 
these findings lead to the conclusion that Copine III does, most probably, not bind pTyr 
through its C2 domains. We therefore propose that Copine III might bind to pTyr1248 via Shc. 
We and others have shown that Shc binds to this site in a HRG-dependent manner (Dankort et 
al., 2001a; Schulze et al., 2005).  
An interesting follow-up on these results would be to analyze the binding of Copine III to ErbB2 
in Shc KD cells. Furthermore, it could be interesting to investigate to which Shc isoforms 
Copine III binds. Shc encodes three widely expressed isoforms: p46shc, p52shc and p66shc that 
occur due to differential transcription and alternative splicing (Ravichandran, 2001). These 
isoforms differ in their tissue specificity, cellular localization and function. The shorter isoforms, 
p46shc, and p52shc are constitutively and ubiquitously expressed, whereas p66Shc expression 
is tissue specific. p52Shc is found in the cytosol and acts as adaptor in pathways triggered by 
surface receptors controlling proliferation, chemotaxis, and survival.  p46Shc localizes to 
mitochondria. Its function is not known. p66Shc is expressed in the cytosol and in 
mitochondria. It has both antimitogenic and proapoptotic functions and inhibits the activation 
of the Ras/MAPK pathway by competing with p52Shc (Finetti et al., 2008). As the functions of 
the three Shc isoforms are quite diverse it would be of great interest to find out whether 
Copine III binds to one of them preferentially. This finding could either imply a different 
function of Copine III apart from its role in migration or it could help to further elucidate its role 
in cellular migration in more detail. 
 
Copine III domain architecture- implications for a function? 
Another way to analyze the interaction of Copine III with Shc or with ErbB2 is by studying 
which domain of Copine III is involved in binding. As mentioned, both C2 domains do probably 
not interact with pTyr. Copine III additionally carries an A domain that is known to be involved 
in protein-protein binding in other human Copines and could therefore mediate receptor- or 
Shc-binding. 
 We have made deletion mutations of Copine III in order to express individual domains or 
combinations of different domains. All constructs carry a Flag-tag and can be expressed in 
mammalian cells (Figure 7-1).  
 






Figure 7-1 Schematic outline for domain expression of Copine III in mammalian 
cells 
These constructs have been cloned into a mammalian expression vector and are ready 
to be used in upcoming experiments. 
 
 
These constructs could be used to determine, which domain (or domains) of Copine III are 
required for receptor binding. Such experiments should be performed in both wt and Shc KD 
cells to verify once more if the domain required for binding, binds the receptor via Shc. 
 
Furthermore, these constructs could be utilized to monitor other specific functions of the 
individual Copine III domains. It has been suggested that one or both C2 domains mediate 
membrane binding in a Ca2+-dependent manner. We have shown in our study that stimulation 
of Ca2+ influx by ionomycin leads to a translocation of full-length (fl) Copine III to the plasma 
membrane and the nucleus. Additionally, a stimulation of ErbB2 through HRG also leads to 
membrane localization of Copine III. Which domains mediate this translocation and membrane 
binding? T47D and SKBr3 breast cancer cell could be transfected with the individual domain 
constructs and their localization could be tested via immunofluorescence (IF) microscopy after 
Ca2+- or HRG-stimulation. One interesting aspect concerning membrane localization of Copine 
III is the Lysine-rich cluster (LRC) found within the C2B domain of Copine III. It is well-known 
that other proteins also carry such LRCs and it has been postulated that these domains stabilize 
membrane association by binding to PIP2. Through deletion of the complete LRC or mutation 
of the conserved Lysine residues to Alanines, one could investigate its function in Copine III 
membrane localization. 
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What seems to be of even greater interest is the involvement of the individual Copine III 
domains in its function. Which domain (or domains) is sufficient to restore proper wound 
healing in Copine III KD cells? Our analysis showed that a KD of Copine III in T47D, but also in 
SKBr3 (data not shown) and MDA-MB-231 breast cancer cells, leads to a defect in cell migration.  
Migration into the wound is slower after HRG stimulation in Copine III KD cells compared to 
control LacZ cells.  It would be intriguing to connect this function of Copine III to its individual 
domains.  
 
A putative role for Copine III in the nucleus 
When analyzing the list of putative Copine III binding partners (Table 5-1) we found that out of 
the six proteins, three can shuttle between the nucleus and the cytoplasm and three are 
nuclear proteins. Moreover, we have shown in our studies that Copine III localizes to the 
nucleus in a Ca2+- and HRG-dependent manner.  The first question to address in this context is 
whether Copine III truly can be found in the nucleus or whether it localizes to the nuclear 
membrane. When we analyzed the amino acid (AA) sequence of Copine III no nuclear 
localization signal (NLS) was found using bioinformatic prediction tools. Usually NLS consist of 
bipartite basic AA stretch separated by roughly 10 AAs. Copine III contains a basic AA stretch in 
the LRC. However, again this sequence is not predicted to be an NLS. Experimentally, this could 
be analyzed by performing confocal microscopy on ionomycin- or HRG-treated cells. However, 
the pictures already obtained by immunofluorescence (IF) microscopy and the data from 
putative Copine III binding partners strongly argue that Copine III can reside in the nucleus.  
Another way to approach the localization of Copine III would be to extract nuclei from starved 
and stimulated cells and analyze them for Copine III. Furthermore, it would be very interesting 
to determine the function of Copine III in the nucleus. One way to address this question is to 
look closer at the functions of the nuclear Copine III binding proteins. Out of these, nucleolin 
seems to be of special interest, since it has been identified as an ErbB receptor interacting 
protein (Di Segni et al., 2008). Could this imply that Copine III also interacts with ErbB2 in the 
nucleus? Another hypothesis could be that Copine III is shuttling between the nucleus and the 
cytoplasm/plasma membrane and that it transports other proteins back and forth. However, so 
far, we have found no evidence that directly supports this hypothesis. Therefore, concerning 
Copine III and the nucleus many open questions remain and it would be a worthwhile 
challenge to solve them.   
 
The interaction of Copine III and RACK1 - functional aspects 
We demonstrated in this study that a KD of Copine III leads to a decrease in Src activity, 
monitored by phosphorylation of pTyr418, as well as a subsequent decrease of pTyr925 FAK 
phosphorylation. How does Copine III achieve this? We identified several putative binding 




partners of Copine III, one of them being RACK1, receptor of activated C kinase 1. RACK1 has 
been shown to localize to nascent focal adhesions and to mediate chemotactic cell migration. 
It was shown, that RACK1 regulates chemotactic migration through binding to Src (Cox et al., 
2003). RACK1 deficient cells show increased Src activity and Paxillin phosphorylation, 
suggesting that RACK1 is a negative regulator of Src activity (Doan and Huttenlocher, 2007). 
However, there are other reports showing that an overexpression of RACK1 leads to reduced 
cell migration arguing for a biphasic effect of RACK1 on cell migration (Buensuceso et al., 2001; 
Doan and Huttenlocher, 2007). With respect to these findings, it is possible, that in our set-up 
RACK1 acts as a negative regulator of Src activity. Copine III then blocks this activity of RACK1 
when it interacts with RACK1 in HRG-stimulated cells. Therefore, in this case, we see an increase 
of Src phosphorylation upon stimulation. When Copine III is depleted from the cells (Copine III 
KD), it cannot interact and thus inhibit RACK1 anymore and therefore RACK1 can exert its 
negative regulation upon Src. This becomes obvious in that there is no increase of Src 
phosphorylation in Copine III KD cells upon HRG stimulation (Figure 5-9). 
Interestingly, RACK1 also binds to PKC and the integrin β subunit. It has been postulated that 
RACK1 directs “cross-pathway-control” by integrating communication from different signaling 
pathways (McCahill et al., 2002). Since we also see an effect of Copine III on FAK, a protein that 
has been shown to interact with integrins, it is well possible that Copine III interacts with 
RACK1 to mediate inter-pathways crosstalk, e.g. between integrin and RTK signaling in focal 
adhesions to control cell migration. 
 
A putative role for Copine III in mediating local translation 
Another interesting, but far more speculative, idea about the function of Copine III together 
with RACK1 is that these two proteins together mediate local translation at focal adhesions.  
Mass spectrometry studies have demonstrated the association of RACK1 with the small subunit 
of eukaryotic ribosomes (Sengupta et al., 2004). Cryo-electron microscopy studies showed that 
RACK1 localizes to the head region of the 40S subunit in the vicinity of the messenger RNA 
(mRNA) exit channel (Nilsson et al., 2004). Furthermore, RACK1 acts as a linker between signal-
transduction and local translation by recruiting PKC to the ribosomes, which leads to the 
initiation of translation through the phosphorylation of initiation factor 6 (Nilsson et al., 2004).  
The notion that Copine III, together with RACK1, could play a role in mediating local 
transcription was underlined by the fact that many ribosomal and ribosome-associated 
proteins were purified together with RACK1. However, since ribosomal proteins are very 
abundant within the cell we excluded these proteins from the final protein quantification 
assuming they were mostly background contamination. Retrospectively, and with the evidence 
given by studies on RACK1, it is possible that Copine III indeed recruits ribosomes to sites of 
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local translation and therefore these proteins were true interactors rather than background 
contaminating proteins. Interestingly, RACK1, through its negative regulation of Src, stimulates 
the translation of hnRNPK-bound RNAs. Thus, by recruiting RACK1 and/or ribosomes to focal 
adhesions Copine III could directly influence local RNA translation. 
To test this hypothesis a first experiment to do would be to check whether Copine III itself (or 
through its interaction partner RACK1) can bind RNAs. For this, Copine III should be 
immunoprecipitated (IPed) from cell extracts and RNAs should be extracted. If any RNAs are 
associated with Copine III these can then be extracted from the gel and analyzed on an array or 
by deep sequencing to determine their identity. In this way, one could identify the target RNAs 
of Copine III and then look at their translation specifically in wt versus Copine III KD cells or in 
starved versus stimulated cells.  
Another approach to solving this question would be to analyze a polysome profile of focal 
adhesion-associated polysomes from wt and Copine III KD cells. The problem of this approach 
is to specifically separate only membrane-associated polysomes. However, if this is successful, 
one should be able to determine whether Copine III is involved in local translation initiation.  
 
Copine III in the context of other ErbB2 interacting proteins 
Interestingly, Copine III is not the only ErbB2-interacting protein that has been associated with 
cellular migration. Memo, a recently identified interactor of pTyr1222, is required for tumor cell 
migration (Marone et al., 2004; Meira et al., 2009).  Intriguingly, it has recently been shown that 
Memo reduces Src activity and subsequent FAK phosphorylation. Moreover, Memo links to 
another ErbB2 binder, namely PLCγ, which interacts with pTyr1196 of ErbB2. Memo KD cells 
show a difference in PLCγ phosphorylation kinetics compared to control cells.  
All three of these ErbB2 interacting proteins are interconnected in one or the other way: PLCγ 
activates intracellular Ca2+-influx from ER stores and can, in this way, be linked to the activation 
of Copine III through Ca2+. Yet, it seems that PLCγ activity itself is regulated by Memo. Memo 
and Copine III display similar functions in the cells: both act on Src and influence cell migration.  
Thus, the immediate questions to answer in this respect are:  What is the nature of the spatial 
and temporal binding of these three proteins to ErbB2? Do they influence each other in their 
binding and/or release from the receptor? Do they influence the activity of one another? 
The hypothetical model in Figure 7-2 shows the binding of PLCγ, Memo and Copine III to the 



































































Figure 7-2 Hypothetical model for the function of Copine III in ErbB2- dependent 
cell migration including Memo and PLCγ 
Upon stimulation of ErbB2/ErbB3 heterodimers with HRG (1), PLCγ1 binds pTyr1996, 
Memo pTyr1222 and Copine pTyr1248 of ErbB2. Since we do not know whether all 
three proteins bind the receptor simultaneously, we have drawn the binding with 
dotted lines. Memo exerts a function on PLCγ phosphorylation kinetics (2). PLCγ 
cleaves PIP2 into DAG and IP3 (3), which binds IP3R (4) leading to the release of Ca2+ 
from intracellular stores and through store-operated channels following the 
replenishment of intracellular Ca2+ by influx through the plasma membrane (5). Ca2+ 
influx allows Copine-III to re-locate to the plasma membrane (6). At the PM, RACK1 
directs it to a specific membrane location in close proximity to ErbB2, presumably in 
spreading initiation centers. It is possible that Copine-III interacts with RACK1 via a 
conserved motif in the C2D domain (McCahill et al., 2002). Copine-III associates with 
pTyr1248, very likely via Shc. We have seen a direct interaction of Src with ErbB2 in our 
experiments, which we have shown here. We have drawn a direct Shc-Copine-III 
interaction; however, as indicated by the dots, it is possible that another protein 
mediates the interaction. Memo is also found in spreading initiation centers and 
might be bound to ErbB2 there. Both Copine III and Memo influences Src activation 
(7), thereby influencing ErbB2-induced cell migration (8).  
 
 
To answer at least some of these questions we are planning to analyze whether Copine III, 
Memo and PLCγ can be found in one complex. This can be done in a first attempt by 
immunoprecipitations. Another approach to analyze whether Copine III, Memo and PLCγ 
influence the binding of each other to ErbB2 is FRET acceptor photobleaching experiments 
with different protein pairs in various cellular backgrounds: one could study the interaction of 
Copine III and Memo or Copine III and ErbB2 in Memo or PLCγ KD cells, Memo and ErbB2 in 
Copine III KD cells, PLCγ and ErbB2 in Copine III KD, Memo KD or Copine III and Memo double 
KD cells.  




Such double KD cells, with reduced protein levels of Copine III and Memo could provide the 
basis for further analysis. Since maybe both proteins act synergistically, the migration potential 
of these cells might be further reduced when both proteins are missing. Moreover, the effect of 
a double KD on Src activity and subsequent FAK phosphorylation should be tested.   
 
Memo has been shown to localize to spreading initiation centers. As the name implies these 
structures only exist during the early stages of cell spreading. They precede the formation of 
focal adhesions and are characterized by the fact that they contain RACK1.  We have identified 
RACK1 as a binding partner of Copine III and have shown that Copine III co-localizes with focal 
adhesions. Since Memo KD cells have been shown to have less short lived focal adhesions at 
the migratory front of the cell (Zaoui et al., 2008), a phenomenon that it associated with the 
migration phenotype of these cells, it would be of great interest to study these sites in Copine 
III/Memo double KD cells. There are indications that Copine III might be present in these 
structures as well, as Copine III interacts with RACK1, a protein that has been identified as a 
component of nascent focal adhesions (Figure 7-2). An approach to test whether Copine III and 
Memo both play a role in nascent focal adhesions would be to perform live cell imaging of cells 
expressing GFP-Copine III or GFP-Memo (or a combination of both with different fluorophores). 
In this way one could follow the localization of both molecules over time in migrating cells. 
Subsequently, the localization of each molecule in a background of a KD of the other could be 
visualized. Since both Copine III and Memo bind to ErbB2 and seem to exhibit a similar function 
on the cell, it might well be possible that they can compensate the loss of the other in single 
KD cells.  
 
Could Copine III be important in tumor metastasis? 
The process of metastasis requires a series of biological events that enables tumor cells to 
move from the primary neoplasm to a distant location (Figure 7-3). Tumor cells must first 
invade into the tissue surrounding the primary tumor, then enter into and survive in either the 
lymphatic system or bloodstream where they eventually arrest and extravasate into a tissue 
and proliferate at the new site (Steeg, 2006).  
The contribution of ErbB2 overexpression to the increased metastatic potential of cancer cells 
is evident from a number of studies. In fact, a correlation between the number of lymph node 
metastases and the degree of ErbB2 overexpression has been established in ErbB2 positive 
breast cancer patients (Slamon et al., 1987).   
We have shown that Copine III plays an important role downstream of ErbB2 in tumor 
migration in vitro. Therefore, it would be of great interest to examine whether Copine III is also 








(Bacac and Stamenkovic, 2008) 
Figure 7-3 Principal steps in metastasis 
Transformation of normal epithelial cells leads to carcinoma in situ, which, as a result 
of loss of adherens junctions, evolves toward the invasive carcinoma stage. Following 
basement membrane degradation, tumor cells invade the surrounding stroma, 
migrate and intravasate into blood or lymph vessels, and become transported until 
they arrest in the capillaries of a distant organ. 
 
 
We could increase our understanding of the contribution of Copine III to the process of 
invasion during metastasis by performing in vitro matrigel invasion assays and transendothelial 
migration assays with our control and Copine III KD cells.  In the former, cells must first degrade 
and then move through a layer of matrigel in a ligand gradient. Such an experiment would 
provide insight into the role of Copine III in ECM degradation and invasion. In the latter 
experiment, fibronectin is added to the top compartment of a Boyden chamber and then 
overlaid with a layer of fluorescently-labeled endothelial cells. The tumor cells are then plated 
on top of this layer and left to migrate for 24h. This assay allows one to determine the number 
of cells that can “extravasate” and further allows one to visualize the changes brought about to 
the endothelial cell layer. 
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In addition, in vivo metastasis assays could be performed: either by monitoring the metastases 
originating from the primary tumor at a specific site, e.g. the lungs, or by injecting tumor cells 
directly into the bloodstream of the mice through the tail vein. By using control and Copine III 
KD cells, these experiments could clearly elucidate the function of Copine III in in vivo 
metastasis. 
Tumor metastasis is the major cause of mortality in cancer patients. Many primary site 
neoplasms are effectively controlled by surgery and radiation therapy. Most metastatic lesions 
are not treated by surgery, but rather by chemotherapy, hormonal therapy, targeted therapies 
or radiation, all of which can lead to a significant extension in survival time. However, the fact 
remains that progression to metastatic disease still correlates with a poor prognosis, thus 
elucidating the underlying mechanisms of metastasis, including the possible role of Copine III, 
may have a direct impact on patient survival.  
 
Copine III in cancer 
Finally, we showed in this study that Copine III might play a more general role in cancer. In a set 
of 49 breast tumor samples, 10 of 11 tumors with ERBB2 amplification showed high levels of 
Copine III. Furthermore, in a panel of breast cancer cell lines we saw a tendency that the 
protein expression level of Copine III correlates with ErbB2 amplification. Perhaps most 
importantly, in tissue microarrays from breast, prostate and ovarian tumor samples we found 
higher expression levels of Copine III in the tumor samples as compared to the healthy tissues. 
Furthermore, published trancriptome data also showed that the levels of Copine III are higher 
in prostate and ovarian tumor samples as compared to normal tissue. 
Although descriptive, these data are very intriguing, since they imply a general role for     
Copine III in cancer progression. If increased sample analysis would statistically confirm these 
data, it would strengthen the argument for Copine III as a new prognostic or diagnostic factor 
in cancer. This would further justify studies to uncover the underlying mechanism of the 
function of Copine III. Future experiments will have to shed light on its function in the 
development and progression of this disease. Given that Copine III influences cell migration, it 
would be of great interest to investigate its role in tumor metastasis, which is the major cause 
of cancer-related deaths. This would certainly clarify whether Copine III is a suitable therapeutic 
target. 
In summary, herein we present evidence that supports the conclusion that Copine III is an 





8 APPENDIX  
8.1 Abbreviations 
AA amino acid 
AD A domain 
ADAM a disintegrin and metalloproteinase 




BSA bovine serum albumin 
BTC betacellulin 
C2D C2 domain 
Ca2+ Calcium 
Cbl E3 ubiquitin ligase 
CR cysteine rich 
DAG diacylglycerol 
DMEM  dulbeccos modified eagles medium 
DN dominant negative 
E2 estradiol 
ECM   extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
EGF epidermal growth factor 
EPI  epiregulin 
ER estrogen receptor 
ERK extracellular signal-regulated kinase 
ESI electrospray ionization 
FAK focal adhesion kinase 
FCS fetal calf serum 
FT Fourier transformation 
Gap GTPase-activating protein 
Gem Gon extragenic modifier 
GFP  green fluorescent protein 
Gon gonadogenesis 
GPCR G-protein coupled receptor 
Grb growth factor receptor-bound protein 
GTP guanidine triphosphate   
HB-EGF heparin binding EGF 
HRG heregulin β-1 
ICAT isotope-coded affinity tags 
IGF insulin growth factor 
IR insulin receptor 
IHC immunohistochemistry 
IP3 inositoltriphosphate 
IP3R inositoltriphosphate receptor 
iTRAQ isotope tags for rel. and abs. quant. 
Jak Janus tyrosine kinase 
KD knockdown 
LC liquid chromatography 
m/z mass to charge ratio 
mAb monoclonal antibody 
MALDI matrix assisted laser desorption/ionization 
MAPK mitogen-activated protein kinase 
Memo mediator of ErbB2-driven cell motility 
Mg2+ Magnesium 
MIDAS metal ion-dependent adhesion site 
MMP matrix metalloproteinase 
Mn2+ Manganese 
MRM multiple reaction monitoring 
mRNA messenger RNA 
MS mass spectrometry 
nAChR nicotinic achetylcholine receptor 
NCCLC non-small cell lung cancer 
NFκB nuclear factor kappa-light-chain-
enhancer of activated B-cells 
NRG neuregulin    
OCT optimal cutting temperature 
p phosphorylated 
PA phosphatidic acid 
PAGE polyacrylamide gel electrophoresis 
Pak p21-activated kinase 
PBS phosphate buffered saline 




PKC protein kinase C 
PLC phospholipase C 
PS phosphatidylserine 
PTB phosphotyrosine-binding domain 
PTEN phosphatase and tensin homolog 
deleted on chromosome ten 
PUFA polyunsaturated fatty acid 
RNA ribonucleic acid 
RNAi RNA interference 
RT room temperature 
RTK receptor tyrosine kinase   
SCCHN squamous cell carcinomas of head 
and neck 
SDS sodium dodecylsulfate 
SH2 Src homology 2  
shRNA short hairpin RNA 
SILAC stable isotope labeling by amino 
acids in cell culture 
STAT signal transducer and activator of 
transcription 
TGF transforming growth factor 
TIC total ion chromatogram 
TKI tyrosine kinase inhibitor 
TOF time of flight 
VEGF vascular endothelial growth factor  
VPC vulval precursor cell 
VWA von Willebrand A  
WCE whole cell extract 
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